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Summary	
		
The	vast	majority	of	human	cancers	utilise	a	telomere	maintenance	mechanism	(TMM)	to	compensate	for	
the	gradual	telomere	shortening	that	accompanies	cellular	proliferation,	and	thereby	obtain	an	unlimited	
replicative	capacity.	This	can	be	accomplished	by	activation	of	 the	ribonucleoprotein	 telomerase	which	
adds	telomeric	repeats	onto	the	ends	of	linear	chromosomes	by	reverse	transcription	of	an	RNA	template	
molecule,	or	by	the	homologous	recombination	(HR)‐mediated	alternative	lengthening	of	telomeres	(ALT)	
pathway.	 Telomere	 length	maintenance	 is	 a	 characteristic	 of	 almost	 all	 cancers,	which	means	 there	 is	
considerable	interest	in	the	use	of	telomere	maintenance	inhibitors	as	a	broad‐spectrum	cancer	therapy.	
Therefore	 successful	 therapeutic	 targeting	 of	 telomere	 maintenance	 in	 cancers	 will	 encompass	 the	
development	of	ALT	inhibitors.	This	will	be	facilitated	by	insights	into	the	molecular	details	of	ALT	and	how	
this	mechanism	is	activated.	Telomeres	in	cells	that	utilise	ALT	elicit	a	DNA	damage	response	(DDR)	that	is	
partly	independent	of	telomere	length,	suggesting	the	existence	of	underlying	structural	defects.	The	aim	
of	this	thesis	was	to	investigate	whether	ALT	telomeres	contain	structural	alterations	that	contribute	to	
ALT	activity,	and	may	be	targeted	by	potential	ALT	inhibitors.		
It	has	previously	been	demonstrated	that	the	proximal	2	kb	regions	of	normal	human	telomeres	contain	a	
non‐random	distribution	of	canonical	(TTAGGG)	and	variant	repeats	(TCAGGG,	TGAGGG	and	TTGGGG).	In	
addition,	ALT‐mediated	telomere	exchange	events	have	been	detected	within	these	variant	repeat‐dense	
proximal	regions.	Here	we	used	next	generation	sequencing	to	analyse	the	DNA	content	of	ALT	telomeres.	
We	discovered	that	variant	repeats	were	interspersed	throughout	the	telomeres	of	ALT	cells.	We	propose	
that	 variant	 repeat	 interspersion	 is	 specific	 to	ALT	 telomeres,	 and	 results	 from	HR‐mediated	 telomere	
copying	and	spreading	of	variant	repeats	that	are	normally	restricted	to	the	proximal	regions.	We	found	
that	 the	C‐type	 (TCAGGG)	 variant	 repeat	predominated	 and	 created	 a	high‐affinity	 binding	 site	 for	 the	
nuclear	receptors	COUP‐TF2	and	TR4.	Nuclear	receptors	were	directly	recruited	to	telomeres	following	
incorporation	of	the	C‐type	variant	repeat	using	a	mutant	telomerase,	and	resulted	in	an	undersaturation	
of	shelterin	binding	and	the	induction	of	ALT‐associated	characteristics.	We	propose	that	nuclear	receptor	
binding	 to	 variant	 repeats	 within	 ALT	 telomeres	 alters	 the	 telomeric	 architecture	 to	 facilitate	 further	
recombination.		
We	then	demonstrated	that	the	nucleosome	remodelling	and	histone	deacetylation	(NuRD)	complex	was	
recruited	to	nuclear	receptors	by	an	N‐terminal	RRK	motif	within	ZNF827,	a	zinc	finger	protein	of	unknown	
function.	 We	 found	 that	 recruitment	 of	 the	 NuRD‐ZNF827	 complex	 resulted	 in	 histone	 deacetylation	
indicative	of	chromatin	compaction.	NuRD‐ZNF827	also	recruited	HR	proteins,	and	promoted	ALT	activity.	
Finally,	NuRD‐ZNF827	binding	caused	telomeres	to	interact	with	each	other	as	well	as	ALT‐associated	PML	
bodies	 (APBs).	 ZNF827	 depletion	 elevated	 the	 telomeric	 DDR	 followed	 by	 the	 onset	 of	
senescence/apoptosis	 in	 ALT	 cells.	 We	 propose	 that	 NuRD‐ZNF827	 provides	 a	 molecular	 scaffold	 for	
telomeric	HR,	by	simultaneously	enabling	telomeric	 interactions,	recruiting	HR	proteins,	and	protecting	
telomeres	from	the	DDR.	Together	these	data	implicate	NuRD‐ZNF827	as	a	potential	target	in	ALT‐specific	
cancer	therapeutics.		
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Introduction	
		
1.1	Telomeres	and	immortalisation	
The	linearity	of	eukaryotic	chromosomes	presents	the	cell	with	numerous	obstacles	that	must	be	overcome	
in	 order	 to	 attain	 biological	 immortality.	 Firstly,	 due	 to	 the	 discontinuous	 nature	 of	 lagging‐strand	
synthesis,	the	DNA	replication	machinery	is	unable	to	completely	copy	DNA	molecules	through	to	the	end	
of	each	chromosome	(Watson,	1972;	Olovnikov,	1973).	Aside	from	this	so	called	‘end‐replication	problem,’	
similarly	erosive	processes	such	as	oxidative	damage	(von	Zglinicki	et	al.,	1995;	von	Zglinicki,	2000;	von	
Zglinicki,	 2002)	 and	nucleolytic	 degradation	 (Wellinger	 et	 al.,	 1996)	 also	 contribute	 to	 the	progressive	
chromosome	shortening	that	leads	the	cell	to	a	state	of	permanent	growth	arrest	referred	to	as	replicative	
senescence.	Secondly,	DDR	pathways	must	be	able	to	distinguish	the	natural	ends	of	linear	chromosomes	
from	sites	of	damaged	or	broken	DNA.	Without	such	recognition	chromosomal	 fusion	would	 inevitably	
occur,	 resulting	 in	 the	 formation	 of	 dicentric	 chromosomes	which	may	 cause	 chromosomal	 breakages	
during	mitosis	followed	by	the	need	for	further	repair.	Continuation	of	this	breakage‐fusion‐bridge	cycle	
will	 ultimately	 lead	 to	 rampant	 genome‐wide	 instability	 and	 the	 elimination	 of	 critical	 genes,	 often	
resulting	in	the	death	of	the	cellular	lineage.	To	this	end,	eukaryotes	have	evolved	protective	nucleoprotein	
structures	at	the	termini	of	each	of	their	chromosomes	known	as	telomeres,	which	prevent	recognition	by	
DNA	surveillance	and	repair	mechanisms,	and	diminish	the	loss	of	telomeric	DNA	that	accompanies	cellular	
replication	(d'Adda	di	Fagagna	et	al.,	2003).	However,	despite	the	protective	action	of	telomeres,	gradual	
chromosome	 shortening	 still	 occurs,	with	 human	 telomere	 lengths	 progressively	 declining	 at	 a	 rate	 of	
approximately	40‐200	base	pairs	(bp)	per	cellular	division	(Harley	et	al.,	1990;	Hastie	et	al.,	1990;	Blasco	
et	 al.,	 1997).	As	 a	 result,	 somatic	 cells	possess	 a	 finite	 replicative	 capacity.	To	bypass	 this	proliferative	
barrier	imposed	upon	them	and	escape	senescence,	also	referred	to	as	mortality	stage	1	(M1),	cells	must	
inactivate	the	potent	p53	and	retinoblastoma	protein	(pRb)	tumour	suppressor	pathways,	enabling	their	
continual	proliferation	 for	an	extended	period	of	 time	(Shay	et	al.,	1991a).	Further	cessation	of	cellular	
division	 then	 arises	 upon	 generation	 of	 critically	 short	 or	 dysfunctional	 telomeres,	 as	 the	 cells	 enter	 a	
second	 phase	 of	 growth	 arrest	 called	 crisis	 or	mortality	 stage	 2	 (M2),	 characterised	 by	 chromosomal	
aberrations	and	cell	death	(Wright	et	al.,	1989;	Girardi	et	al.,	1965).	Finally,	escape	from	this	state	of	crisis,	
while	 extremely	 rare,	 can	 be	 achieved	 by	 cells	 via	 activation	 of	 a	 means	 to	 replenish	 lost	 telomeric	
sequence,	thus	enabling	cells	to	effectively	become	immortal	(Harley,	1991;	Colgin	and	Reddel,	1999).		
1.2	Telomere	structure	and	function	
The	telomeric	DNA	of	all	vertebrates	is	composed	of	tandem	arrays	of	the	hexa‐nucleotide	repeat	sequence	
5'‐TTAGGG‐3'	(Moyzis	et	al.,	1988)	(Figure	1.1A).	The	average	length	of	human	telomeres	ranges	from	4‐
15	 kb,	 although	 variability	 in	 telomere	 length	 may	 exist	 among	 different	 individuals,	 organs,	 cells,	
chromosomes	and	in	some	instances	even	sister	chromatids	(Harley,	1991).	Telomeres	primarily	consist	
of	double‐stranded	DNA	but	also	possess	an	obligate	3'	single‐stranded	overhang	rich	in	guanosine	and	
devoid	of	cytosine	with	an	average	length	in	humans	of	130‐210	bp	(Makarov	et	al.,	1997).	This	3'	overhang	
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can	invade	upstream	duplex	telomeric	DNA	and	anneal	to	the	complementary	C‐rich	strand,	resulting	in	
the	formation	of	a	higher	order	lariat	structural	arrangement	known	as	a	telomere	loop	(T‐loop)	(Griffith	
et	al.,	1999)	(Figure	1.1B).	This	T‐loop	structure	has	an	important	role	in	the	protection	of	chromosome	
ends	through	the	sequestration	of	telomeric	DNA,	by	providing	a	protective	cap	that	defines	the	natural	
end	of	the	chromosome	thereby	masking	it	from	recognition	via	the	DNA	damage	machinery	(de	Lange,	
2004).	At	present	relatively	little	is	known	concerning	the	dynamics	of	T‐loop	formation,	the	frequency	or	
possible	cell	cycle	specificity	at	which	T‐loops	occur	at	telomeres	and	how	such	structures	are	displaced	to	
enable	DNA	replication.		
1.3	Shelterin	complex	
In	 addition	 to	 the	 protective	 action	 of	 the	 telomeric	 DNA	 itself,	 and	 the	 higher	 order	 structural	
arrangements	these	terminal	repetitive	sequences	are	able	to	form,	telomeres	also	provide	specific	binding	
sites	 for	 a	plethora	 of	 telomere‐associated	proteins.	The	most	notable	 of	 these	 is	 a	 six‐subunit	 protein	
complex	known	as	shelterin,	which	is	able	to	shield	telomeres	from	recognition	as	sites	of	DNA	damage	and	
prevent	 the	 action	 of	 the	 cellular	 repair	 machinery	 (Figure	 1.1C	 and	 D).	 Furthermore,	 without	 these	
necessary	 capping	 mechanisms	 cells	 would	 become	 vulnerable	 to	 recombination,	 facilitated	 by	 the	
presence	of	highly	repetitive	sequences.	The	shelterin	complex	binds	directly	to	double‐stranded	telomeric	
DNA	 via	 two	 sequence‐specific	 DNA	 binding	 proteins,	 telomeric	 repeat	 binding	 factor	 1	 (TRF1)	 and	
telomeric	repeat	binding	factor	2	(TRF2)	(Chong	et	al.,	1995;	Broccoli	et	al.,	1997;	Bilaud	et	al.,	1997).	Some	
shelterin	complexes	bound	to	telomeres,	however,	appear	to	contain	only	one	of	these	double‐stranded	
DNA	binding	proteins	(Mattern	et	al.,	2004).	TRF2	itself	aids	in	the	formation	of	T‐loops	via	stimulation	of	
Holliday	junction	formation	and	the	prevention	of	their	cleavage	by	resolvases	(Stansel	et	al.,	2001;	Poulet	
et	al.,	2009),	as	well	as	suppressing	the	ataxia	telangiectasia	mutated	(ATM)‐dependent	DDR	(Denchi	and	
de	 Lange,	 2007).	 Telomeres	 present	 a	 challenge	 to	 the	 DNA	 replication	 machinery,	 giving	 rise	 to	
replication‐dependent	defects,	and	they	consequently	resemble	fragile	sites.	It	is	unclear	what	aspect	of	
telomere	 structure	 confers	 this	 fragile	 nature;	 however,	 TRF1	 is	 required	 to	 prevent	 these	 replication	
problems	(Sfeir	et	al.,	2009).		
The	high	specificity	of	the	third	shelterin	component,	protection	of	telomeres	1	(POT1),	for	single‐stranded	
telomeric	DNA	ensures	that	the	complex	associates	with	the	telomeric	3'	overhang	(Baumann	and	Cech,	
2001)	 as	well	 as	displaced	non‐terminal	 single‐stranded	 sites	 found	at	 the	base	of	 the	T‐loop	 (D‐loop)	
(Loayza	et	al.,	2004).	POT1	plays	a	role	in	the	suppression	of	the	ataxia	telangiectasia	and	RAD3‐related	
(ATR)‐dependent	DDR	pathway	(Denchi	and	de	Lange,	2007).	Interestingly,	due	to	alternative	splicing	of	
the	POT1	mRNA	humans	possess	two	separate	forms	of	POT1,	however	the	function	of	the	truncated	form	
remains	 unknown	 (Hockemeyer	 et	 al.,	 2005).	 These	 three	 DNA‐binding	 proteins	 serve	 to	 anchor	 the	
remainder	 of	 the	 shelterin	 components	 along	 the	 entirety	 of	 the	 telomere.	 Another	 shelterin	member,	
TRF1‐	and	TRF2‐interacting	nuclear	factor	2	(TIN2),	as	the	name	suggests,	can	simultaneously	bind	to	both	
TRF1	and	TRF2,	 an	 interaction	which	effectively	 stabilises	 the	 localisation	of	 these	 two	proteins	 at	 the	
telomere	(Kim	et	al.,	1999;	Ye	et	al.,	2004a;	Kim	et	al.,	2004).	Tripeptidyl‐peptidase	1	(TPP1)	does	not	bind	
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to	telomeres	directly	but	through	an	interaction	with	POT1	bound	to	single‐stranded	telomeric	DNA	(Ye	et	
al.,	2004b).	Both	POT1	and	TPP1	serve	to	protect	the	single‐stranded	portion	of	the	telomere,	as	loss	of	
these	 shelterin	 components	 has	 been	 shown	 to	 impair	 telomere	 capping	 function	 (Wu	 et	 al.,	 2006;	
Hockemeyer	et	al.,	2007;	Hockemeyer	et	al.,	2005).	Also	bound	indirectly,	is	the	final	shelterin	component,	
repressor‐activator	protein	1	(RAP1),	which	interacts	with	the	telomere	by	binding	with	TRF2	(Li	et	al.,	
2000).	The	interaction	between	these	two	factors	is	necessary	for	the	recruitment	of	RAP1	to	telomeric	
DNA	and	is	essential	for	the	stability	of	RAP1	protein	levels	(Li	et	al.,	2000).	Nevertheless,	the	exact	function	
of	 RAP1	 at	 telomeres,	 for	 the	 most	 part,	 remains	 to	 be	 elucidated.	 Collectively,	 these	 six	 shelterin	
components	are	involved	in	a	multitude	of	telomere‐associated	processes	including	the	suppression	of	the	
DDR,	 HR	 and	 non‐homologous	 end	 joining	 (NHEJ)	 repair	 pathways,	 telomeric	 fusions,	 and	 excessive	
nuclease	activity	at	chromosomal	termini,	as	well	as	playing	additional	roles	in	the	regulation	of	telomere‐
length	 homeostasis.	 Consequently,	 failure	 of	 these	 protective	 telomeric	 attributes	 leads	 to	 telomere	
dysfunction.	Significant	insight	into	the	nature	of	telomere	dysfunction	has	arisen	almost	exclusively	from	
experimentally	 induced	 genetic	 alterations	 to	 shelterin	 components.	 Given	 the	 role	 of	 shelterin	 in	 the	
suppression	 of	 the	 DDR	 it	 is	 perhaps	 not	 surprising	 that	 experimental	 disruption	 of	 some	 shelterin	
components	results	in	the	colocalisation	of	telomeres	and	various	markers	associated	with	the	DDR,	such	
as	phosphorylated	histone	H2AX	(γ‐H2AX)	and	tumour	suppressor	p53‐binding	protein	1	(TP53BP1)	in	
telomere	dysfunction‐induced	foci	(TIFs)	(Takai	et	al.,	2003).	These	TIFs	occur	in	a	manner	dependent	on	
ATM	or	ATR	protein	kinases	after	disruption	of	shelterin	components	TRF2	or	POT1,	respectively	(Denchi	
and	de	Lange,	2007;	Guo	et	al.,	2007).	
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Figure	1.1	–	The	structure	of	human	telomeres.	(A)	Human	chromosomes	end	in	long	stretches	of	the	repetitive	sequence	5'‐
TTAGGG‐3',	most	of	which	is	double‐stranded	apart	from	the	terminus	which	contains	a	G‐strand	3'	overhang.	(B)	The	telomere	
can	fold	back	on	itself,	and	the	single‐stranded	3'	overhang	can	invade	duplex	telomeric	DNA	resulting	in	the	formation	of	a	T‐loop.	
(C)	 and	(D)	The	shelterin	 complex	derives	 its	 specificity	 for	 telomeric	DNA	 from	TRF1	and	TRF2	as	well	 as	 the	 single‐strand	
telomere	binding	protein	POT1.	The	bridging	molecules	TIN2	and	TPP1	connect	POT1	to	TRF1	and	TRF2	while	RAP1	binds	directly	
to	TRF2.	Shelterin	is	sufficiently	abundant	to	cover	the	majority	of	the	double‐stranded	telomeric	DNA,	and	there	is	sufficient	POT1	
to	cover	single‐stranded	telomeric	DNA	either	in	the	3'	overhang	or	in	the	D	loop.	In	addition	to	the	protective	nature	of	the	T‐loop	
secondary	conformation,	the	telomere	is	able	to	prevent	the	action	of	the	DNA	damage	machinery	via	the	inhibitory	action	of	TRF2	
and	POT1	in	the	ATM‐	and	ATR‐dependent	signalling	pathways,	respectively.		
	
1.4	Epigenetic	regulation	of	telomeric	chromatin	
An	additional	layer	of	telomeric	regulation	exists	at	the	epigenetic	level,	with	telomeric	chromatin	carrying	
histone	 modifications	 characteristic	 of	 transcriptional	 repression	 (Grewal	 and	 Jia,	 2007)	 (Figure	 1.2).	
Indeed,	 mammalian	 telomeric	 chromatin	 shares	 similarities	 with	 that	 of	 pericentric	 heterochromatin	
(Blasco,	 2004).	 Telomere	 nucleosome	 repeats	 are	 approximately	 40	 bp	 shorter	 than	 those	 of	 bulk	
heterochromatin,	resulting	in	telomeres	being	maintained	in	a	heterochromatic	state	(Tommerup	et	al.,	
1994;	 Lejnine	 et	 al.,	 1995).	 This	 state	 is	 characterised	 by	 the	 presence	 of	 epigenetic	markers	 such	 as	
H3K9me3	 and	 H4K20me3	 (trimethylation	 of	 histone	 H3	 at	 lysine	 9	 and	 histone	 H4	 at	 lysine	 20),	 the	
accumulation	 of	 several	 isoforms	 of	 heterochromatin	 protein	 1	 (HP1α,	 HP1β	 and	 HP1γ),	 histone	
hypoacetylation	(Benetti	et	al.,	2007a;	Michishita	et	al.,	2008),	and	DNA	hypermethylation	at	subtelomeric	
regions	(Garcia‐Cao	et	al.,	2004;	Gonzalo	et	al.,	2006;	Hagemann	et	al.,	2008;	Blasco,	2007).	Enrichment	for	
H3K9me3	is	mediated	via	the	action	of	the	SUV39H1	and	SUV39H2	histone	methyltransferases	(HMTs)	
(Garcia‐Cao	et	al.,	2004;	Peters	et	al.,	2001).	These	H3K9me3	marks	provide	a	high	affinity‐binding	site	for	
telomeric	 recruitment	 of	 HP1	 (Garcia‐Cao	 et	 al.,	 2004;	 Lachner	 et	 al.,	 2001).	 In	 accordance	 with	 the	
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sequential	recruitment	of	constitutive	heterochromatin,	SUV4‐20H1	and	SUV4‐20H2	HMTs	are	recruited	
through	an	interaction	with	HP1	and	establish	telomeric	H4K20me3	(Benetti	et	al.,	2007b).		
Proteins	of	the	retinoblastoma	(Rb)	family	of	tumour	suppressors	also	interact	with	the	SUV4‐20H	HMTs	
to	maintain	H4K20me3	at	telomeric	repeats	(Garcia‐Cao	et	al.,	2002;	Gonzalo	and	Blasco,	2005).	However,	
with	the	exception	of	the	role	of	SIRT6	in	H3K9	deacetylation	at	human	telomeres	(Michishita	et	al.,	2008),	
little	is	known	about	the	enzymatic	activities	mediating	the	low	levels	of	acetylated	telomeric	histones	H3	
and	H4.	In	addition	to	these	heterochromatic	histone	marks,	telomeric	repeats	also	contain	dimethylated	
histone	H3	at	 lysine	79	(H3K79me2),	which	 is	mediated	by	the	DOT1L	HMT	(Jones	et	al.,	2008).	These	
repressive	 chromatin	modifications	 are	 also	 enriched	 at	 subtelomeric	 repeats,	 in	 particular	H3K9me3,	
H4K20me3	and	HP1,	as	well	as	hypoacetylated	H3	and	H4	(Benetti	et	al.,	2007a;	Benetti	et	al.,	2007b).	
Furthermore,	 telomeric	 heterochromatin	 can	 also	 spread	 and	 silence	 reporter	 genes	 inserted	
subtelomerically,	a	phenomenon	referred	to	as	the	telomere	position	effect	(TPE)	(Gottschling	et	al.,	1990).	
TPE	 in	human	cells	 is	 influenced	by	 telomere	 length	and	 involves	histone	hypoacetylation,	as	 it	 can	be	
disrupted	by	treatment	with	the	deacetylase	inhibitor	trichostatin	A	(TSA)	(Baur	et	al.,	2001;	Koering	et	al.,	
2002).		
In	light	of	mounting	evidence	it	has	been	proposed	that	these	chromatin	modifications	have	a	role	in	the	
maintenance	of	telomere‐length	homeostasis	(Garcia‐Cao	et	al.,	2004;	Gonzalo	et	al.,	2005;	Gonzalo	et	al.,	
2006;	 Garcia‐Cao	 et	 al.,	 2002).	 Alterations	 to	 these	 modifications	 within	 telomeric	 or	 subtelomeric	
chromatin	 correlate	with	defective	 telomere	 functions	manifested	 as	 telomere	 length	deregulation	 and	
chromosomal	instability	(Benetti	et	al.,	2007b;	Garcia‐Cao	et	al.,	2004;	Gonzalo	et	al.,	2006;	Benetti	et	al.,	
2007a;	Garcia‐Cao	et	al.,	2002;	Gonzalo	and	Blasco,	2005;	Gonzalo	et	al.,	2005),	which	exemplifies	that	these	
repressive	 epigenetic	markers	 are	 crucial	 to	 the	 regulation	 of	 telomere	 length.	 In	 addition,	 shortened	
telomeres	have	been	linked	to	decreased	H3K9me3	and	H4K20me3	and	increased	H3	and	H4	acetylation	
within	both	telomeric	and	subtelomeric	chromatin	as	well	as	a	decrease	in	subtelomeric	DNA	methylation	
in	murine	cells	(Benetti	et	al.,	2007a).	Recent	investigation	into	the	nature	of	telomeric	heterochromatin	
has	led	to	the	hypothesis	that	progressive	loss	of	telomeric	repeats	during	cellular	proliferation	induces	a	
change	in	the	architecture	of	telomeric	and	subtelomeric	chromatin,	resulting	in	a	loss	of	heterochromatic	
features	leading	to	a	more	open	chromatin	structure	(Schoeftner	and	Blasco,	2010).	Interestingly,	in	direct	
contrast	 to	 the	 original	 dogma	 suggesting	 that	 mammalian	 telomeric	 heterochromatin	 is	 strictly	
transcriptionally	inactive,	studies	have	revealed	that	telomeres	are	in	fact	transcribed,	giving	rise	to	non‐
coding,	telomeric	repeat	containing	RNA	(TERRA)	(Azzalin	et	al.,	2007;		Schoeftner	and	Blasco,	2008;	Luke	
and	 Lingner,	 2009).	 TERRA	 has	 been	 implicated	 in	 the	 regulation	 of	 telomere	 length	 and	 telomeric	
chromatin	 structure,	 having	 been	 shown	 to	 facilitate	 heterochromatin	 formation	 at	 telomeres	 via	
recruitment	of	telomeric	H3K9me3	(Deng	et	al.,	2009).	Additionally,	recent	studies	conducted	in	the	plant	
model	organism	Arabidopsis	thaliana	suggest	a	role	for	telomeric	siRNA	transcripts	in	the	promotion	of	
methylated	telomeric	DNA	(Vrbsky	et	al.,	2010).		
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Figure	1.2	–	Epigenetic	modifications	at	 telomeric	and	subtelomeric	heterochromatin.	Both	 telomeric	 and	 subtelomeric	
chromatin	possess	hallmarks	of	constitutive	heterochromatin,	consisting	of	trimethylation	of	histone	H3	at	lysine	9	(H3K9me3)	
and	histone	H4	at	lysine	20	(H4K20me3),	and	several	isoforms	of	heterochromatin	protein	1	(HP1).	H3K9me3	are	carried	out	by	
the	SUV39H	histone	methyltransferases	 (HMTs)	while	pRb	(Rb)	 family	of	proteins	 interacts	with	SUV4‐20H	HMTs	 to	produce	
H4K20me3.	Furthermore,	telomeric	chromatin	is	characterised	by	dimethylation	of	histone	H3	at	lysine	79	(H3K79me2)	mediated	
via	the	action	of	the	DOT1L	HMT.	The	removal	of	acetyl	groups	at	telomeres	is	mediated	by	SIRT6	and	appears	to	be	necessary	for	
regulating	the	association	of	accessory	proteins	to	telomeres.	In	addition,	subtelomeric	DNA	is	heavily	methylated,	particularly	at	
5‐methylcytosine	(5metC)	by	the	DNA	methyltransferase	(DNMT)	enzymes.		
	
1.5	Telomere‐length	maintenance	mechanisms	(TMMs)	
Telomere	renewal	is	a	critical	determinant	for	cellular	immortalisation.	Thus,	in	order	to	circumvent	the	
inherent	limitation	upon	their	proliferative	capacity,	cells	must	activate	a	means	to	replenish	lost	telomeric	
sequence.	 Apart	 from	 the	 requirement	 of	 certain	 normal	 cell	 types	 to	 inhibit	 telomere	 shortening	
(particularly	those	of	the	germline	to	prevent	intergenerational	telomere	attrition),	the	establishment	of	a	
telomere‐length	maintenance	mechanism	(TMM)	is	crucial	for	the	development	of	the	vast	majority,	if	not	
all	human	cancers	(Harley,	1991;	Shay	et	al.,	1991b)	(Figure	1.3).		
1.5.1	Telomerase	
The	 majority	 of	 human	 cancers	 maintain	 their	 telomeres	 via	 activation	 of	 the	 ribonucleoprotein	
holoenzyme	complex	known	as	telomerase,	which	utilises	an	internal	RNA	template	to	reverse	transcribe	
the	addition	of	telomeric	DNA	to	the	ends	of	chromosomes	(Morin,	1989).	Indeed	approximately	85%	of	
human	tumours	demonstrate	reactivation	of	telomerase	(Shay	and	Bacchetti,	1997).	Telomerase	activity	is	
tightly	regulated,	exhibiting	a	distinct	spatial	and	temporal‐specific	expression	pattern	during	mammalian	
embryogenesis.	Ultimately	however,	telomerase	is	strictly	suppressed	in	most	tissues	after	birth,	with	the	
exception	of	proliferative	tissues	of	high	renewal	potential	such	as	the	basal	layer	of	the	epidermis	(Harle‐
Bachor	and	Boukamp,	1996),	gastrointestinal	crypt	epithelium	(Bachor	et	al.,	1999),	anagenic	hair	follicles	
(Ramirez	et	al.,	1997),	activated	lymphocytes	(Liu	et	al.,	1999)	as	well	as	haematopoietic	stem	cells	of	the	
bone	marrow	(Yui	et	al.,	1998).	Such	cells	stringently	regulate	the	modest	levels	of	telomerase	activity	they	
possess	in	order	to	preserve	necessary	proliferative	barriers	against	tumorigenesis	(Cong	et	al.,	2002).	The	
active	 telomerase	 enzyme	 is	 composed	 of	 a	 catalytic	 component	 known	 as	 human	 telomerase	 reverse	
transcriptase	(hTERT),	the	human	telomerase	RNA	(hTR),	and	the	associated	protein	dyskerin	(Cohen	et	
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al.,	2007).	This	core	telomerase	enzyme	may	complex	with	additional	telomerase	binding	proteins,	with	its	
activity	 regulated	 both	 transcriptionally	 and	 post‐transcriptionally.	 Ectopic	 expression	 of	 hTERT	 is	
sufficient	to	induce	telomerase	activity	and	enable	immortal	growth	of	telomerase‐negative	somatic	cells	
in	 vitro	 (Weinrich	 et	 al.,	 1997;	 Bodnar	 et	 al.,	 1998).	 In	 contrast	 to	 hTERT,	 however,	which	 is	 virtually	
undetectable	 in	many	somatic	cells,	hTR	 is	ubiquitously	expressed	but	 in	 limiting	amounts	 (Feng	et	al.,	
1995;	Cristofari	and	Lingner,	2006;	Cao	et	al.,	2008b;	Cao	et	al.,	2008a).	hTR	is	commonly	up‐regulated	in	
immortal	 cell	 lines	 (Feng	et	 al.,	 1995)	and	human	 tumours	 (Cao	et	 al.,	 2008a)	which	demonstrates	 the	
crucial	role	of	both	hTERT	and	hTR	levels	in	the	regulation	of	telomerase	activity.		
1.5.2	Alternative	lengthening	of	telomeres	(ALT)	
Some	immortalised	mammalian	cell	 lines	and	tumours	are	capable	of	maintaining	their	telomere	length	
over	numerous	population	doublings	in	the	absence	of	telomerase	activity,	which	suggests	the	existence	of	
one	or	more	telomerase‐independent	TMMs	collectively	referred	to	as	alternative	lengthening	of	telomeres	
(ALT)	(Bryan	et	al.,	1995;	Bryan	and	Reddel,	1997;	Bryan	et	al.,	1997).	An	estimated	10‐15%	of	all	human	
tumours	are	thought	to	employ	ALT	to	elongate	their	telomeres	and	thus	achieve	an	unlimited	proliferative	
capacity	(Henson	et	al.,	2002).	Therefore,	it	appears	that	TMMs	are	utilised	by	the	vast	majority	of	human	
cancers	(Reddel,	2000)	and	hence	provide	an	attractive	target	for	cancer	detection	and	anticancer‐based	
drug	design.	Although	ALT	occurs	in	common	cancers	such	as	lung	and	breast	carcinomas,	there	is	a	greater	
prevalence	in	some	tumour	types	that	have	a	particularly	poor	prognosis	such	as	glioblastoma	multiforme	
(the	 most	 common	 and	 most	 aggressive	 type	 of	 primary	 malignant	 brain	 tumour	 in	 humans),	
osteosarcomas,	various	types	of	soft	tissue	sarcomas,	peritoneal	mesotheliomas,	and	HER2‐positive	breast	
cancers	(Bryan	et	al.,	1997;	Hakin‐Smith	et	al.,	2003;	Henson	et	al.,	2005;	Costa	et	al.,	2006;	Villa	et	al.,	2008;	
Subhawong	et	al.,	2009;	Heaphy	et	al.,	2011b).	The	molecular	details	of	the	ALT	mechanism	are	not	yet	
completely	understood	(see	below).	However,	it	has	been	shown	that	both	intra‐	and	inter‐telomeric	HR	
events	mediate	telomere	copying,	by	providing	a	template	for	synthesis	of	telomeric	repeat	DNA	and	thus	
telomere	elongation	(Dunham	et	al.,	2000;	Muntoni	et	al.,	2009).		
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Figure	 1.3	 –	 Relationship	 between	 telomere	 length	 and	 cellular	 immortalisation.	 Cells	 of	 the	 germline	 are	 capable	 of	
maintaining	 their	 telomeres	 in	order	 to	prevent	 intergenerational	 telomere	 shortening.	However,	normal	 somatic	 cells	have	a	
limited	proliferative	capacity	due,	at	least	in	part,	to	the	progressive	telomere	attrition	that	accompanies	each	cellular	division.	
This	shortening	continues	until	a	threshold	length	is	reached,	at	which	point	cells	enter	replicative	senescence.	A	subset	of	cells	
are	 able	 to	 overcome	 this	 proliferative	 barrier	 via	 inactivation	 of	 the	 p53	 and	 pRb	 tumour	 suppressor	 pathways.	 Inevitably,	
however,	once	the	telomeres	of	these	cells	become	critically	short,	they	enter	a	second	phase	of	growth	arrest	called	crisis.	In	rare	
events,	a	cell	may	overcome	crisis	via	activation	of	a	TMM	leading	to	the	eventual	stabilisation	of	telomere	length,	resulting	in	
cellular	immortalisation.		
	
1.6	Phenotypic	characteristics	of	ALT	cells		
Despite	significant	developments	in	the	field,	a	detailed	understanding	of	the	underlying	ALT	mechanism	
remains	elusive.	Until	 recently,	no	biochemical	assay	has	existed	to	definitively	determine	ALT	activity.	
Consequently,	 the	 telomere	 field	 has	 relied	 on	 a	 series	 of	 phenotypic	 markers	 to	 detect	 telomere	
maintenance	by	ALT.	This	is	often	problematic,	with	variations	in	ALT	marker	expression,	the	requirement	
for	 proliferating	 cells	 and	 the	 need	 for	 long‐term	 culture	 of	 samples	 to	 confirm	 telomere	 length	
maintenance.	The	phenotypic	markers	used	to	determine	ALT	activity	are	detailed	in	this	section	and	are	
commonly	used	in	combination,	rather	than	individually,	to	classify	ALT	telomere	maintenance.		
1.6.1	Telomere	length	heterogeneity		
ALT	cell	lines	have	a	number	of	phenotypic	hallmarks	distinct	from	telomerase‐positive	cells,	most	notably	
the	generation	of	intracellular	telomere	length	heterogeneity.	The	telomere	length	of	telomerase‐positive	
human	cancers	and	immortal	cell	lines	are	relatively	homogeneous	with	an	average	length	usually	<10	kb	
(Allshire	et	al.,	1989;	de	Lange	et	al.,	1990).	In	contrast,	all	human	ALT	tumours	and	cell	lines	analysed	to	
date	have	a	very	broad	telomere	length	distribution	ranging	from	critically	short	(<3	kb)	to	extremely	long	
(>50	kb),	possessing	a	mean	length	of	~20	kb	as	measured	by	terminal	restriction	fragment	(TRF)	length	
analysis	(Murnane	et	al.,	1994;	Bryan	et	al.,	1995;	Bryan	et	al.,	1997;	Grobelny	et	al.,	2000;	Opitz	et	al.,	2001)	
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(Figure	1.4A).	Telomere	length	heterogeneity	can	also	be	visualised	in	metaphase	spreads	by	fluorescence	
in	situ	hybridisation	(FISH)	using	a	fluorochrome‐labelled	telomeric	repeat‐specific	probe	(Lansdorp	et	al.,	
1997;	Perrem	et	al.,	2001)	(Figure	1.4B).	Upon	activation	of	the	ALT	mechanism	during	immortalisation	of	
cells	in	vitro,	there	is	a	strong	temporal	correlation	between	the	immortalisation	event	and	the	occurrence	
of	this	variability	of	telomere	length	distribution	(Yeager	et	al.,	1999).	Hence	telomere	length	heterogeneity	
is	a	well‐established	detection	strategy	for	ALT	(Bryan	et	al.,	1997)	and	has	been	useful	for	determining	the	
ALT	status	of	 tumours	as	 it	 can	be	used	on	paraffin	embedded	specimens	and	 is	not	 affected	by	 intra‐
tumoural	heterogeneity	due	to	the	ability	to	assess	individual	cells	(Meeker	et	al.,	2002).		
1.6.2	Telomere	length	fluctuation	
The	telomere	length	distribution	in	ALT	cells	is	dynamic,	with	rapid,	unsynchronised	fluctuations	in	length	
of	individual	telomeres	during	cellular	proliferation.	The	rate	at	which	this	heterogeneity	is	generated	was	
studied	by	Southern	blot	analysis,	using	a	plasmid‐tagged	telomere	in	clonal	populations	of	a	human	ALT	
cell	line	(Murnane	et	al.,	1994).	The	type	of	telomere	length	changes	varied	from	gradual,	with	telomeres	
shortening	at	a	rate	comparable	to	that	seen	during	normal	cell	telomere	erosion,	to	rapid,	involving	highly	
heterogeneous	increases	in	telomere	length	of	both	critically	short	and	long	telomeres,	as	well	as	rapid	
decreases	in	telomere	length.	The	incidence	of	chromosomal	fusion	events	seemed	to	be	proportional	to	
the	frequency	of	rapid	length	changes.	The	rate	of	telomere	length	fluctuation	has	also	been	assessed	by	
calculating	 the	 ratio	 of	 p	 arm	 and	 q	 arm	 telomere	 fluorescence	 signal	 intensities	 from	 a	 marker	
chromosome	 in	 individual	metaphases	 again	within	a	 clonal	population.	This	produces	a	 characteristic	
telomere	 length	 fluctuation	 profile	 that	 clearly	 distinguishes	 ALT	 and	 telomerase‐positive	 cell	 lines	
(Perrem	et	al.,	2001)	(Figure	1.4C).	Nevertheless,	Flow‐FISH	analysis	of	telomere	length	fluctuations	in	cell	
subpopulations	of	human	cell	lines	revealed	significant	gains	and	losses	of	telomeric	DNA	in	1	out	of	19	
non‐ALT	cell	lines	and	in	1	of	2	analysed	ALT	cell	lines	(Cabuy	et	al.,	2004),	thus	caution	must	be	taken	
when	using	this	characteristic	as	the	sole	means	by	which	to	determine	whether	a	cell	employs	the	ALT	
mechanism.		
1.6.3	ALT‐associated	PML	bodies	(APBs)	
Promyelocytic	 leukaemia	 nuclear	 bodies	 (PML‐NBs)	 are	 distinct	 nuclear	 foci	 interspersed	 between	
chromatin	and	present	 in	the	majority	of	mammalian	cells	(Bernardi	and	Pandolfi,	2007).	PML‐NBs	are	
functionally	 heterogeneous,	 dynamic	 protein	 structures	 (Muratani	 et	 al.,	 2002;	 Eskiw	 et	 al.,	 2003),	
composed	of	several	isoforms	of	PML	protein	(Jensen	et	al.,	2001)	and	other	constitutively	or	transiently	
associated	 proteins	 (Bernardi	 and	 Pandolfi,	 2007).	 PML‐NBs	 appear	 to	 play	 a	 multifaceted	 role	 as	
macromolecular	 platforms	 involved	 in	 numerous	 cellular	 processes,	 having	 been	 implicated	 in	 the	
regulation	of	the	cell	cycle	and	DDR	(Bernardi	and	Pandolfi,	2003;	Dellaire	and	Bazett‐Jones,	2004;	Dellaire	
et	al.,	2006),	induction	of	apoptosis	and	cellular	senescence	(Jiang	and	Ringertz,	1997;	Ferbeyre	et	al.,	2000;	
Bischof	et	al.,	2002;	Bernardi	and	Pandolfi,	2003;	Dellaire	and	Bazett‐Jones,	2004),	tumour	suppression	(He	
et	al.,	1997),	antigen	presentation	and	the	 immune	response	(Zheng	et	al.,	1998),	protein	refolding	and	
degradation	 (Mattsson	 et	 al.,	 2001),	 transcriptional	 regulation	 (Zhong	 et	 al.,	 2000)	 and	 chromatin	
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modification	(Luciani	et	al.,	2006),	viral	replication	(Chung	and	Tsai,	2009)	and	neoangiogenesis	(Bernardi	
et	al.,	2006).	Despite	the	discovery	of	this	vast	array	of	physiological	processes	in	which	they	are	involved,	
the	exact	function	of	PML‐NBs	within	the	cell	is	not	entirely	clear.	What	is	more	certain,	however,	is	that	a	
subset	of	PML‐NBs	that	contain	telomeric	DNA,	telomere	binding	proteins	as	well	as	proteins	involved	in	
DNA	 repair	 and	 recombination	 are	 highly	 characteristic	 of	 cells	 that	 use	 the	 ALT	mechanism	 and	 are	
therefore	referred	to	as	ALT‐associated	PML	bodies	(APBs)	(Yeager	et	al.,	1999;	Wu	et	al.,	2003;	Nabetani	
et	al.,	2004;	Henson	et	al.,	2005;	Venturini	et	al.,	2008)	(Figure	1.4D).	Although	the	telomeric	DNA	present	
within	APBs	was	originally	 thought	 to	be	predominantly	of	 extrachromosomal	origin,	 it	has	since	been	
proven	that	APBs	can	associate	with	chromosomal	termini,	with	additional	evidence	raising	the	intriguing	
possibility	 that	 these	 structures	 transiently	 associate	with	 and	dissociate	 from	 telomeres	 in	 a	dynamic	
fashion	(Molenaar	et	al.,	2003).		
Strong	circumstantial	evidence	has	led	to	speculation	that	these	nuclear	bodies	act	as	platforms	for	ALT	
activity.	First,	APB	formation	is	cell	cycle‐dependent,	increasing	in	number	and	being	present	in	a	greater	
percentage	 of	 cells	 during	 G2	 phase	 (Grobelny	 et	 al.,	 2000)	 –	 the	 stage	 of	 the	 cell	 cycle	 in	 which	 the	
recombinogenic	processes	of	the	ALT	mechanisms	are	predicted	to	occur	(Wu	et	al.,	2000).	Second,	APBs	
with	 telomeric	 signal	greater	 than	 that	arising	at	 the	 telomeres	usually	occur	 in	approximately	10%	of	
interphase	nuclei	within	an	exponentially	growing	ALT	cell	line	(Yeager	et	al.,	1999),	and	usually	increase	
in	frequency	with	any	cellular	stress	that	causes	cell	cycle	arrest,	including	senescence	(Jiang	et	al.,	2007;	
Fasching	et	al.,	2007;	Jiang	et	al.,	2009).	However,	smaller	localisations	of	PML	and	telomeric	DNA	can	be	
seen	 in	 the	majority,	 if	 not	 all	ALT‐positive	 nuclei	 under	 optimal	 conditions	 (A.	Muntoni,	H.	 Pickett,	R.	
Reddel,	unpublished	results).	Third,	in	situations	in	which	ALT	activity	is	 inhibited,	the	number	of	APB‐
positive	nuclei	often	decreases	(Perrem	et	al.,	2001;	Jiang	et	al.,	2005).	For	instance,	repression	of	the	ALT	
mechanism	 via	 sequestration	 or	 knockdown	of	 the	HR‐associated	MRN	 complex	 (which	 is	made	 up	 of	
meiotic	recombination	11	(MRE11),	RAD50	and	Nijmegen	breakage	syndrome	1	(NBS1))	has	been	shown	
to	suppress	APB	formation	(Jiang	et	al.,	2005;	Zhong	et	al.,	2007;	Potts	and	Yu,	2007;	Jiang	et	al.,	2007).	
Additionally,	 the	structural	maintenance	of	chromosomes	(SMC)	5/6	complex,	was	shown	to	 localise	to	
PML‐NBs	in	ALT	cells,	to	sumoylate	TRF1	and	TRF2	and	to	be	required	for	telomere	lengthening	(Potts	and	
Yu,	2007).		
These	data	indicate	that	one	of	the	functions	of	the	PML‐NBs	in	ALT	could	be	to	provide	a	platform	for	the	
efficient	sumoylation	of	proteins	which	associate	with	telomeric	chromatin.	Nonetheless,	several	findings	
appear	to	be	inconsistent	with	speculation	that	APBs	are	sites	of	telomeric	 lengthening	in	ALT	cells.	To	
date,	at	least	two	ALT	cell	lines	have	been	shown	not	to	contain	APBs	(Fasching	et	al.,	2005;	Marciniak	et	
al.,	 2005;	 Cerone	 et	 al.,	 2005)	 showing	 that	 APBs	 are	 not	 essential	 for	 ALT	 activity.	 Furthermore,	 the	
formation	of	 telomere	 circles	 (T‐circles)	 in	 telomerase‐positive	human	 cancer	 cells	 by	 the	 trimming	of	
overlengthened	telomeres	was	accompanied	by	the	formation	of	APBs,	but	no	evidence	was	found	for	ALT‐
mediated	telomere	maintenance	(Pickett	et	al.,	2009).	These	data	suggest	that	the	functions	of	APBs	include	
sequestration	of	 extrachromosomal	DNA,	 rather	 than	 the	ALT	mechanism	 itself	 (Fasching	et	 al.,	 2007).	
Whilst	the	precise	role	of	APBs	within	the	ALT	mechanism	has	yet	to	be	elucidated,	current	hypotheses	
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propose	that	APBs	are	an	active	component	of	the	ALT	mechanism	that	serve	to	supply,	remove	or	stabilise	
ALT‐associated	 factors	 (Yeager	 et	 al.,	 1999;	 Grobelny	 et	 al.,	 2000;	 Wu	 et	 al.,	 2000)	 or	 by	 creating	 a	
chromatin	milieu	that	is	permissive	to	recombination	(Bernardi	and	Pandolfi,	2007).	Alternatively,	these	
nuclear	bodies	may	merely	 act	 as	 a	 repository	 for	by‐products	 of	 the	ALT	process.	Regardless	 of	 their	
specific	function	however,	 like	telomere	length	heterogeneity,	APBs	are,	for	the	most	part,	considered	a	
robust	 hallmark	 of	 ALT	 cells,	 emphasised	 by	 the	 fact	 that	 the	 colocalisation	 of	 PML	with	 telomeres	 is	
currently	being	used	for	the	detection	of	ALT	in	human	tumour	specimens	(Henson	et	al.,	2005;	Costa	et	al.,	
2006;	Heaphy	et	al.,	2011b).		
1.6.4	Extrachromosomal	telomeric	DNA	
Currently	 one	 of	 the	 most	 striking	 phenotypic	 characteristics	 of	 ALT	 cells	 is	 an	 abundance	 of	
extrachromosomal	DNA	composed	of	telomeric	repeat	sequences.	This	extrachromosomal	telomeric	DNA	
may	assume	numerous	forms,	including	the	double‐stranded	T‐circles	described	previously	(Cesare	and	
Griffith,	 2004;	Wang	 et	 al.,	 2004),	 both	 linear	 single‐	 (Henson,	 2006;	 Grudic	 et	 al.,	 2007)	 and	 double‐
stranded	DNA	(Tokutake	et	al.,	1998;	Ogino	et	al.,	1998),	partially	single‐stranded	circles	(referred	to	as	C‐
circles	or	G‐circles	depending	on	whether	it	is	the	C‐rich	or	G‐rich	strand,	respectively,	that	is	essentially	
continuous)	(Nabetani	and	Ishikawa,	2009;	Henson	et	al.,	2009)	as	well	as	highly	branched	structures	of	
telomeric	DNA	with	 large	 amounts	 of	 internal	 single‐stranded	portions	 referred	 to	 as	 ‘t‐complex’	DNA	
(Nabetani	and	Ishikawa,	2009).	In	the	past,	an	increase	in	the	level	of	T‐circles	has	been	used	as	a	marker	
for	ALT	activity	(Fasching	et	al.,	2005;	Cesare	and	Griffith,	2004;	Wang	et	al.,	2004;	Cerone	et	al.,	2005;	
Zellinger	et	al.,	2007;	Zeng	et	al.,	2009),	however	T‐circles	do	not	seem	to	be	a	functional	requirement	for,	
or	 strictly	 limited	 to,	 the	 ALT	 mechanism.	 The	 generation	 of	 T‐circles	 is	 thought	 to	 result	 from	 the	
resolution	of	T‐loop	junctions,	an	event	which	is	dependent	upon	the	recombination	proteins	X‐ray	repair	
cross‐complementing	3	 (XRCC3)	 and	NBS1	 (Wang	 et	 al.,	 2004;	 Compton	 et	 al.,	 2007)	whilst	 ordinarily	
suppressed	by	the	basic	domain	of	the	shelterin	component,	TRF2	(Cesare	and	Griffith,	2004;	Wang	et	al.,	
2004).	 Electron	microscopy	 has	 revealed	 a	 close	 correlation	 between	 the	 size	 of	 T‐loops	 and	T‐circles	
within	ALT	cells	(Cesare	and	Griffith,	2004)	which	strengthens	the	notion	that	T‐circles	are	derived	from	
T‐loops	via	 a	HR	resolution	event.	 Interestingly,	 these	 cells	have	been	shown	 to	be	able	 to	 continue	 to	
proliferate	in	the	absence	of	detectable	T‐circles	(Compton	et	al.,	2007).	Also,	the	only	known	ALT	cell	line	
without	 long	 telomeres	 is	 also	 the	 only	ALT	 cell	 line	with	 low	 levels	 of	 T‐circles	 (Cerone	 et	 al.,	 2005).	
Therefore	the	abundance	of	T‐circles	in	ALT	cells	may	perhaps	be	due	to	the	production	of	non‐specific	by‐
products	generated	 from	telomere	 trimming	counteracting	 the	otherwise	abnormally	high	rate	of	ALT‐
mediated	telomere	lengthening	events,	rather	than	being	directly	involved	in	the	ALT	mechanism	itself.		
C‐circles	are	partially	single‐stranded	telomeric	(CCCTAA)n	DNA	circles	which	appear	 to	be	much	more	
specific	 than	 T‐circles	 to	 cells	 that	 employ	 the	 ALT	 mechanism.	 Recent	 findings	 have	 established	 a	
quantitative	 relationship	between	 the	amount	of	ALT	activity	and	 the	number	of	C‐circles	within	a	cell	
(Henson	et	al.,	2009).	ALT	cells	also	contain	G‐circles,	but	these	are	100‐fold	less	abundant	(Henson	et	al.,	
2009).	C‐circles	are	self‐priming	telomeric	C‐strand	templates	for	rolling	circle	amplification	(Henson	et	
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al.,	2009)	which	are	distinguishable	 from	T‐circles	that	have	nicks	or	gaps	in	both	strands	(Wang	et	al.,	
2004),	causing	them	to	be	incapable	of	sustaining	any	rolling	circle	amplification	mechanism	(Henson	et	
al.,	2009).	We	have	developed	a	quantitative	assay	in	which	rolling	circle	replication	is	used	to	amplify	and	
detect	 C‐circles.	 This	 assay	 revealed	 an	 average	 of	 750‐fold	more	 C‐circles	 present	within	ALT	 cells	 in	
comparison	 to	 telomerase‐positive	 or	 non‐immortalised	 cell	 lines.	 To	 date,	 all	 19	ALT	 cell	 lines	 tested	
possess	 elevated	 levels	 of	 C‐circles,	 including	 ALT	 cell	 lines	 which	 lack	 other	 well‐established	 ALT‐
associated	attributes	such	as	an	abundance	of	T‐circles,	APBs	and	telomere	length	heterogeneity	(Henson	
et	al.,	2009),	suggesting	that	C‐circles	may	be	the	most	specific	marker	of	ALT	yet	identified.	C‐circles	also	
correlated	temporally	with	ALT	activation	and	the	majority	of	these	C‐circles	decay	rapidly	within	24	hours	
of	ALT	inhibition.	Given	the	observed	specificity	of	C‐circles	for	the	ALT	mechanism	and	their	relatively	
short	half	life,	it	is	likely	that	they	are	an	integral	part	of	the	ALT	mechanism,	although	the	exact	origin	of	
these	C‐circles	remains	to	be	determined	(Henson	and	Reddel,	2010).	Moreover,	assaying	for	C‐circles	may	
be	a	useful	means	by	which	to	screen	for	chemical	inhibitors	of	the	ALT	mechanism	(Cesare	and	Reddel,	
2010).	 C‐circles	 were	 also	 detected	 in	 blood	 samples	 from	 patients	 with	 ALT‐positive	 osteosarcomas	
(Henson	et	al.,	2009).	Consequently	the	C‐circle	assay	has	the	potential	to	be	used	in	the	future	as	a	routine	
clinical	test	for	diagnosing	ALT‐positive	tumours.		
1.6.5	Minisatellite	instability		
Minisatellites	 are	 variant	 tandem	 repeats	 of	 6‐100	 bp	 repeat	 units	 that	 can	 span	 0.	 5	 to	 several	 kb	
(Vergnaud	and	Denoeud,	2000).	The	human	minisatellite	MS32	(D1S8)	locus	exhibits	extraordinarily	high	
levels	of	tandem	repeat	instability	in	ALT	cell	lines	and	many	ALT‐positive	soft	tissue	sarcomas	compared	
to	telomerase‐positive	and	non‐immortalised	cell	lines	(Jeyapalan	et	al.,	2005;	Jeyapalan	et	al.,	2008).	The	
MS32	minisatellite	contains	10‐1000	tandem	arrays	of	a	29	bp	repeat	unit	that	has	a	GC	content	of	62%	as	
well	as	a	moderate	segregation	of	G	and	C	onto	opposite	strands.	The	MS32	locus	is	ordinarily	unstable	due	
to	conversion	or	crossover	events	during	meiosis	in	the	germline.	However,	the	instability	identified	in	ALT	
cells	involved	a	variety	of	different	types	of	mutations	over	the	entire	length	of	the	array,	which	suggests	
an	ALT‐specific	mechanism.	Tandem	repeat	variability	was	also	discovered	at	minisatellites	detected	by	
the	33.15	and	33.6	multi‐locus	probes	in	ALT	cell	lines	derived	from	a	patient	with	Li‐Fraumeni	syndrome	
(Tsutsui	et	al.,	2003),	but	not	at	any	other	minisatellite	loci	or	within	microsatellites,	which	usually	consist	
of	shorter	repeat	units	and	array	lengths	in	comparison	to	minisatellite	repeats	(Jeyapalan	et	al.,	2005).	All	
tandem	repeats	known	to	have	such	length	instability	in	ALT	cells	have	G	and	C	segregated	into	one	G‐rich	
and	 one	 C‐rich	 strand	 and	 are	 known	 to	 mispair	 to	 form	 intrahelical	 pseudoknots	 and	 interhelical	
associations	 in	 vitro	 (Coggins	 et	 al.,	 1992).	While	 causality	 of	 this	minisatellite	 instability	 is	 unknown,	
speculation	has	arisen	that	this	event	may	be	linked	with	the	underlying	processes	of	the	ALT	mechanism,	
or	 alternatively	 the	 ALT	 mechanism	 may	 independently	 cause	 destabilisation	 of	 these	 particular	
minisatellites.		
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1.6.6	Telomeric	recombination	
Another	characteristic	of	ALT	cells	is	the	more	frequent	occurrence	of	post‐replicative	telomeric	exchanges	
in	relation	to	telomerase‐positive	cell	lines	(Londono‐Vallejo	et	al.,	2004;	Bechter	et	al.,	2004).	Telomere	
exchange	events	that	involve	post‐replicative	exchange	between	leading	and	lagging	strands	can	be	readily	
detected	within	cell	 lines	by	chromosome	orientation‐FISH	(CO‐FISH)	(Meyne	et	al.,	1994;	Bailey	et	al.,	
2004b;	 Londono‐Vallejo	 et	 al.,	 2004).	 CO‐FISH	 involves	 the	 incorporation	 of	 5‐bromo‐2'‐deoxyuridine	
(BrdU)	 into	 the	newly	 synthesised	DNA	strand,	 followed	by	 its	degradation	while	 leaving	 the	 template	
strand	intact	for	which	telomere‐specific	FISH	can	be	employed	in	order	to	indicate	whether	a	cross‐over	
event	occurred	after	replication	between	a	 leading	and	 lagging	strand	telomere	(Londono‐Vallejo	et	al.,	
2004).	The	characteristic	strand	asymmetry	of	telomeres	means	that	hybridisation	to	a	telomere‐specific	
single‐stranded	probe	will	show	one	signal	per	chromosome	extremity	unless	a	telomeric	repeat	exchange	
has	occurred,	in	which	instance	double	signals	will	occur	(Londono‐Vallejo	et	al.,	2004).	It	is	important	to	
note	however,	that	this	technique	is	unable	to	distinguish	between	telomere‐sister	chromatid	exchanges	
(T‐SCEs),	 exchanges	 that	 occur	 between	 telomeres	 on	 different	 chromosomes,	 or	 those	 that	 involve	
extrachromosomal	telomeric	DNA.	Extensive	CO‐FISH	analysis	of	in	vitro	immortalised	and	cancer‐derived	
cell	lines	as	well	as	mortal	cell	strains	has	shown	that	post‐replicative	telomere‐repeat	exchanges	occurred	
frequently	in	ALT	cells,	but	seldom	in	non‐ALT	cells	(Londono‐Vallejo	et	al.,	2004).	There	is	also	no	direct	
correlation	 between	 the	 rate	 of	 T‐SCE	 and	 non‐telomeric	 HR	 or	 sister	 chromatid	 exchange	 (SCE)	 at	
interstitial	locations	elsewhere	in	the	genome,	as	the	frequency	of	these	non‐telomeric	exchange	events	
has	been	shown	to	be	similar	in	both	telomerase‐	and	ALT	cell	lines	(Londono‐Vallejo	et	al.,	2004;	Bechter	
et	al.,	2003;	Bechter	et	al.,	2004;	Bailey	et	al.,	2004a).	Additionally,	 telomeric	exchange	events	were	not	
observed	in	cells	derived	from	Bloom	syndrome	patients,	which	possess	10‐	to	12‐fold	higher	levels	of	SCEs	
in	comparison	to	the	cells	of	their	non‐diseased	counterparts	(Londono‐Vallejo	et	al.,	2004),	signifying	the	
specificity	of	telomeric	repeat	exchanges	to	the	ALT	mechanism.		
Amplification	of	specially	designed	telomeric	tags	within	ALT	cells	but	not	in	telomerase‐positive	cells	has	
also	 been	 utilised	 to	 demonstrate	 that	 the	 telomere	 can	 be	 used	 as	 a	 template	 for	 the	 ALT‐mediated	
telomere	elongation	of	either	itself	(Muntoni	et	al.,	2009)	or	another	telomere	(Dunham	et	al.,	2000).	Within	
ALT	cells,	a	progressive	increase	in	the	number	of	these	tagged	telomeres	was	observed	with	increasing	
population	doublings	of	clonally	derived	cells.	Furthermore,	similar	intertelomeric	recombination	events	
have	not	been	observed	in	telomerase‐positive	cells,	or	 in	ALT	cells	 in	which	the	tag	had	been	inserted	
subtelomerically,	demonstrating	that	the	increased	telomeric	recombination	in	ALT	cells	does	not	extend	
into	 the	 subtelomeric	 region	 (Dunham	 et	 al.,	 2000;	 Henson	 et	 al.,	 2002).	 Techniques	 such	 as	 this	 are	
therefore	specific	to	the	ALT	mechanism,	and	are	used	to	confirm	ALT	status	(Fasching	et	al.,	2005;	Pickett	
et	al.,	2009).		
1.6.7	ATRX/DAXX	mutations	
Recent	studies	of	ALT	tumours	and	immortalised	cell	lines	found	a	strong	correlation	between	telomere	
maintenance	by	ALT	and	loss	of	activity	of	the	SWI/SNF	family	ATP‐dependent	helicase	ATRX	or	its	binding	
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partner	DAXX	(Heaphy	et	al.,	2011a;	Schwartzentruber	et	al.,	2012;	Lovejoy	et	al.,	2012;	Bower	et	al.,	2012).	
ATRX	and	DAXX	form	a	chromatin	remodelling	complex	that	localises	to	PML	nuclear	bodies	(Xue	et	al.,	
2003),	 although	 the	precise	mechanism	of	 chromatin	 remodelling	 remains	elusive.	Nevertheless,	 it	 has	
been	 shown	 that	 ATRX	 and	 DAXX	 act	 in	 concert	 to	 deliver	 the	 histone	 variant	 H3.3	 to	 telomeres	 in	 a	
replication‐independent	manner	 (Law	et	al.,	 2010;	Lewis	et	 al.,	 2010;	Goldberg	et	 al.,	 2010).	While	 the	
purpose	of	this	H3.3	deposition	at	telomeres	is	not	understood,	it	has	been	postulated	that	inhibition	of	
ATRX/DAXX	function	may	result	in	the	loss	of	heterochromatic	marks	thought	to	suppress	the	inherently	
recombinogenic	nature	of	repetitive	telomeric	DNA.		
Some	ALT	 tumours,	however,	have	mutations	 in	both	H3.3	 and	a	member	of	 the	ATRX/DAXX	complex	
(Schwartzentruber	et	al.,	2012),	which	indicates	that	the	loss	of	some	function	of	ATRX/DAXX	other	than	
H3.3	deposition	is	selected	for	in	ALT	tumours.	ATRX	also	appears	to	have	a	function	in	the	repression	of	
TERRA	(Goldberg	et	al.,	2010),	which	is	consistent	with	the	observation	that	elevated	levels	of	TERRA	exist	
in	many	ALT	tumours	and	cell	lines	compared	to	those	which	have	activated	telomerase	(Ng	et	al.,	2009;	
Sampl	et	al.,	2012;	Lovejoy	et	al.,	2012).	ATRX	depletion	in	mouse	embryonic	stem	cells	has	also	been	shown	
to	 reduce	 HP1α	 recruitment	 to	 telomeres	 and	 to	 cause	 an	 increase	 in	 telomere	 dysfunction	 as	
demonstrated	by	 localisation	of	γ‐H2AX	at	chromosome	ends	 (Wong	et	al.,	2010).	Alternatively,	 loss	of	
ATRX/DAXX	function	may	act	elsewhere	in	the	genome	and	lead	to	altered	gene	expression,	e.	g.,	by	binding	
to	DNA	structures	such	as	G‐quadruplexes	(Law	et	al.,	2010),	thus	indirectly	affecting	changes	that	promote	
ALT	activity.	Nonetheless,	depletion	of	either	ATRX	or	DAXX	failed	to	activate	ALT	in	SV40‐transformed	
fibroblasts	(Lovejoy	et	al.,	2012;	Bower	et	al.,	2012),	suggesting	that	loss	of	ATRX/DAXX	function	alone	is	
not	sufficient	for	ALT	to	be	initiated.		
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Figure	 1.4	 –	 Phenotypic	 characteristics	 of	 ALT	 cells.	 The	 telomere	 length	 heterogeneity	 of	 ALT	 cells	 in	 comparison	 to	
telomerase‐positive	cells	can	be	shown	by	terminal	restriction	fragment	(TRF)	length	analysis	(A),	or	alternatively,	visualised	via	
FISH	using	a	telomere‐specific	probe	(yellow)	on	metaphase	chromosomes	(red)	(B)	(Axel	A.	Neumann,	unpublished	results).	This	
highly	heterogeneous	telomere	length	phenotype	arises	due	to	an	elevated	degree	of	telomere	length	fluctuations	illustrated	by	
obtaining	 the	 telomere	 length	 ratios	 of	 the	 short	 and	 long	 arm	 of	 the	 Y	 chromosome	 from	 the	 telomere	 fluorescence	 signal	
intensities	of	20	metaphase	spreads	in	an	ALT	cell	line,	GM847,	and	a	comparable	telomerase‐positive	cell	line,	GM639	(C)	(Axel	
A.	Neumann,	unpublished	results).	APBs	may	also	be	identified	by	the	colocalisation	of	TRF2	(green)	and	PML	protein	(red)	by	
immunostaining	of	ALT	interphase	nuclei	(blue)	(D)	(from	Jeremy	D.	Henson,	2005).		
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1.7	Models	of	ALT‐mediated	telomere	elongation	
Two	proposed	structural	models	for	ALT‐mediated	telomere	elongation,	which	are	by	no	means	mutually	
exclusive,	are	known	as	the	unequal	T‐SCE	model	and	the	HR‐dependent	DNA	replication	model.		
1.7.1	Unequal	T‐SCE	model	
The	first	model	suggested	that	ALT	could	occur	without	amplification	of	telomeric	DNA,	based	upon	the	
observation	that	T‐SCE	events	are	a	significantly	more	frequent	occurrence	within	ALT	cells	compared	to	
telomerase‐positive	or	mortal	cell	 lines	(Londono‐Vallejo	et	al.,	2004;	Bechter	et	al.,	2004).	The	precise	
details	of	this	mechanism	are	unclear,	however	it	is	proposed	to	involve	selective	segregation	of	all	sister	
chromatids	with	 longer	 telomeres	 into	 the	same	daughter	cell	during	cellular	replication	and	 therefore	
bestowing	a	prolonged	proliferative	capacity	upon	the	cell,	leaving	the	other	sacrificial	daughter	cell	with	
predominately	short	telomeres	and	decreased	proliferative	capacity	(Blagoev	and	Goodwin,	2008).	Such	a	
mechanism	could,	in	theory,	result	in	the	unlimited	proliferation	of	the	cellular	population,	provided	there	
is	a	means	for	segregating	every	lengthened	telomere	into	one	daughter	cell	and	every	shortened	telomere	
into	 the	 other	 (Muntoni	 and	 Reddel,	 2005;	 Blagoev	 and	 Goodwin,	 2008).	 To	 date	 this	model	 remains	
hypothetical	due	to	 lack	of	sufficient	evidence;	nonetheless	recent	 findings	have	shown	significant	non‐
random	sister	chromatid	segregation	in	a	subset	of	murine	cells	(Falconer	et	al.,	2010).	However,	there	is	
no	direct	evidence	 to	suggest	 the	occurrence	of	unequal	T‐SCE	events	within	ALT	cells,	or	 for	selective	
segregation	 of	 the	 chromatids	 with	 longer	 telomeres	 into	 one	 of	 the	 daughter	 cells.	 Furthermore,	
amplification	of	telomeric	DNA	is	known	to	occur	in	ALT	(Dunham	et	al.,	2000;	Muntoni	et	al.,	2009),	and	
quite	commonly	from	inter‐telomeric	sources	(Dunham	et	al.,	2000;	Varley	et	al.,	2002;	Jeyapalan	et	al.,	
2008).	 Thus	 it	 is	 reasonable	 to	 suggest	 that	 if	 unequal	 T‐SCE	 is	 indeed	 responsible	 for	 ALT‐mediated	
telomere	elongation	it	must	occur	in	conjunction	with	the	mechanism	postulated	below.		
1.7.2	HR‐dependent	DNA	replication	model	
The	most	widely	accepted	model	is	that	the	ALT	mechanism	is	the	result	of	HR‐mediated	DNA	synthesis	of	
new	telomeric	DNA	via	the	utilisation	of	an	adjacent	chromosomal	telomere	as	a	copy	template	(Dunham	
et	 al.,	 2000;	Henson	 et	 al.,	 2002)	 and	 in	 contrast	 to	 the	previous	model,	 is	 accompanied	by	 a	 total	 net	
increase	 in	 the	 quantity	 of	 telomeric	 DNA.	 Substantial	 experimental	 evidence	 exists	 in	 support	 of	 this	
mechanism	and	includes	the	observation	described	in	section	1.6.6	above,	in	which	a	DNA	tag	placed	into	
telomeres	was	copied	to	other	chromosome	ends	in	ALT	cells	whilst	remaining	uncopied	in	telomerase‐
positive	cells	(Dunham	et	al.,	2000).	Furthermore,	the	observed	increase	in	the	number	of	tagged	telomeres	
(Dunham	et	al.,	2000)	and	the	observed	DNA	sequence	changes	at	 telomeres	of	ALT	cells	(Varley	et	al.,	
2002)	are	not	predicted	by	the	unequal	exchange	and	asymmetric	segregation	model.	In	the	HR‐dependent	
DNA	replication	model,	the	template	DNA	required	for	ALT	activity	can	be	another	telomere	(Figure	1.5A),	
or	the	same	telomere	(Muntoni	et	al.,	2009)	via	rolling	circle	replication	of	 the	T‐loop	(Figure	1.5B),	or	
template‐directed	DNA‐copying	of	one	sister	chromatid	by	another.	While	both	intra‐	and	inter‐telomeric	
recombination	 have	 been	 proven	 to	 occur	 it	 has	 also	 been	 postulated	 that	 linear	 extrachromosomal	
telomeric	DNA	may	act	as	a	copy	template	analogous	to	the	telomere	of	another	chromosome	(Figure	1.5C),	
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or	 that	 T‐circles	 may	 also	 act	 as	 a	 template	 for	 telomeric	 extension	 by	 a	 rolling	 circle	 amplification	
mechanism	(Henson	et	al.,	2002)	(Figure	1.5D),	similar	to	that	observed	within	the	unicellular	eukaryote	
Kluyveromyces	lactis,	where	circular	extrachromosomal	telomeric	DNA	was	used	as	a	template	for	rolling	
circle	replication	to	generate	long	tracts	of	telomeric	repeat	sequence	(Natarajan	et	al.,	2003;	Natarajan	
and	McEachern,	2002).	In	addition,	C‐circles	have	been	shown	to	serve	as	an	effective	template	for	rolling	
circle	amplification	in	vitro	(Henson	et	al.,	2009),	and	it	seems	reasonable	to	speculate	that	they	may	also	
serve	as	a	substrate	for	rolling	circle‐mediated	elongation	of	telomeres	in	ALT	cells	in	vivo.	Regardless	of	
the	source	of	telomeric	DNA,	this	HR‐dependent	model	involves	the	invasion	of	the	3'	overhang	into	duplex	
telomeric	DNA,	using	it	as	a	template	to	replicate	telomeric	DNA	and	hence	extend	the	telomere.		
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Figure	1.5	–	Proposed	model	for	HR‐dependent	elongation	of	telomeres.	According	to	the	HR‐dependent	replication	model,	it	
is	proposed	that	the	copy	template	used	for	alternative	lengthening	of	telomeres	(ALT)‐mediated	telomere	lengthening	may	be	
another	 telomere	 (A),	 the	 T‐loop	 of	 the	 same	 telomere	 (B),	 linear	 extrachromosomal	 telomeric	 DNA	 (C)	 or	 circular	
extrachromosomal	 telomeric	DNA	 (D).	 Regardless	of	 the	 template,	 in	 each	 instance	 the	3’	 telomeric	overhang	 invades	duplex	
telomeric	DNA	from	each	of	the	different	sources	and	uses	it	as	a	template	to	copy	and	extend	the	telomere.		
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1.8	Proteins	involved	in	the	ALT	mechanism	
Numerous	recombination‐associated	proteins	have	been	shown	to	be	crucial	for	the	ALT	mechanism,	many	
of	which,	as	discussed	above	are	proteins	present	within	APBs.	Most	notably,	the	MRN	complex	and	the	
structural	maintenance	of	chromosome	5/6	(SMC5/6)	complex	are	necessary	for	ALT‐mediated	telomere	
maintenance	(31966;	38485;	38334}.	As	some	of	 the	 first	proteins	 to	be	 identified	as	essential	 for	ALT	
activity,	the	constituents	of	the	MRN	complex	collectively	act	in	order	to	recruit	the	ATM	protein	to	DNA	
double‐strand	breaks	and	facilitate	5'	to	3'	resection	of	the	chromosome	ends	to	create	3'	overhangs	for	the	
strand	 invasion	 crucial	 for	HR	 (Lee	 and	Paull,	 2007).	 This	 has	 led	 to	 the	 hypothesis	 that	 this	 complex	
promotes	ALT	activity	by	recruiting	ATM	to	telomeres,	initiating	the	recombination	process	and	processing	
the	chromosome	end	to	form	an	extended	telomeric	3'	overhang	that	can	invade	adjacent	telomeric	DNA,	
which	can	then	be	used	as	a	template	for	elongation	of	the	telomere.	Despite	three	of	the	subunits	of	the	
SMC5/6	complex	(SMC5,	SMC6	and	methyl	methanesulfonate‐sensitivity	21	(MMS21))	being	required	for	
ALT‐mediated	 telomere	 maintenance	 (Potts	 and	 Yu,	 2007),	 little	 is	 known	 about	 the	 function	 of	 the	
complex	 in	 this	process.	However,	 in	 light	 of	 recent	 evidence	 that	 the	 SMC5/6	 complex	 can	 sumoylate	
shelterin	components	in	ALT	cells	(Potts	and	Yu,	2007),	and	assuming	that	APBs	are	in	fact	sites	of	ALT	
activity,	the	complex	may	facilitate	ALT	activity	by	recruiting	telomeres	to	APBs	via	sumoylation	of	these	
proteins.	 Alternatively,	 the	 complex	 may	 by	 some	 means	 promote	 telomere	 elongation	 within	 APBs	
themselves.		
Other	proteins,	including	the	endonuclease	MUS81	(Zeng	et	al.,	2009),	flap	endonuclease	1	(FEN1)	(Saharia	
and	Stewart,	2009),	Fanconi	anaemia	group	A	(FANCA)	and	Fanconi	anaemia	group	D2	(FANCD2)	(Fan	et	
al.,	2009),	have	a	telomere	maintenance	role	in	ALT	cells,	but	differ	from	the	MRN	and	SMC5/6	complexes	
in	that	overall	genome‐wide	telomere	shortening	does	not	ensue	when	they	are	depleted.	It	has	therefore	
been	proposed	that	these	proteins	have	a	role	in	telomere	maintenance	rather	than,	or	in	addition	to,	being	
involved	 in	ALT‐mediated	 telomere	 lengthening	 (Cesare	 and	Reddel,	 2010).	 Recent	 findings	 show	 that	
these	proteins	repair	broken	telomeric	replication	forks	in	ALT	cells	(Verdun	and	Karlseder,	2006;	Saharia	
and	Stewart,	2009;	Zeng	et	al.,	2009;	Fan	et	al.,	2009;	Saharia	et	al.,	2010),	which	is	necessary	for	ALT‐
mediated	telomere	maintenance	in	order	to	prevent	substantial	loss	of	telomeric	DNA.	Topoisomerase	3α	
(TOP3A)	may	also	possess	a	similar	function	in	repairing	stalled	replication	forks,	as	TOP3A	depletion	was	
found	 to	not	only	 result	 in	 reduced	survival	of	ALT	cells	but	 also	promoted	 the	 formation	of	 anaphase	
bridges,	induced	the	degradation	of	the	3'	overhang,	and	resulted	in	the	appearance	of	an	increased	DDR	
at	 telomeres	 (Temime‐Smaali	 et	 al.,	 2008).	 While	 this	 may	 very	 well	 be	 an	 indirect	 response	 to	 the	
concomitant	 decrease	 in	 TRF2	 levels	 also	 observed	 in	 this	 study,	 TRF2	 reduction	was	 not	 detected	 in	
telomerase‐positive	cells	after	TOP3A	knockdown	(Temime‐Smaali	et	al.,	2008).	Interestingly,	despite	the	
necessity	 for	 recombination‐mediated	 repair	of	broken	 replication	 forks,	 the	Werner	 syndrome	 (WRN)	
helicase,	generally	responsible	for	the	unwinding	and	separation	of	double‐stranded	DNA	is	not	essential	
for	ALT	(Fasching	et	al.,	2005).	This	may	be	due	to	the	fact	that	other	RecQ	helicases	such	as	the	Bloom	
syndrome	(BLM)	helicase	provide	redundant	functions	within	ALT	cells.	Nonetheless,	the	many	roles	of	
helicases	in	the	disruption	of	alternative	DNA	structures,	resolution	of	intermediates	of	HR,	and	replication,	
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as	well	as	acting	as	an	interface	between	DNA	replication	and	HR	suggests	they	may	be	involved	in	the	ALT	
mechanism,	 perhaps	 by	 directly	 facilitating	 HR‐mediated	 copying	 of	 telomeric	 repeats	 that	 would	 be	
otherwise	inefficient	(Hickson,	2003;	Cheok	et	al.,	2005).		
1.9	Telomeric	recombination	in	normal	cell	biology	
Thus	far	the	majority	of	studies	have	focused	upon	the	use	of	recombination	as	a	TMM	within	immortalised	
cells	and	cancers;	however,	there	is	evidence	to	suggest	that	ALT	exists	at	low	levels	in	normal	cells	as	an	
inherent	mechanism.	For	example,	loss	of	the	yeast	equivalent	of	telomerase	in	Saccharomyces	cerevisiae,	
produces	 two	 distinct	 types	 of	 survivors	 which	 use	 a	 recombination‐based	 mechanism	 of	 telomere	
maintenance	that	appears	to	be	analogous	to	human	ALT	(Lundblad	and	Blackburn,	1993;	Teng	and	Zakian,	
1999).	Type	I	survivors	possess	tandem	duplications	of	Y´	subtelomeric	elements	whereas	type	II	survivors	
are	characterised	by	long	heterogeneous	telomeric	repeat	extensions	similar	to	those	seen	in	human	ALT	
cells	(Chen	et	al.,	2001).	Similarly,	a	recombination‐mediated	lengthening	of	telomeres	may	occur	within	
murine	cells	 in	vivo	that	have	 lost	 the	telomerase	activity	which	they	ordinarily	possess	(Herrera	et	al.,	
2000).	 The	 fruit	 fly	 Drosophila	melanogaster	 utilises	 a	 retrotransposition‐mediated	 TMM	 (Mason	 and	
Biessmann,	 1995)	 while	 the	 mosquito	 Anopheles	 gambiae	 uses	 a	 recombination‐based	 mechanism	 of	
telomere	 maintenance	 (Roth	 et	 al.,	 1997).	 In	 addition,	 the	 telomeric	 elongation	 that	 accompanies	
dedifferentiation	of	A.	thaliana	protoplasts	also	involves	a	telomerase‐independent	mechanism	which	may	
be	similar	to	ALT	(Grafi	et	al.,	2007).	Also,	examination	of	the	telomeres	within	normal	human	fibroblasts	
in	culture	suggested	that	low	levels	of	telomeric	recombination	may	occur	prior	to	senescence	(Martens	et	
al.,	2000).	Recently	we	observed	copying	of	the	telomere	tag	described	previously	(Dunham	et	al.,	2000)	
within	 the	telomeres	of	normal	mouse	somatic	cells	 (Neumann	et	al.,	2013).	 It	 is	 therefore	 tempting	to	
speculate	 that	 an	 ALT‐like	 mechanism	 is	 conserved	 throughout	 evolution,	 having	 been	 found	 within	
divergent	eukaryotes	such	as	yeast,	mammals	and	plants.	 Indeed,	 it	has	been	proposed	 that	ALT	 is	 the	
ancestral	TMM	of	all	eukaryotic	organisms,	being	subsequently	displaced	by	telomerase	over	the	course	of	
evolutionary	history	(de	Lange,	2004).	It	is	possible	that	the	ALT	TMM	that	exists	in	cancer	cells	originates	
from	a	dysregulated	version	of	a	normal,	 inherent	cellular	process.	Consequently,	a	critically	 important	
question	is	what	prevents	all	cells	 from	elongating	their	telomeres	through	an	ALT	mechanism?	Hybrid	
clones	 formed	 by	 the	 fusion	 of	 an	 ALT‐	 and	 telomerase‐positive	 immortalised	 cell	 possess	 telomerase	
activity,	no	APBs	and	initially	showed	rapidly	decreasing	telomere	lengths,	followed	by	rates	of	telomere	
erosion	comparable	with	natural	telomere	attrition,	and	finally	telomere	length	maintenance	(Perrem	et	
al.,	 2001).	 Furthermore,	 when	 ALT	 cells	 were	 fused	with	 diploid	 fibroblasts,	 the	 ALT	mechanism	was	
repressed	in	the	resulting	hybrids	(Perrem	et	al.,	1999)	and	correlated	with	the	presence	of	wild‐type	ATRX	
(Bower	 et	 al.,	 2012).	 These	 data	 indicate	 that	 normal	 non‐immortalised	 and	 telomerase‐positive	 cells	
possess	factors	that	repress	the	ALT	mechanism	and	thus	ALT	can	only	be	activated	in	cells	that	lack	these	
repressive	 elements	 (Perrem	 et	 al.,	 1999;	 Perrem	 et	 al.,	 2001).	 The	 identity	 of	 these	 factors,	 how	 this	
repression	 is	 lifted,	 and	 thus	 how	 the	 ALT	mechanism	 becomes	 activated	 in	 cancer	 cells	 is	 essentially	
unknown.		
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1.10	Epigenetic	state	and	the	ALT	mechanism	
As	discussed	previously,	epigenetic	modification	of	telomeric	chromatin	is	essential	for	telomere	length	
regulation	 and	may	 also	 be	 important	 for	 the	ALT	mechanism.	 Indeed,	 alterations	 in	DNA	and	histone	
marks	are	quite	common	in	many	human	cancers	(Jones	and	Baylin,	2002;	Fraga	and	Esteller,	2005;	Fraga	
et	al.,	2005;	Esteller,	2006).	Thus,	it	is	possible	that	epigenetic	changes	may	be	involved	in	activation	of	the	
ALT	mechanism	in	certain	cancers.	This	is	exemplified	via	studies	conducted	in	mice	in	which	impairment	
of	histone	modifications	within	telomeric	and	subtelomeric	heterochromatin	was	revealed	to	not	only	alter	
telomere‐length	homeostasis,	but	also	cause	a	dramatic	increase	in	T‐SCEs,	driving	aberrant	elongation	of	
telomeres	 supposedly	via	 an	ALT	mechanism	(Benetti	 et	 al.,	 2007b;	Gonzalo	 et	 al.,	 2006;	Benetti	 et	 al.,	
2007a).	This	may	be	due	to	the	telomeric	chromatin	becoming	more	open	and	accessible,	thus	facilitating	
HR.	In	support	of	this	hypothesis,	activation	of	ALT	by	transformation	of	human	fibroblasts	with	human	
papilloma	virus	 (HPV)	 oncogenes	 appears	 to	 require	 the	E7	protein	 (Yamamoto	 et	 al.,	 2003),	which	 is	
responsible	 for	 the	 inactivation	 of	 Rb	 family	 proteins	 (Helt	 and	 Galloway,	 2003)	 that	 have	 a	 role	 in	
maintaining	 both	 telomeres	 and	 subtelomeres	 in	 a	 heterochromatic	 state	 (Gonzalo	 et	 al.,	 2005).	 Thus	
opening	up	and	increasing	the	accessibility	of	the	telomeric	chromatin	by	decreased	function	of	Rb	family	
proteins	may	be	necessary	for	ALT.		
As	 mentioned	 previously,	 the	 telomeric	 elongation	 that	 accompanies	 dedifferentiation	 of	 A.	 thaliana	
protoplasts	 involves	 a	 telomerase‐independent	mechanism,	 possibly	 similar	 to	 ALT,	 and	 experimental	
evidence	has	shown	that	this	process	is	affected	by	alterations	in	telomeric	heterochromatin	(Grafi	et	al.,	
2007).	 Furthermore,	 numerous	 studies	 conducted	 in	 mice	 have	 shown	 that	 loss	 of	 telomeric	
heterochromatin	leads	to	an	increase	in	the	number	of	APBs	per	cell	(Benetti	et	al.,	2007b;	Garcia‐Cao	et	
al.,	 2004;	 Gonzalo	 et	 al.,	 2006;	 Benetti	 et	 al.,	 2007a;	 Benetti	 et	 al.,	 2008a).	 Loss	 of	 the	 SUV39H	 HMT	
abrogates	binding	of	the	HP1	family	to	telomeres	which	may	contribute	to	the	opening	of	the	telomeric	
chromatin	 into	 a	 more	 accessible	 state	 (Garcia‐Cao	 et	 al.,	 2004).	 Interestingly,	 beside	 the	 role	 of	 HP1	
proteins	in	defining	telomeric	heterochromatin,	HP1	mutation	in	yeast	and	flies	augments	non‐telomerase	
telomere	maintenance	(Downs	et	al.,	2003;	Savitsky	et	al.,	2002;	Cenci	et	al.,	2003).	In	addition	HP1α	and	
HP1γ	are	involved	in	the	formation	of	APBs,	suggesting	that	HP1	proteins	can	exert	diverse	functions	in	
telomere	regulation	(Jiang	et	al.,	2009).	Disruption	of	DNA	methylation	within	the	subtelomeres	of	murine	
cells	was	reported	to	be	associated	with	increased	telomeric	recombination	frequency	and	ALT	(Gonzalo	
et	al.,	2006;	Vera	et	al.,	2008).	However,	recent	studies	also	reported	that	defects	in	human	subtelomeric	
DNA	methylation	do	not	significantly	impact	upon	the	frequency	of	T‐SCEs	within	human	tumour	cells	(Ng	
et	al.,	2009;	Tilman	et	al.,	2009).	Nevertheless,	 it	 is	possible	that	other	epigenetic	modifications	such	as	
H3K9me3	and	H4K20me3	within	telomeric	and	subtelomeric	regions	may	suppress	T‐SCEs	in	human	cells.	
In	further	support	of	this	idea,	changes	in	chromatin	structure	have	also	been	found	within	dysfunctional	
telomeres,	for	example,	changes	in	H4K20me2	levels	result	in	the	recruitment	of	TP53BP1	to	telomeres	
(Blasco,	2007).	This	implies	that	alteration	of	epigenetic	modification	may	be	connected	to	the	abundance	
of	TIFs	within	ALT	cells.	Also,	recently	it	was	shown	that	reduced	chromatin	compaction	at	telomeres	is	a	
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characteristic	of	ALT	(Episkopou	et	al.,	2014).	Together	these	data	suggest	that	a	repressive	environment	
at	telomeric	and	subtelomeric	DNA	is	crucial	to	the	repression	of	the	ALT	mechanism.		
In	addition	to	the	epigenetic	modifications	observed	within	murine	telomeric	and	subtelomeric	chromatin,	
it	has	been	shown	that	the	presence	of	various	histone	modifications	in	the	hTERT	and	hTR	promoters	
correlate	with	the	expression	of	hTERT	and	hTR	in	both	telomerase‐	and	ALT‐positive	tumour	cells	as	well	
as	non‐immortalised	cell	lines	(Atkinson	et	al.,	2005).	Specifically,	these	promoters	contain	hypoacetylated	
H3	and	H4	and	H3K9me	in	ALT	cells	which	repress	expression	of	the	telomerase	components.	Conversely,	
these	promoters	 in	telomerase‐positive	cells,	when	transcriptionally	active,	contain	hyperacetylated	H3	
and	H4	and	methylated	H3K4.	It	was	also	discovered	that	H4K20me	was	not	connected	to	hTERT	and	hTR	
activation,	but	rather	was	specific	to	the	hTERT	and	hTR	promoters	of	ALT	cell	lines	(Atkinson	et	al.,	2005).	
Forced	chromatin	remodelling	in	ALT	cells	via	the	synergistic	action	of	both	the	DNA	methyltransferase	
inhibitor	5‐azadeoxycytidine	and	TSA	resulted	in	the	reactivation	of	hTERT	and	hTR	expression	(Atkinson	
et	al.,	2005).	This	unearthed	the	possibility	that	epigenetic	modification	of	the	hTERT	and	hTR	promoters	
is	 directly	 responsible	 for	 their	 transcriptional	 state	 and	 that	 certain	 cell	 types,	 for	 instance	 those	 of	
mesenchymal	 origin	 which	 are	 thought	 to	 be	 more	 likely	 to	 activate	 ALT,	 strictly	 repress	 chromatin	
remodelling	processes,	thus	inhibiting	telomerase	activation	in	favour	of	initiating	ALT	activity.		
1.11	Telomeric	structural	abnormalities	associated	with	the	ALT	mechanism	
Telomere	capping	function	is	accomplished	by	the	presence	of	a	sufficient	number	of	telomeric	repeats,	the	
ability	of	the	telomere	to	form	a	T‐loop	secondary	structure,	and	binding	of	the	shelterin	complex	(de	Lange,	
2009).	However,	 just	as	 insufficient	 telomeric	DNA	at	 chromosomal	 termini	 can	promote	dysfunctional	
telomeres,	so	too	can	loss	of	end‐capping	function.	As	stated	previously,	deficiencies	in	this	nucleoprotein	
structure	result	 in	dysfunctional	telomeres	that	may	manifest	as	telomere‐specific	DDRs	known	as	TIFs	
(d'Adda	di	Fagagna	et	 al.,	 2003;	Takai	 et	 al.,	 2003),	 or	 chromosomal	 fusions	 (van	Steensel	 et	 al.,	 1998;	
Counter	et	al.,	1992;	Smogorzewska	et	al.,	2002).	In	addition	to	the	alterations	in	telomeric	chromatin	that	
occur	within	ALT	cells,	and	which	are	discussed	in	the	section	above,	a	number	of	observations	suggest	that	
structural	abnormalities	exist	within	ALT	telomeres.	First	and	foremost,	recent	work	discovered	that	many	
telomeres	in	ALT	cells	spontaneously	elicit	a	DDR	independently	of	telomere	length,	but	retain	the	ability	
to	repress	chromosomal	end‐to‐end	fusions,	indicative	of	a	structural	defect	at	these	telomeres	(Cesare	et	
al.,	2009).	Interestingly,	given	the	fact	that	loss	of	p53	is	required	to	overcome	DNA	damage‐induced	cell	
cycle	arrest	that	initiates	in	response	to	such	telomere	dysfunction	(Chin	et	al.,	1999;	Smogorzewska	and	
de	Lange,	2002),	it	is	perhaps	not	surprising	that	the	majority	of	ALT	cell	lines	and	tumours	lack	functional	
p53	(Cesare	and	Reddel,	2008;	Chen	et	al.,	2006).	TIFs	may	cause	the	chromosome	ends	to	be	identified	as	
double‐strand	 breaks,	 thus	 recruiting	 repair	 proteins	 by	HR.	 It	would	 also	 seem	 likely	 that	 binding	 of	
shelterin	to	the	length	of	the	telomere	would	provide	adequate	telomere	capping	to	prevent	access	by	ALT‐
associated	proteins,	for	instance	proteins	involved	in	HR	and	DNA	repair.	In	accordance	with	this,	TRF2	
and	POT1	have	been	shown	to	exhibit	anti‐recombinogenic	capabilities	within	telomerase‐positive	murine	
cells	 (Palm	et	al.,	2009;	Celli	et	al.,	2006;	Wu	et	al.,	2006;	He	et	al.,	2006).	Also	 the	role	of	TRF2	 in	 the	
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formation	 of	 T‐loops	 and	 four‐strand	 DNA	 junctions,	 in	 addition	 to	 the	 protection	 of	 these	 structures	
against	enzymatic	cleavage,	implicates	TRF2	in	the	regulation	of	telomeric	recombination	by	promoting	T‐
loop	formation	while	preventing	resolution	of	telomeric	recombination	intermediates	(Stansel	et	al.,	2002;	
Fouche	et	al.,	2006;	Poulet	et	al.,	2009).	The	shelterin	complex	could	therefore	potentially	maintain	the	
integrity	 of	 the	 T‐loop,	 preventing	 rolling	 circle	 replication	 and	 the	 formation	 of	 T‐circles	 or	 other	
extrachromosomal	 telomeric	 DNA.	 In	 fact,	 the	majority	 of	 the	 telomere	 in	 ALT	 cells	 is	 commonly	 not	
included	in	the	T‐loop	structure,	leaving	exposed	telomeric	DNA	(Cesare	and	Griffith,	2004),	which	in	turn	
may	serve	as	substrates	for	recombination	if	such	regions	remain	unstabilised	via	inadequate	binding	of	
shelterin.	In	ALT	cells	the	total	quantity	of	telomeric	DNA	is	significantly	increased,	whereas	the	total	levels	
of	 TRF2	 seem	 to	 be	 slightly	 lower	 or	 at	 the	 very	 least	 unchanged	 (Cesare	 et	 al.,	 2009).	 In	 addition,	
overexpression	 of	 TRF2	 is	 able	 to	 suppress	 the	 formation	 of	 TIFs	 (Cesare	 et	 al.,	 2009)	 and	may	 even	
suppress	ALT	activity	itself	(L.	Colgin,	unpublished	results),	suggesting	that	the	structural	defect	results,	at	
least	in	part,	from	a	functional	deficiency	of	shelterin	at	ALT	telomeres	which	is	crucial	for	ALT	activity.		
Additional	evidence	to	suggest	that	structural	abnormalities	exist	within	ALT	telomeres	comes	from	a	study	
of	the	DNA	repeat	composition	of	the	proximal	telomeric	regions	of	ALT	cells	which	identified	large	blocks	
of	uncharacterised	repeats	that	differ	from	the	canonical	TTAGGG	repeat	(Varley	et	al.,	2002).	The	ALT	cell	
line	 AG11395	was	 found	 to	 contain	 extensive	 amounts	 of	 viral	 sequence	within	 its	 telomeres,	 despite	
displaying	 all	 other	 ALT	 phenotypic	 characteristics,	with	 the	 exception	 of	 APBs	 (Fasching	 et	 al.,	 2005;	
Marciniak	et	al.,	2005).	Analysis	of	the	C‐circle	composition	of	ALT	cells	also	revealed	an	average	C‐circle	
level	1.6‐fold	higher	following	the	inclusion	of	dCTP	in	the	assay	(Henson	et	al.,	2009),	 indicative	of	the	
presence	of	significant	amounts	of	variant	or	non‐telomeric	sequence	 in	 the	C‐circles,	which	reflect	 the	
sequence	of	the	ALT	telomeres	from	which	they	were	ultimately	derived.	The	incorporation	of	such	variant	
sequences	into	telomeres	could	alter	the	amount	of	telomere	repeat‐specific	proteins	such	as	shelterin	that	
can	bind	to	the	telomere,	effectively	leading	to	structural	and	consequently	functional	abnormalities	within	
the	telomere.	Some	circumstantial	evidence	for	altered	epigenetic	state	in	ALT	telomeres	was	obtained	via	
a	technique	known	as	proteomics	of	isolated	chromatin	segments	or	PICh	(so	named	due	to	its	ability	to	
use	DNA	to	retrieve	protein	information,	the	so	called	‘opposite’	of	chromatin	immunoprecipitation	(ChIP)),	
in	which	telomeric	DNA	can	be	isolated	using	a	telomere‐specific	probe	and	the	protein	bound	to	a	specific	
segment	 of	 chromatin	 identified	 by	 mass	 spectrometric	 analysis	 (Dejardin	 and	 Kingston,	 2009).	 PICh	
analysis	identified	numerous	chromatin	remodelling	proteins	present	at	the	telomeres	of	ALT	cells	which	
were	undetected	within	telomerase‐positive	cells.	In	a	similar	manner	to	the	results	of	studies	conducted	
in	murine	cells	in	vivo	these	findings	suggest	the	possibility	that	the	chromatin	state	of	ALT	cells	may	be	
different	from	that	of	other	cell	types,	but	this	remains	to	be	tested	definitively.	Hence	chromatin	status	as	
well	 as	 undersaturation	 of	 shelterin	 components	 may	 in	 fact	 share	 a	 dual	 causality	 in	 enhancing	 the	
recombinogenicity	 of	 ALT	 telomeres.	 While	 it	 is	 known	 that	 the	 recruitment	 of	 shelterin	 proteins	 to	
telomeres	is	independent	of	the	presence	of	H3K9me3,	H4K20me3	and	HP1	(Benetti	et	al.,	2007b;	Garcia‐
Cao	et	al.,	2004),	it	may	be	possible	that	an	undersaturation	of	shelterin	components	can	significantly	alter	
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telomeric	chromatin	status,	given	evidence	that	TRF2	may	be	involved	in	telomeric	chromatin	assembly	
(Benetti	et	al.,	2008b),	effectively	enabling	ALT	activation	and/or	facilitating	the	ALT	process.		
It	is	difficult	to	ascertain	how	such	telomeric	structural	abnormalities	originate	and	whether	they	have	a	
causal	 relationship	 to	 the	 ALT	 mechanism	 or	 whether	 ALT	 itself	 causes	 these	 structural	 defects.	 The	
findings	presented	here	have	led	to	speculation	that	accrued	telomere	dysfunction	in	conjunction	with	the	
loss	of	a	tumour	suppressor	function	initially	results	in	rare	stochastic	events	that	cause	recombination‐
mediated	 lengthening	of	a	 telomere.	This	 leads	 to	disparity	between	 the	amount	of	 telomeric	DNA	and	
telomere	binding	proteins	 resulting	 in	 a	 threshold	 being	 crossed	 that	 permits	 further	 dysregulation	 of	
telomeric	recombination,	additional	accumulation	of	telomeric	DNA	and,	ultimately,	fully	established	ALT	
activity	(Cesare	and	Reddel,	2010).	ALT,	like	telomerase,	may	be	an	attractive	target	for	telomere‐directed	
cancer	therapy,	but	due	to	the	DNA	replicative	and	recombinogenic	nature	of	the	ALT	mechanism	(Dunham	
et	 al.,	 2000),	 it	may	 prove	 quite	 challenging	 to	 design	 ALT	 inhibitors	 that	 do	 not	 interfere	with	 these	
intrinsic	cellular	functions.	However,	structural	alterations	in	ALT	telomeres	may	provide	an	opportunity	
for	targeted	therapies,	regardless	of	whether	they	are	causal	or	an	effect	of	the	ALT	mechanism.	It	may	thus	
be	possible	either	to	target	these	alterations	in	telomere	structure	directly,	or	perhaps	restore	the	normal	
cellular	downstream	consequences	of	these	structural	defects	for	therapeutic	benefit.		
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Materials	&	Methods	
		
2.1	Cell	culture	and	synchronisation	
All	cell	 lines	were	cultured	 in	Dulbecco’s	modified	Eagle’s	medium	(DMEM;	GIBCO,	Rockville,	MD,	USA)	
supplemented	with	10%	(v/v)	fetal	bovine	serum	in	a	humidified	incubator	at	37°C	with	5%	CO2.	Cell	lines	
were	 authenticated	 by	 16‐locus	 short	 tandem	 repeat	 (STR)	 profiling	 and	 confirmed	 to	 be	 free	 of	
Mycoplasma	species	by	CellBank	Australia	(CMRI,	Westmead,	NSW,	Australia).	Cell	synchronisation	was	
performed	by	 treating	 cells	with	 low	concentrations	of	 aphidicolin	 (Sigma‐Aldrich;	1	µg/mL),	RO‐3306	
(Merck	Millipore;	9	µM)	and	colcemid	(Life	Technologies;	10	ng/mL)	for	24	hrs	to	establish	G1/S,	G2/M	
and	M	phase	populations,	respectively.		
2.2	Vectors	
Myc‐DDK‐tagged	TR2	 (RC218582),	 TR4	 (RC219184),	 COUP‐TF2	 (RC206753),	 ZNF827	 (RC221405)	 and	
empty	(PS100001)	pCMV6‐Entry	vectors	were	obtained	from	Origene	Technologies.		
2.3	Generation	and	expression	of	wild‐type	and	mutant	hTR	constructs	
The	pBABEpuroU3‐hTR	(Wong	and	Collins,	2006)	and	pApex‐U3‐hTR	(Stern	et	al.,	2012)	plasmids	were	
used	to	overexpress	hTR	encoding	wild‐type	and	variant	telomeric	repeats.	Variant	repeat‐encoding	hTR	
plasmids	were	produced	by	site‐directed	mutagenesis	(Agilent	Technologies).	Specifically,	positions	three	
and	nine	of	 the	 template	region	of	hTR	were	modified	using	 the	 following	 forward	(F)	and	reverse	(R)	
primers	and	mutagenesis	confirmed	by	DNA	sequencing	(Australian	Genome	Research	Facility):	
C‐type	F:	GGCCATTTTTTGTCTGACCCTGACTGAGAAGGGCGTAG;		
C‐type	R:	CTACGCCCTTCTCAGTCAGGGTCAGACAAAAAATGGCC;		
G‐type	F:	GGCCATTTTTTGTCTCACCCTCACTGAGAAGGGCGTAG;		
G‐type	R:	CTACGCCCTTCTCAGTGAGGGTGAGACAAAAAATGGCC	
The	 telomerase‐positive	 human	 fibrosarcoma	 cell	 line	 HT1080	 stably	 overexpressing	 wild‐type	 hTR	
(designated	HT1080	hTR	(Pickett	et	al.,	2009))	was	transfected	at	early	passage	with	either	wild‐type,	C‐	
or	G‐type	pApex‐U3‐hTR	plasmids	using	siPORT	NeoFX	Transfection	Agent	(Ambion).	HT1080‐6TG	cells	
were	 stably	 transfected	 in	 the	 same	 manner	 with	 wild‐type	 pApex‐U3‐hTR.	 These	 cells,	 designated	
HT1080‐6TG	 hTR,	 were	 then	 retrovirally	 transduced	with	 wild‐type,	 C‐	 or	 G‐type	 pBABEpuroU3‐hTR.	
Stable	mass	populations	were	selected	and	maintained	with	0.	4	µg/mL	puromycin	(Sigma‐Aldrich)	and	
150	µg/mL	hygromycin	B	(Roche).		
2.4	Generation	and	expression	of	ZNF827	and	ZNF827	ΔRRK	constructs	
Site‐directed	mutagenesis	(Agilent	Technologies)	was	used	to	mutate	the	N‐terminal	RRK	motif	of	a	Myc‐
DDK‐tagged	 ZNF827	 containing	 plasmid	 (from	 Origene	 Technologies)	 (Figure	 2.1)	 to	 GGA	 using	 the	
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forward	 primer:	 CGCCGCGATCGCCATGCCCGGAGGAGCACAGGAGCAGCCCAAGCGCC	 and	 reverse	 primer:	
GGCGCTTGGGCTGCTCCTGTGCTCCTCCGGGCATGGCGATCGCGGCG.		
Mutagenesis	was	 confirmed	by	 sequencing	 (Australian	Genome	Research	Facility).	 For	 overexpression,	
cells	were	transfected	with	FuGENE	6	Transfection	Reagent	(Promega)	and	harvested	after	48	hrs.		
	
Figure	2.1	–	Plasmid	map	of	ZNF827	construct.	The	plasmid	consists	of	the	ZNF827	cDNA	sequence	with	a	C‐terminal	Myc‐DDK	
tag	under	the	control	of	a	CMV	promoter	with	a	kanamycin/neomycin	resistance	gene	(plasmid	map	from	Origene	Technologies).	
	
2.5	Antibodies	
A	complete	list	of	all	primary	antibodies	used	throughout	this	study	can	be	found	in	Table	2.1.	Fluorophore‐
conjugated	 secondary	 antibodies	 (Life	 Technologies;	 A21202,	 A21206,	 A21203,	 A21207,	 A31571	 and	
A31573)	were	used	 for	 indirect	 immunofluorescence.	Polyclonal	goat	anti‐mouse	and	 rabbit	as	well	as	
rabbit	anti‐goat	immunoglobulin	conjugated	to	horseradish	peroxidase	were	used	for	western	blot	analysis	
(DAKO;	P0447,	P0448	and	P0449).		
2.6	Indirect	immunofluorescence	and	fluorescence	in	situ	hybridisation	(FISH)	
Cell	cultures	were	treated	with	10	ng/mL	colcemid	for	3‐6	hrs	when	required,	harvested	by	trypsinisation,	
resuspended	in	0.	2%	(w/v)	KCl	and	0.	2%	(w/v)	trisodium	citrate	hypotonic	buffer	at	room	temperature	
for	10	min,	and	cytocentrifuged	onto	SuperFrost	Plus	glass	slides	(Menzel‐Glaser)	at	450	g	for	10	min	in	a	
Shandon	 Cytospin	 4	 at	 high	 acceleration.	 Slides	 were	 subjected	 to	 pre‐extraction	 by	 incubation	 in	
permeabilisation	solution	(20	mM	HEPES‐KOH	(pH	7.9),	20	mM	NaCl,	5	mM	MgCl2,	300	mM	sucrose,	0.	5%	
(v/v)	NP‐40)	for	10	min.	For	microscopic	analysis	of	interphase	nuclei,	cells	were	cultured	on	sterile	glass	
coverslips	for	24‐48	hrs,	washed	twice	in	PBS	before	pre‐extraction.	Slides	were	then	washed	in	PBS,	fixed	
at	room	temperature	for	10	min	in	PBS	with	4%	(v/v)	formaldehyde	and	blocked	with	100	µg/mL	DNase‐
free	RNase	A	(Sigma‐Aldrich)	in	antibody	dilution	buffer	(20	mM	Tris‐HCl	(pH	7.5),	2%	(w/v)	BSA,	0.	2%	
(v/v)	fish	gelatin,	150	mM	NaCl,	0.	1%	(v/v)	Triton	X‐100	and	0.	1%	(w/v)	sodium	azide)	for	30	min	at	
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37°C.	Slides	were	incubated	with	primary	antibody	diluted	in	antibody	dilution	buffer	for	1	hr	at	37°C	or	
overnight	at	4°C,	washed	in	PBST	(PBS	with	0.	1%	(v/v)	Tween‐20),	incubated	with	secondary	antibody	
diluted	in	antibody	dilution	buffer	for	30	min	at	37°C,	washed	in	PBST	and	fixed	for	10	min	in	PBS	with	4%	
(v/v)	formaldehyde	at	room	temperature.	To	dehydrate,	slides	were	subjected	to	a	graded	ethanol	series	
(70%	(v/v)	for	3	min,	90%	(v/v)	for	2	min	and	100%	for	2	min)	and	then	allowed	to	air‐dry.	Dehydrated	
slides	were	then	overlaid	with	either	0.	3	µg/mL	Alexa	488–OO‐(CCCTAA)3	or	Texas	Red–OO‐(TTAGGG)3	
telomeric	or	Alexa	488–OO‐(TCAGGG)3	or	(TGAGGG)3	PNA	probes	(Panagene,	Korea)	in	PNA	hybridisation	
solution	(70%	(v/v)	deionised	formamide,	0.	25%	(v/v)	NEN	blocking	reagent	(PerkinElmer),	10	mM	Tris‐
HCl	(pH	7.5),	4	mM	Na2HPO4,	0.	5	mM	citric	acid	and	1.25	mM	MgCl2),	denatured	for	3	min	at	80°C	and	
hybridised	for	2	hrs	at	room	temperature.	Slides	were	washed	in	PNA	wash	A	(70%	(v/v)	formamide	and	
10	mM	Tris‐HCl	(pH	7.5)),	then	in	PNA	wash	B	(50	mM	Tris‐HCl	(pH	7.5),	150	mM	NaCl	and	0.	08%	(v/v)	
Tween‐20)	and	DAPI	at	50	ng/mL	added	to	the	final	wash.	Finally,	slides	were	rinsed	briefly	in	deionised	
water	 and	 mounted	 in	 DABCO	 (2.3%	 (v/v)	 1,4‐diazabicyclo(2.2.	 2)octane	 (Sigma‐Aldrich),	 90%	 (v/v)	
glycerol	and	50	mM	Tris‐HCl	(pH	8.0)).	For	the	ZNF827	overexpression	studies,	only	cells	with	detectable	
Myc‐Tag	signal	were	quantitated.		
2.7	Preparation	of	chromatin	fibres	
Chromatin	 fibres	were	 prepared	 as	 described	 in	 published	 protocols	with	minor	 alterations	 (Sullivan,	
2010).	Briefly,	cells	were	harvested	by	trypsinisation	and	resuspended	in	hypotonic	solution	(25	mM	KCl	
and	0.	27%	(w/v)	trisodium	citrate)	at	a	concentration	of	6.1	×	104/mL	for	5	min	at	room	temperature.	
Cells	 were	 cytocentrifuged	 onto	 SuperFrost	 Plus	 glass	 slides	 (Menzel‐Glaser)	 at	 300	 g	 for	 4	 min	 in	 a	
Shandon	Cytospin	4	at	high	acceleration.	Slides	were	then	immediately	immersed	in	fibre	lysis	buffer	(2.5	
mM	Tris‐HCl	(pH	7.5),	0.	5	NaCl,	1%	(v/v)	Triton	X‐100	and	0.	5	M	urea)	for	16	min,	then	slowly	removed	
at	 a	 steady	 rate	 of	 ~20	 s/slide.	 Fibres	 were	 then	 fixed	 at	 room	 temperature	 in	 PBS	 with	 4%	 (v/v)	
formaldehyde	for	10	min	and	extracted	with	0.	1%	(v/v)	Triton	X‐100	in	PBS	at	room	temperature	for	10	
min.	 RNase	 A	 treatment,	 followed	 by	 indirect	 immunofluorescence	 or	 FISH	 was	 then	 performed	 as	
described	in	the	previous	paragraph.		
2.8	Chromosome	orientation‐FISH	(CO‐FISH)	
Cells	were	cultured	in	fresh	medium	supplemented	with	7.5	µM	BrdU	and	2.5	µM	5‐bromo‐2'‐deoxycytidine	
(BrdC)	(3:1	ratio;	Sigma‐Aldrich)	for	16–24	hrs	depending	upon	the	growth	rate	of	the	cell	line.	Cell	cultures	
were	treated	with	20	ng/mL	colcemid	(Life	Technologies)	for	the	last	4	hrs	of	incubation	to	accumulate	
mitotic	cells.	Chromosome	preparations	were	then	obtained	according	to	standard	cytogenetic	methods	
and	CO‐FISH	conducted	as	described	previously	with	minor	modifications	(Pickett	et	al.,	2009).	Briefly,	
cells	were	harvested	by	trypsinisation	and	incubated	in	hypotonic	buffer	for	no	longer	than	15	min	at	37°C.	
Cells	were	then	fixed	in	3:1	methanol/acetic	acid,	spun	at	300	g	for	8	min	and	washed	3	times	in	fixative.	
Concentrated	cells	in	fixative	were	then	dropped	onto	clean,	dry	microscope	slides,	left	for	~20	sec	then	
held	over	a	water	bath	at	75°C	 for	3	sec	and	 left	 to	dry	overnight.	Slides	were	then	RNase	A	treated	as	
described	above	in	the	section	on	indirect	immunofluorescence	and	FISH,	rinsed	in	PBS	and	subjected	to	a	
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postfix	in	4%	(v/v)	formaldehyde	in	PBS	at	room	temperature	for	10	min.	Slides	were	then	dehydrated	
again	as	described	in	the	section	on	indirect	 immunofluorescence	and	FISH,	then	stained	in	0.	5	µg/mL	
Hoechst	33258	(Sigma‐Aldrich)	in	2	×	SSC	for	15	min	at	room	temperature.	Slides	were	then	flooded	with	
50	µL	2	×	SSC,	 coverslip	 applied	and	exposed	 to	 long	wave	 (~365	nm)	UV	 light	 (Stratalinker	1800	UV	
irradiator)	for	40	min.	The	BrdU/BrdC	substituted	DNA	strands	were	then	digested	in	10	U/µL	Exonuclease	
III	solution	(New	England	Biolabs,	Inc.	)	in	buffer	supplied	by	the	manufacturer	for	15	min	at	37°C.	Slides	
were	then	rinsed	in	PBS	and	subjected	to	another	ethanol	series.	Dehydrated	slides	were	then	overlaid	with	
0.	3	µg/mL	Texas	Red–OO‐(TTAGGG)3	 telomeric	probe	 in	PNA	hybridisation	solution	and	hybridised	at	
room	temperature	for	2	hrs.	Slides	were	then	washed	in	PNA	wash	A	for	15	min	then	overlaid	with	0.	3	
µg/mL	Alexa	488–OO‐(CCCTAA)3	and	hybridised	again	at	room	temperature	for	2	hrs.	Finally,	slides	were	
washed	in	PNA	wash	A	and	B,	stained	with	DAPI	and	mounted	in	DABCO	as	described	in	the	section	on	
indirect	immunofluorescence	and	FISH.	Only	T‐SCE	events	observed	with	both	leading‐	and	lagging‐strand	
probes	simultaneously	were	scored	as	positive.		
2.9	NeoR‐FISH	
HT1080	 hTR	 C‐type	 and	 G‐type	 cells	 at	 approximately	 150	 pds	 post	 expression	 of	 mutant	 hTR	 were	
transfected	with	 linearised	 telomere‐targeting	plasmid,	Tel	 (Dunham	et	al.,	2000),	using	siPORT	NeoFX	
Transfection	Agent	(Ambion).	Approximately	48	hrs	post‐transfection,	cells	were	seeded	at	 low	density	
and	selected	in	500	μg/mL	Geneticin	(G418).	Isolated	clones	were	then	assayed	at	early	(pd	+175)	and	late	
(pd	+210)	 pds	 for	 integration	 of	 the	 telomeric	 plasmid	 sequence	by	neoR‐FISH.	 The	plasmid	backbone	
pSXneo	was	labelled	with	biotin‐16‐dUTP	using	the	Biotin‐Nick	Translation	Mix	(Roche)	according	to	the	
manufacturer’s	instructions.	NeoR‐FISH	was	then	carried	out	as	described	previously	(Dunham	et	al.,	2000;	
Fasching	 et	 al.,	 2005;	 Pickett	 et	 al.,	 2009).	 Briefly,	 chromosomes	were	prepared	 according	 to	 standard	
cytogenetic	methods,	RNase	A	treated,	postfixed	and	dehydrated	with	an	ethanol	series	as	explained	in	the	
previous	section.	Chromosomes	were	then	denatured	in	70%	(v/v)	formamide/2	×	SSC	for	2	min	at	72°C	
and	 subjected	 to	 a	 cold	 ethanol	 dehydration	 series.	 Approximately	 10	 ng/mL	 of	 pSXneo	 probe	 was	
denatured	at	90°C	for	5	min,	added	to	slides	and	hybridised	overnight	in	a	humidified	chamber	at	37°C.	
Slides	were	then	washed	three	times	in	50%	(v/v)	formamide/2	×	SSC	(pH	7.0)	for	5	min	at	42°C	followed	
by	 another	 three	washes	 in	 2	 ×	 SSC	 for	 5	min	 at	 room	 temperature.	 The	 probe	was	 then	 detected	 by	
incubating	slides	with	FITC‐conjugated	avidin	DCS	(Vector	Laboratories,	1:400)	with	3%	(w/v)	skim	milk	
in	4	×	SSC/0.	1%	(v/v)	Tween‐20	for	30	min	in	the	dark	at	37°C.	Slides	were	then	washed	three	times	in	4	
×	SSC/0.	1%	(v/v)	Tween‐20	for	5	min	at	42°C.	Finally,	slides	were	counterstained	with	DAPI	and	mounted	
in	 DABCO	 as	 described	 in	 the	 section	 on	 indirect	 immunofluorescence	 and	 FISH.	 We	 analysed	 ~100	
metaphases	for	each	clone.	Individual	chromosome	ends	were	scored	as	positive	for	the	neoR	signal	if	a	
signal	could	be	detected	on	both	sister	chromatids	of	the	respective	chromosome	in	multiple	metaphases.		
2.10	BrdU	pulse	experiment	
Fresh	medium	supplemented	with	100	μM	BrdU	(Sigma‐Aldrich)	was	added	to	transfected	cells	8	hrs	prior	
to	harvest.	Slides	were	denatured	in	70%	(v/v)	formamide	in	2	×	SSC	at	72°C	for	2	min	then	dehydrated	in	
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a	graded	ice‐cold	ethanol	series	(70%	(v/v)	for	3	min,	90%	(v/v)	for	2	min	and	100%	for	2	min)	and	indirect	
immunofluorescence	and	telomere‐FISH	performed	as	described	above.		
2.11	Imaging	
All	 cells	were	 visualised	 using	 a	 Zeiss	 Axio‐Imager	M1	microscope	 at	 room	 temperature,	with	 a	 Plan‐
Apochromat	×63	or	×100	objective	(numerical	aperture,	1.4)	and	an	AxioCam	MRm	digital	camera	(Carl	
Zeiss).	Metaphase	cells	were	imaged	in	12	Z	planes	with	0.	3	µm	increments	for	the	green	and	red	filters	
and	as	a	single	focal	plane	in	the	blue	filter,	and	then	merged	using	the	extended‐focus	setting	(Metafer4	
software,	MetaSystems).	Images	of	metaphase	spreads	were	also	analysed	with	Isis	software.		
2.12	Next	generation	sequencing	and	bioinformatics	
DNA	was	extracted	from	WI38‐VA13/2RA	and	HeLa	cell	lines	and	underwent	indexed	library	construction.	
Briefly,	 the	genome	was	 fragmented	by	sonication	and	 the	 fragment	ends	were	phosphorylated	and	A‐
tailed.	Indexed	forked	adapters	were	then	ligated,	and	the	resultant	libraries	were	amplified	and	applied	
to	 a	 lane	of	 an	 Illumina	HiSeq.	Results	were	 aligned	 to	 the	 genome	using	Burrows‐Wheeler	Alignment	
(BWA)	 tool	 (Li	 and	Durbin,	2009).	The	 telomeric	 subset	of	 reads	were	extracted	using	a	 custom	script	
(motif_counter)	 incorporating	 functions	 from	 SAMtools	 (Li	 et	 al.,	 2009)	 and	 standard	 Linux	 pattern‐
matching	programs	(http://sourceforge.	net/projects/motifcounter/)		
2.13	RNA	interference	
The	 following	 Stealth	 RNAiTM	 siRNA	 were	 designed	 and	 synthesised	 by	 Life	 Technologies:	 TR2,	
GGCATGGAAGGAAGTGTACACCTAA;	 TR4,	 TGTCTATCCCATCTGCCAAGCTTGG;	 COUP‐TF2,	
AAAGCTTTCCGAATCTCGTCGGCTG;	 ZNF827,	 GGGCAGTCTTCTGGCTGAGAAATCA	 and	 the	 Stealth	 RNAiTM	
siRNA	Negative	Control	Med	GC	Duplex	#2	(12935‐112).	Cells	were	seeded	at	5.0	×	105/T‐75	flask	and	
reverse	transfected	using	Lipofectamine	RNAiMAX	(Life	Technologies)	with	an	siRNA	concentration	of	20	
µM	as	per	the	manufacturer’s	instructions	and	harvested	for	telomere‐ChIP,	western	blot,	real‐time	RT‐
PCR,	C‐circle	assay	and	microscopic	analysis	72	hrs	post‐transfection.		
2.14	Electrophoretic	mobility	shift	assay	(EMSA)	
The	 G‐strand	 consensus	 telomeric	 (5'‐ACATGTTAGGGTTAGGGTTAGGGTTAG‐3'),	 C‐type	 (5'‐
ACATGTCAGGGTCAGGGTCAGGGTCAG‐3')	 and	 G‐type	 (5'‐ACATGTGAGGGTGAGGGTGAGGGTGAG‐3')	
sequences	 and	 their	 respective	 complementary	 C‐strands	 were	 used	 to	 form	 a	 double‐stranded	
oligonucleotide.	G‐strands	were	 labelled	 at	 the	 5'	 end	with	 [γ‐32P]‐ATP	using	T4	polynucleotide	kinase	
(Promega).	Double‐stranded	probes	were	assembled	by	the	addition	of	labelled	G‐strand	and	unlabelled	C‐
strand	(200	nM)	in	TEN	buffer	(20	mM	Tris‐HCl	(pH	7.5),	1	mM	EDTA,	250	mM	NaCl),	followed	by	heating	
at	90°C	for	3	min	and	slowly	cooling	for	1	hr	at	room	temperature.	EMSA	reactions	were	performed	in	13%	
(v/v)	glycerol,	10	mM	HEPES‐KOH	(pH	8.0),	100	mM	KCl,	0.	5	mM	EDTA,	10	mM	MgCl2,	100	μg/mL	BSA,	1	
mM	dithiothreitol	(DTT),	0.	004%	(w/v)	xylene	cyanol	incubated	with	either	purified	human	TR4	or	TRF2	
(Origene	Technologies).	Increasing	concentrations	of	TR4	(0,	50,	100,	200,	300	nM)	and	TRF2	(0,	100,	200,	
400,	600	nM)	were	added	to	the	double‐stranded	substrate	and	incubated	at	room	temperature	for	30	min.	
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The	5%	(v/v)	native	polyacrylamide	gel	(using	1.5	mm	spacers)	was	run	in	0.	5	×	Tris‐borate‐EDTA	(TBE)	
at	200	V	for	1	hr	at	4°C.	The	gel	was	dried	on	Whatman	paper	under	vacuum	at	70°C	for	1	hr,	visualised	by	
a	phosphorimager	 (Typhoon)	and	analysed	using	 ImageQuant	TL	software	 (Molecular	Dynamics).	DNA	
probes	 containing	 less	 than	 four	 telomeric	 repeats	were	 used	 for	 the	 EMSA	 experiments	 due	 to	 their	
inability	to	form	G‐quadruplexes.		
2.15	Western	blotting	
Cells	were	harvested	via	trypsinisation,	washed	in	PBS	and	resuspended	in	ice‐cold	RIPA	buffer	(50	mM	
Tris‐HCl	(pH	8.0),	150	mM	NaCl,	1%	(v/v)	NP‐40,	0.	5%	(w/v)	Na‐deoxycholate,	0.	1%	(w/v)	SDS,	1	mM	
EDTA,	1	×	complete	protease	inhibitor	(CPI),	1	mM	phenylmethylsulfonyl	fluoride	(PMSF))	at	100	μL	per	
106	cells,	rocking	on	ice	for	30	min.	Cell	lysates	were	then	centrifuged	at	14,000	g	for	15	min	at	4°C	and	the	
supernatant	removed	immediately.	Samples	were	prepared	and	run	on	NuPAGE®	Novex®	Bis‐Tris	Mini	
Gels	(Life	Technologies)	according	to	 the	manufacturer’s	 instructions.	The	membrane	was	stained	with	
Ponceau‐S	for	5	min,	blocked	for	1	hr	at	room	temperature	in	PBST	containing	5%	(w/v)	skim	milk.	The	
membrane	was	then	incubated	with	primary	antibody	containing	0.	5%	(w/v)	skim	milk	in	PBST	overnight	
at	4°C.	The	membrane	was	washed	 in	PBST	 followed	by	 incubation	 for	1	hr	at	 room	temperature	with	
secondary	antibody	(DAKO)	diluted	1:1,000	in	PBST.	The	membrane	was	rinsed	with	PBS	before	incubation	
with	SuperSignal®	West	Pico	Chemiluminescent	Substrate	(Thermo	Fisher	Scientific)	for	5	min	at	room	
temperature.	 The	 blot	 was	 then	 exposed	 to	 a	 LAS‐4000	 Luminescent	 Image	 Analyser	 (FujiFilm)	 and	
quantitated	using	Multigauge	software.		
2.16	Genomic	DNA	extraction	
Cells	were	harvested	via	trypsinisation,	washed	in	PBS	and	resuspended	in	lysis	solution	(100	mM	Tris‐HCl	
(pH	7.5),	10	mM	EDTA,	100	mM	NaCl	and	1%	(w/v)	N‐lauroylsarcosine).	Lysates	were	then	subjected	to	
RNase	A	(50	µg/mL)	treatment	for	20	min	at	room	temperature	followed	by	Proteinase	K	(100	µg/mL)	
treatment	for	6	hrs	at	55°C.	DNA	was	extracted	using	equal	volumes	of	phenol/chloroform/isoamyl	alcohol	
(25:24:1)	and	the	resulting	phases	separated	by	centrifugation	at	500	g	for	10	min	at	room	temperature	
using	Phase	Lock	GelTM	Light	tubes	(5	PRIME).	The	aqueous	layer	was	discarded	and	the	DNA	was	ethanol	
precipitated	(0.	1	volume	sodium	acetate	and	2.5	volumes	100%	ethanol)	and	resuspended	in	TE	(10	mM	
Tris‐HCl	(pH	8.0)	and	1	mM	EDTA).		
2.17	Terminal	restriction	fragment	(TRF)	analysis	
Telomeric	restriction	fragments	were	prepared	by	HinfI	and	RsaI	digestion	of	genomic	DNA	and	separated	
by	pulsed‐field	gel	electrophoresis	as	described	previously	with	some	alterations	(Perrem	et	al.,	1999).	
Briefly,	genomic	DNA	was	prepared	via	phenol/chloroform	extraction	described	in	the	previous	paragraph	
and	digested	with	4	U/µg	HinfI	and	RsaI	overnight	at	37°C.	The	DNA	was	then	ethanol	precipitated	and	1	
µg	loaded	on	a	1%	(w/v)	agarose	gel	in	0.	5	×	TBE.	Pulsed‐field	gels	were	run	at	6	V	for	14	hrs	at	14°C	with	
an	initial	switch	time	of	1	and	a	final	switch	time	of	6.	The	gels	were	dried	for	2	hrs	at	60°C,	denatured	in	0.	
5	M	NaOH/1.5	M	NaCl	for	1	hr	and	neutralised	in	0.	5	M	Tris‐HCl	(pH	8.0)/1.5	M	NaCl	for	1	hr.	Gels	were	
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then	rinsed	in	2	×	SSC	and	pre‐hybridised	in	Church	buffer	(250	mM	sodium	phosphate	buffer	(pH	7.2),	7%	
(w/v)	SDS,	1%	(w/v)	BSA	fraction	V	grade	and	1	mM	EDTA)	for	2	hrs	at	37°C.	Finally,	gels	were	hybridised	
overnight	with	a	[γ‐32P]‐ATP‐labelled	(CCCTAA)3,	(CCCTGA)3	or	(CCCTCA)3	oligonucleotide	probe	specific	
to	one	of	the	three	telomeric	repeat	types,	washed	three	times	in	0.	1	×	SSC	for	15	min	at	37°C	and	exposed	
to	a	PhosphorImager	screen	overnight.		
2.18	C‐circle	assay	
The	 C‐circle	 assay	 was	 conducted	 using	 20	 ng	 of	 genomic	 DNA	 as	 described	 previously	 with	 some	
modifications	 (Henson	 et	 al.,	 2009).	 Genomic	 DNA	was	 prepared	 via	 phenol/chloroform	 extraction	 as	
described	in	the	Genomic	DNA	extraction	section	and	resuspended	in	TE.	For	the	C‐circle	reaction,	10	μL	of	
DNA	was	added	to	10	μL	200	μg/mL	BSA,	0.	1%	(v/v)	Tween‐20,	1	mM	each	dNTP,	1×	Φ29	buffer	(New	
England	Biolabs,	Inc.)	and	7.5	U	Φ29	DNA	polymerase	(New	England	Biolabs,	Inc.)	and	incubated	for	8	hrs	
at	30°C,	then	for	20	min	at	65°C.	The	reaction	products	were	then	dot	blotted	onto	a	2	×	SSC‐soaked	Biodyne	
B	0.	45	µm	nylon	membrane	(Pall).	The	DNA	was	then	UV‐cross‐linked	onto	the	membrane	(~254	nm)	and	
pre‐hybridised	in	PerfectHyb	Plus	hybridisation	buffer	(Sigma‐Aldrich)	for	1	hr	at	37°C.	The	signal	was	
then	detected	by	hybridisation	with	end‐labelled	γ32P‐(CCCTAA)3	overnight	at	37°C.	The	membrane	was	
then	washed	three	times	 in	2	×	SSC	for	20	min	shaking	at	room	temperature.	The	membrane	was	then	
exposed	 to	 a	 PhosphorImager	 screen	 for	 8	 hrs	 and	 scanned	 on	 a	 Typhoon	 imager	 with	 ImageQuant	
software	(Molecular	Dynamics),	using	edge	subtraction	for	background	correction.		
2.19	Telomere	dot	blot		
The	analysis	of	total	telomeric	DNA	content	was	performed	by	adding	400	ng	of	genomic	DNA	digested	
with	HinfI	and	RsaI	to	a	dot	blot	as	described	in	the	previous	paragraph	with	the	C‐circle	assay.		
2.20	Telomere‐ChIP	
Subconfluent	cells	were	harvested	by	trypsinisation,	washed	in	PBS	and	1	×	107	cells	resuspended	in	1	mL	
cell	lysis	buffer	(5	mM	HEPES‐KOH	(pH	8.0),	85	mM	KCl,	0.	4%	(v/v)	NP‐40,	1	×	CPI,	1	mM	PMSF).	Cells	
were	incubated	on	ice	for	10	min	and	centrifuged	at	6,000	g	for	15	sec	at	4°C	to	pellet	nuclei.	After	removal	
of	the	supernatant,	nuclei	were	fixed	in	the	same	volume	of	cell	lysis	buffer	lacking	NP‐40	containing	1%	
(v/v)	formaldehyde	at	room	temperature.	Fixed	nuclei	were	incubated	at	room	temperature	for	10	min	
while	mixing	once	by	inversion	during	fixation.	Crosslinking	was	quenched	by	adding	75	μL	of	1.5	M	glycine	
and	 incubating	 for	 5	 min	 at	 room	 temperature,	 inverting	 twice	 during	 incubation.	 The	 mixture	 was	
centrifuged	again	at	6,000	g	for	15	sec	at	4°C	and	the	supernatant	discarded.	To	the	nuclei,	50	μL	of	nuclei	
lysis	buffer	(50	mM	Tris‐HCl	(pH	8.0),	1	mM	EDTA,	1%	(v/v)	SDS,	1	×	CPI,	1	mM	PMSF)	was	added	and	
incubated	for	10	min	on	ice.	The	sample	was	then	diluted	by	the	addition	750	μL	of	ice	cold	buffer	A	(20	
mM	HEPES‐KOH	(pH	8.0),	2	mM	MgCl2,	300	mM	KCl,	1	mM	EDTA,	10%	(v/v)	glycerol,	0.	1%	(v/v)	Triton	X‐
100).	Chromatin	was	fragmented	using	a	Bioruptor®	Twin	Sonication	Device	(Diagenode	Inc.,	Denville,	NJ,	
USA)	for	8	×	60	sec	pulse	on	high	setting	with	a	60	sec	pause,	and	centrifuged	at	17,000	g	for	10	min	at	4°C	
to	 remove	 the	 solubilised	 chromatin	 within	 the	 supernatant.	 For	 the	 immunoprecipitation,	 112	 μL	 of	
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chromatin	was	added	to	225	μL	of	ice	cold	IP	buffer	(20	mM	HEPES‐KOH	(pH	8.0),	150	mM	KCl,	1.5	mM	
EDTA,	1%	(v/v)	Triton	X‐100,	1	×	CPI,	1	mM	PMSF)	on	ice	and	antibody	(5‐10	μg/IP)	added	as	required.	
After	1	hr	of	rotation	at	4°C,	60	μL	BSA	(nuclease‐free)‐blocked	protein	G‐agarose	beads	(Roche,	11	243	
233	001)	(Cohen	and	Reddel,	2008)	were	added	and	samples	were	rotated	at	4°C	overnight.		
The	 following	 day,	 beads	were	 collected	 via	 centrifugation	 of	 samples	 for	 30	 sec	 at	 17,000	g	 at	 room	
temperature	and	removal	of	supernatant,	washed	twice	with	1	mL	of	room	temperature	buffer	A,	followed	
by	1	mL	of	TE	(10	mM	Tris‐HCl,	1	mM	EDTA	(pH	8.0))	and	centrifuged	 for	30	sec	at	17,000	g	at	room	
temperature.	Immunoprecipitated	DNA	was	eluted	from	the	protein	G‐agarose	beads	by	digestion	with	200	
µg	of	proteinase	K	(Roche)	in	100	µL	of	elution	buffer	(50	mM	NaHCO3,	1%	(v/v)	SDS),	incubated	at	45°C	
for	1	hr	and	purified	using	a	QIAquick	PCR	Purification	Kit	 (Qiagen;	28106),	eluting	 in	140	µL	TE.	The	
purified	DNA	(70	µL)	was	added	to	490	µL	of	0.	46	M	NaOH,	heated	at	95°C	for	5	min	and	cooled	on	ice	
before	dot	blotting	onto	Hybond	XL	(GE	Healthcare	Life	Sciences)	according	to	the	manufacturer’s	protocol.	
Membranes	were	air‐dried	for	5	min	and	cross‐linked	with	240	mJ	using	a	Stratalinker	at	254	nm	followed	
by	pre‐hybridisation	in	Church	hybridisation	buffer	(1%	(w/v)	BSA	fraction	V	grade,	1	mM	EDTA,	500	mM	
NaHPO4,	pH	7.2,	7%	(v/v)	SDS)	for	30	min	at	60°C,	then	hybridised	overnight	with	a	DNA	oligonucleotide	
probe	5’‐(CCCTAA)3‐3'	end	labelled	with	[γ‐32P]‐ATP	using	T4	polynucleotide	kinase	(Promega).	A	separate	
blot	was	probed	for	ALU	sequence	(gift	from	T.	de	Lange,	Rockefeller	University,	NY,	USA)	[α‐32P]‐labelled	
using	 the	 DECAprimeTM	 II	 Random	 Primed	 DNA	 Labeling	 Kit	 (Ambion;	 AM1455)	 according	 to	 the	
manufacturer’s	 instructions.	Membranes	were	washed	3	 times	 for	10	min	 in	2	×	SSC	and	exposed	 to	a	
phosphorscreen	followed	by	imaging	and	quantification	of	signal	using	the	array	analysis	function	on	the	
ImageQuant	software	(GE	Healthcare	Life	Sciences),	using	unused	wells	for	background	subtraction.	The	
amount	of	telomeric	DNA	immunoprecipitated	was	normalised	for	each	sample	based	on	the	amount	of	
input	 telomeric	 DNA	 determined	 by	 signal	 intensity	 from	 standard	 curves	 for	 each	 sample.	 All	 ChIP	
experiments	were	carried	out	in	biological	duplicates.		
2.21	Co‐immunoprecipitation	(Co‐IP)	
Nuclear	 extracts	 were	 prepared	 from	 WI38‐VA13/2RA	 cells	 48	 hrs	 after	 ZNF827	 overexpression	 by	
incubating	cells	in	lysis	buffer	(50	mM	Tris‐HCl	(pH	8.0),	150	mM	NaCl,	0.	5%	(v/v)	NP‐40,	1	×	CPI,	1	mM	
PMSF)	rotating	for	30	min	at	4°C.	Lysates	were	subjected	to	centrifugation	at	14,000	g	for	15	min	at	4°C.	
For	the	IP,	400	µg	of	protein	lysate	was	incubated	with	the	appropriate	antibodies	(5‐10	µg)	and	IgG	control	
rotating	overnight	at	4°C.	Then,	50	µL	of	pre‐washed	50%	(v/v)	protein	G‐agarose	beads	(Roche,	11	243	
233	001)	were	added	with	continued	rotation	for	an	additional	3	hrs	at	4°C.	Beads	were	washed	4	times	
with	lysis	buffer	and	centrifuged	at	6,000	g	for	1	min	at	4°C.	Proteins	were	then	eluted	from	the	beads	by	
resuspending	 in	 SDS	 sample	 buffer	 (0.	 2	 M	 Tris‐HCl	 (pH	 6.8),	 28%	 (v/v)	 glycerol,	 13.5%	 (v/v)	 β‐
mercaptoethanol,	6%	(v/v)	SDS,	6	mM	EGTA,	0.	07%	(w/v)	bromophenol	blue)	for	5‐10	min	at	100°C	and	
subjected	to	western	blot	analysis	as	described	previously	(Conomos	et	al.,	2012)	to	detect	various	protein	
interactions.		
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2.22	Real	time	RT‐PCR	
Knockdown	 of	 ZNF827	 was	 verified	 72	 hrs	 post‐transfection	 with	 siRNA	 using	 real	 time	 RT‐PCR	 as	
described	 previously	 (Pickett	 et	 al.,	 2009).	 Briefly,	 total	 RNA	was	 extracted	 using	 the	RNeasy	Mini	 Kit	
(Qiagen),	digested	with	DNase	I	(Invitrogen)	and	quantified	by	spectrophotometry.	cDNA	synthesis	was	
performed	by	random	priming	using	SuperScript	III	reverse	transcriptase	(Invitrogen).	PCR	reactions	for	
ZNF827	and	GAPDH	were	conducted	using	the	following	forward	(F)	and	reverse	(R)	primers:	ZNF827	F:	
TATTATTACTCCCAGTTCCT,	ZNF827	R:	AAACCACATATTGGACACTG,	GAPDH	F:	ACCCACTCCTCCACCTTTG,	
GAPDH	R:	 CTCTTGTGCTCTTGCTGGG	with	 SYBR	Green	 PCR	Master	Mix	 (Roche).	 Reverse	 transcriptase	
negative	controls	were	included.	PCR	conditions	were	95°C	for	10	min	and	40	cycles	of	95°C	for	15	sec,	
60°C	for	20	sec	and	72°C	for	30	sec,	followed	by	melt	curve	analysis.	Primer	PCR	efficiencies	were	calculated	
by	standard	curve,	and	analysis	was	 carried	out	by	 the	comparative	cycle	 threshold	 (Ct)	method	using	
GAPDH	as	the	reference	gene	and	expressed	as	fold	change	relative	to	the	appropriate	control.		
2.23	Flow	cytometry	
Cell	cycle	analysis	using	 flow	cytometry	was	performed	as	described	previously	with	minor	alterations	
(Smyth	et	al.,	1993).	Ethanol	fixed	single	cell	suspensions	were	stained	for	DNA	analysis	by	adding	0.	5	mg	
RNAse	and	25	µg	propidium	iodide	to	1	×	106	cells	resuspended	in	0.	2	mL	PBS.	After	a	30	min	incubation	
at	37°C,	stained	specimens	were	incubated	at	room	temperature	in	the	dark	for	10	min.	Labelled	cells	were	
analysed	by	BD	FACSCanto	Flow	Cytometer	(BD	Biosciences)	containing	a	blue	air	cooled	488	nm	argon	
laser	to	excite	propidium	iodide.	Exactly	10,000	events	were	collected	at	an	approximate	flow	rate	of	200	
events/sec.	The	 forward	scatter	 (FSC,	 size)	and	side	scatter	 (SSC,	 internal	granularity)	of	each	cell	was	
recorded.	 To	 discriminate	 and	 eliminate	 cell	 debris	 and	 doublets,	 the	 pulse	 area	 (FL2‐A)	 was	 plotted	
against	the	pulse	width	(FL2‐W).	Doublets	identified	as	cells	with	4N	DNA	content	and	increasing	pulse	
width	were	eliminated.	A	histogram	displaying	the	cell	counts	against	the	FL2‐A	was	used	to	calculate	the	
percentage	of	cells	in	each	cell	cycle	phase.	Data	analysis	was	conducted	using	BD	FACS	Diva	software	(BD	
Bioscience).		
2.24	TERRA	analysis	
Total	RNA	was	extracted	using	the	RNeasy	Mini	Kit	(Qiagen)	and	digested	with	DNase	I.	Dot	blots	were	
loaded	with	2	µg	RNA	and	hybridised	overnight	with	a	DNA	oligonucleotide	probe	5'‐(CCCTAA)3‐3'	end	
labelled	with	[γ‐32P]‐ATP.		
2.25	β‐galactosidase	and	trypan	blue	staining	
Staining	 for	 senescence‐associated	 β‐galactosidase	 activity	 was	 conducted	 at	 pH	 6.0	 according	 to	 the	
manufacturer’s	instructions	(Cell	Signaling	Technology;	9860).	Cell	viability	was	assessed	by	trypan	blue	
(Sigma‐Aldrich;	T8154)	staining	according	to	standard	dye	exclusion	methods.		
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2.26	Statistical	analyses	
Microsoft	Excel	and	GraphPad	Prism	4	were	used	to	generate	graphs	and	perform	statistical	analysis	by	
calculating	P	values	using	unpaired	Student’s	two‐tailed	t‐tests,	one‐way	ANOVA	tests	or	two‐tailed	Mann‐
Whitney	tests.		
	
Table	2.1	–	Primary	antibodies	used	in	this	study	
	
*	Antibodies	used	for	a	particular	application	are	highlighted	in	blue.	
WB IF Co‐IP ChIP
Shelterin
TRF1 TERF1;	Telomeric	repeat	binding	factor	1 Abcam ab1423 55.5 Mouse
TRF2 TERF2;	Telomeric	repeat	binding	factor	2 Novus	Biologicals NB110‐57130 55.5 Rabbit
RAP1 TERF2IP;	Telomeric	repeat	binding	factor	2‐interacting	protein	1 Novus	Biologicals NB100‐292 44 Rabbit
Nuclear	receptors
TR2 NR2C1;	Testicular	receptor	2 R	&	D	Systems PP‐H0037‐00 67 Mouse
TR2 NR2C1;	Testicular	receptor	2 Santa	Cruz	Biotechnology sc‐365729 67 Mouse
TR4 NR2C2;	Testicular	receptor	4 R	&	D	Systems PP‐H0107B‐00 65 Mouse
COUP‐TF1 NR2F1;	Chicken	ovalbumin	upstream‐promoter	transcription	factor	1 R	&	D	Systems PP‐H8132H 46 Mouse
COUP‐TF2 NR2F2;	Chicken	ovalbumin	upstream‐promoter	transcription	factor	2 R	&	D	Systems PP‐H7147‐00 45.5 Mouse
EAR‐2 NR2F6;	V‐erbA‐related	protein	2 R	&	D	Systems PP‐N2025‐00 43 Mouse
NuRD
p66	alpha p66α;	GATAD2A Novus	Biologicals NBP1‐87359 68 Rabbit
p66	beta p66β;	GATAD2B Novus	Biologicals NBP1‐87358 65 Rabbit
RBBP7 RBAP46 Cell	Signaling	Technology 6882 48 Rabbit
RBBP7 RBAP46 Novus	Biologicals NB120‐3535 48 Rabbit
MTA1 Metastasis‐associated	gene	1 Cell	Signaling	Technology 5647 81 Rabbit
MTA1 Metastasis‐associated	gene	1 Abcam ab71153 81 Rabbit
MTA2 Metastasis‐associated	gene	2 Abcam ab8106 75 Rabbit
MTA3 Metastasis‐associated	gene	3 Novus	Biologicals NB100‐2306 67.5 Rabbit
CHD3 Mi‐2a;	Mi‐2α;	Mi2‐alpha Cell	Signaling	Technology 4241 226.5 Rabbit
CHD4 Mi‐2b;	Mi‐2β;	Mi2‐beta Novus	Biologicals NB100‐57521 218 Rabbit
HDAC1 Histone	deacetylase	1 Cell	Signaling	Technology 5356 62 Mouse
HDAC1 Histone	deacetylase	1 Abcam ab19845 62 Rabbit
HDAC2 Histone	deacetylase	2 Cell	Signaling	Technology 5113 60 Mouse
HDAC2 Histone	deacetylase	2 Santa	Cruz	Biotechnology sc‐7899 60 Rabbit
LSD1 Lysine‐specific	demethylase	1;	KDM1 Abcam ab17721 93 Rabbit
LSD1 Lysine‐specific	demethylase	1;	KDM1 Cell	Signaling	Technology 2139 93 Rabbit
CoREST RCOR1;	REST	corepressor	1 Abcam ab32631 53 Rabbit
Histones
H3 Histone	H3 Cell	Signaling	Technology 4620 15 Rabbit
H4 Histone	H4 Cell	Signaling	Technology 2960 11 Mouse
Histone	modifications
H3K9me3 Trimethylation	of	H3	at	K9 Abcam ab8898 15 Rabbit
H4K20me3 Trimethylation	of	H4	at	K20 Abcam ab9053 11 Rabbit
H3K4me2 Dimethylation	of	H3	at	K4 Cell	Signaling	Technology 9726 15 Rabbit
Pan	acetyl	H4 Acetylation	of	Histone	H4 Merk	Millipore 06‐866 11 Rabbit
Acetyl	H4K5 Acetylation	of	Histone	H4 Cell	Signaling	Technology 9672 11 Rabbit
Acetyl	H4K8 Acetylation	of	Histone	H4 Cell	Signaling	Technology 2594 11 Rabbit
Acetyl	H4K12 Acetylation	of	Histone	H4 Cell	Signaling	Technology 2591 11 Rabbit
Acetyl	H4K16 Acetylation	of	Histone	H4 Cell	Signaling	Technology 8804 11 Rabbit
γ‐H2AX H2A.X	phophorylated	at	Serine	139 Biolegend 613401 15 Mouse
γ‐H2AX H2A.X	phophorylated	at	Serine	139 Cell	Signaling	Technology 9718 15 Rabbit
γ‐H2AX H2A.X	phophorylated	at	Serine	139 Merk	Millipore 05‐636 15 Mouse
γ‐H2AX H2A.X	phophorylated	at	Serine	139 Abcam ab2893 15 Rabbit
Cell	cycle	markers
CDT1 DNA	replication	factor	CDT1 Cell	Signaling	Technology 8064 65 Rabbit
Geminin GMNN Cell	Signaling	Technology 5165 25 Rabbit
Geminin GMNN Abcam ab12147 25 Rabbit
CENP‐F Centromere	protein	F;	Mitosin Cell	Signaling	Technology ab90 368 Mouse
Phospho‐H3 H3	phosphorylated	at	Serine	10 Cell	Signaling	Technology 3377 17 Rabbit
IgG
Ms	IgG Normal	Mouse	IgG Merk	Millipore 12‐371 ‐ Mouse
Rb	IgG Normal	Rabbit	IgG Cell	Signaling	Technology 2729 ‐ Rabbit
Myc‐Tag
Ms	Myc‐Tag ‐ Cell	Signaling	Technology 2276 ‐ Mouse
Rb	Myc‐Tag ‐ Cell	Signaling	Technology 2278 ‐ Rabbit
BrdU
BrdU 5‐bromo‐2'‐deoxyuridine Cell	Signaling	Technology 5292 ‐ Mouse
Other	proteins
BRCA1 Breast	cancer	type	1	susceptibility	protein Cell	Signaling	Technology 9010 220 Rabbit
BRIT1 Microcephaly	primary	type	1;	MCPH1 Abcam ab121277 93 Rabbit
Cleaved	Caspase‐3 Activated	Caspase‐3	cleaved	adjacent	to	Aspartic	acid	175 Cell	Signaling	Technology 9664 17/19 Rabbit
PML Promyelocytic	leukemia	protein Santa	Cruz	Biotechnology sc‐966 97.5 Mouse
PML Promyelocytic	leukemia	protein Santa	Cruz	Biotechnology sc‐5621 97.5 Rabbit
Actin ‐ Sigma‐Aldrich A	2066 42 Rabbit
ZNF827 CDNA	FLJ33811	fis,	clone	CTONG2002095 Santa	Cruz	Biotechnology sc‐249818 119 Goat
ApplicationsName Alternate	names Company MW	(kDa) HostCat.	No.
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Results	I		
		
3.1	Introduction	
Note,	this	chapter	relates	to	a	previous	manuscript	entitled	“Variant	repeats	are	interspersed	throughout	
the	telomeres	and	recruit	nuclear	receptors	in	ALT	cells”	published	in	the	Journal	of	Cell	Biology	(Conomos	
et	al.,	2012)	All	figures	and	supplementary	data	have	subsequently	been	reformatted	to	follow	University	
of	Sydney	thesis	guidelines.		
The	most	proximal	2	kb	region	of	human	telomeres	contains	a	non‐random	distribution	of	variant	 (for	
example	TCAGGG,	TGAGGG,	TTGGGG)	and	canonical	repeats	which	are	in	linkage	disequilibrium	and	have	
evolved	along	haploid	lineages,	whilst	the	distal	ends	comprise	homogeneous	arrays	of	TTAGGG	sequence	
(Allshire	et	al.,	1989;	Baird	et	al.,	1995;	Coleman	et	al.,	1999;	Baird	et	al.,	2000).	To	date	little	is	known	
regarding	 the	 identity,	 abundance	 and	 distribution	 of	 variant	 repeats	 throughout	 the	 telomere.	
Presumably,	however,	this	would	vary	considerably	depending	upon	the	cell	type	or	chromosome	analysed.		
Many	telomeres	in	ALT	cells	elicit	a	DDR	that	is	partly	independent	of	telomere	length	and	occurs	in	the	
absence	of	chromosomal	end‐to‐end	fusions	(Cesare	et	al.,	2009),	suggesting	the	existence	of	underlying	
telomeric	structural	defects.	Here	we	investigated	telomeric	structural	abnormalities	associated	with	the	
ALT	 mechanism.	 We	 show	 for	 the	 first	 time	 that	 variant	 repeats	 are	 interspersed	 throughout	 ALT	
telomeres.	The	presence	of	variant	repeats	leads	to	the	ALT‐specific	telomeric	recruitment	of	a	group	of	
nuclear	 receptors	 and	 may	 also	 contribute	 to	 shelterin	 undersaturation.	 While	 nuclear	 receptors	 are	
capable	of	binding	directly	to	the	canonical	telomere	repeat	in	vitro,	we	show	that	the	nuclear	receptor	TR4	
holds	a	greater	affinity	than	the	shelterin	component	TRF2	for	the	most	common	variant	telomeric	repeat.	
In	ALT	cells	nuclear	receptors	bind	along	 the	entirety	of	 the	 telomere	array,	and	are	not	 limited	 to	 the	
proximal	 regions.	 Finally,	 we	 demonstrate	 that	 incorporation	 of	 variant	 repeats	 into	 the	 telomeres	 of	
telomerase‐positive	 cells	 results	 in	 the	 recruitment	 of	 nuclear	 receptors	 to	 telomeres,	 as	 well	 as	 the	
induction	 of	 numerous	 ALT‐associated	 phenotypic	 characteristics.	 Therefore,	 we	 propose	 that	 the	
presence	of	 variant	 sequences	 in	ALT	 telomeres	 and	 the	 consequent	binding	of	 nuclear	 receptors	may	
destabilise	the	telomere	architecture	through	competitive	inhibition	of	shelterin	binding	and	facilitation	of	
telomeric	recombination.		
3.2	ALT	telomeres	contain	abundant	variant	repeat	sequence	
Telomeric	recombination	as	a	consequence	of	ALT	activity	can	occur	at	variant	repeats	within	the	proximal	
region	of	the	telomere	array	(Varley	et	al.,	2002).	We	hypothesised	that	this	may	result	in	interspersion	of	
variant	 sequences	 throughout	 the	 telomeric	 repeat	 array,	 the	 dissolution	 of	 linkage	 disequilibrium,	 and	
consequent	telomere	structural	ramifications.	To	test	this	hypothesis,	we	utilised	FISH	to	determine	whether	
the	variant	repeats	TCAGGG	(C‐type)	and	TGAGGG	(G‐type)	are	present	throughout	ALT	telomeres.	Using	
fluorophore‐conjugated	peptide	nucleic	acid	 (PNA)	probes,	we	 identified	C‐	and	G‐type	variant	 repeats	
colocalising	 with	 telomeric	 DNA	 in	 ALT	 cells	 (Figure	 3.1A	 and	 S3.1A),	 but	 variant	 repeats	 were	 not	
Results	I		 	
 
 
36 
detectable	in	telomerase‐positive	or	mortal	cells	(Table	3.1	and	Figures	S3.1A	and	B).	The	low	abundance	
and	restriction	of	these	variant	repeats	to	the	proximal	regions	of	the	telomeres	of	telomerase‐positive	and	
mortal	cell	 types	presumably	 limits	 their	detection	by	FISH	analysis.	 In	order	 to	verify	 that	 the	variant	
repeats	were	present	at	 individual	 telomeres	and	not	 restricted	 to	 large	 telomeric	 foci	 (predominantly	
APBs),	 we	 performed	 FISH	 to	 detect	 variant	 repeats	 on	metaphase	 spreads	 (Figure	 3.1B).	While	 FISH	
detected	these	variants	only	in	ALT	telomeres,	their	abundance	varied	considerably	across	different	ALT	
cell	lines	(Figure	S3.1A).	For	instance,	the	C‐type	variant	was	abundant	at	the	telomeres	of	WI38‐VA13/2RA	
chromosomes	(Figure	3.1B),	but	lower	levels	were	detected	at	the	telomeres	of	the	IIICF/c	cell	line.	The	C‐
type	 variant	was	 detected	 at	 individual	 telomeres	 of	 all	 ALT	 cells	 analysed,	while	 the	 G‐type	was	 less	
abundant,	only	detectable	within	APBs	and	at	the	telomeres	of	a	subset	of	WI38‐VA13/2RA	chromosomes	
(Table	 3.1).	 Although	 these	 variants	 were	 detected	 within	 the	 telomeres	 of	 the	 ALT	 cell	 lines	 WI38‐
VA13/2RA,	 JFCF‐6/T.	1M,	 JFCF‐6/T.	1R	and	GM847,	 they	were	not	 found	in	their	respective	mortal	cell	
precursors	 (WI38,	 JFCF‐6	 and	 GM02063,	 respectively)	 (Table	 3.1),	 further	 demonstrating	 that	 these	
variant	repeats	are	a	specific	feature	of	ALT	telomeres.		
A	potential	caveat	to	using	variant	repeat	PNA	probes	for	the	detection	of	 isolated	interspersed	variant	
repeats	 is	 the	 lack	 of	 a	 linear	 signal	 output.	 For	 this	 reason,	 we	 used	 next	 generation	 sequencing	 to	
quantitatively	 determine	 the	 identity	 and	 extent	 of	 variant	 sequence	within	 telomere	 arrays	 of	WI38‐
VA13/2RA	as	well	as	the	telomerase‐positive	HeLa	cell	line.	Samples	were	paired‐end	sequenced	and	75	
nucleotide	reads	containing	>6	non‐consecutive	telomeric	repeats	in	the	format	TBAGGG	were	considered	
to	be	reads	derived	from	telomeres.	This	criterion	was	used	to	enrich	for	telomeric	sequence	rather	than	
interstitial	repeats,	in	order	to	assess	the	frequency	of	variant	repeats	in	the	telomeres	and	to	qualitatively	
establish	variant	repeat	interspersion	patterns.	It	is	important	to	note	that	the	criterion	is	somewhat	biased	
towards	canonical	sequence	and	variants	of	the	format	TBAGGG,	although	interspersed	variants	such	as	
CTAGGG	or	 TTGGGG	 and	 non‐hexameric	 sequences	 are	 detected.	Numerous	 variant	 repeat	 types	were	
identified	at	varying	proportions	 (Figures	3.1C	and	S3.1C).	 Interestingly,	 the	C‐type	variant	constituted	
approximately	21.3%	of	 the	 total	extracted	 telomeric	repeats	 in	WI38‐VA13/2RA	compared	 to	4.7%	in	
HeLa.	In	contrast,	the	G‐type	accounted	for	only	1.2%	of	the	telomeres	in	WI38‐VA13/2RA	and	6.0%	of	
HeLa	telomeres	(Figure	3.1C).	The	representation	of	variant	repeats	is	expressed	as	a	proportion	of	the	
total	 telomeric	 repeats	 and	 is	 therefore	 dependent	 on	 telomere	 length.	 Variant	 repeats	 present	 in	 the	
proximal	regions	of	the	telomeres	will	therefore	be	over‐represented	in	mortal	and	telomerase‐positive	
cell	 lines	with	 short	 telomeres.	 Consequently,	 the	 abundance	of	G‐type	 repeats	 in	HeLa	 cells	 is	 high	 in	
comparison	to	WI38‐VA13/2RA	cells,	which	in	general	display	substantially	longer	telomeres	(see	Figure	
S3.1D	for	quantitation	of	 total	telomeric	DNA	content	 in	the	complete	panel	of	cell	 lines).	Similarly,	 the	
abundance	of	C‐type	repeats	in	HeLa	cells	is	likely	to	be	over‐represented.	Examples	of	the	75‐nucleotide	
telomeric	reads	in	the	WI38‐VA13/2RA	cell	line	clearly	show	that	variant	repeats	are	interspersed	among	
the	canonical	telomeric	repeats	(Figure	3.1D).	Other	sequences	include	incomplete	repeats	at	either	end	of	
the	sequence	read	and	non‐hexameric	repeats	(Figure	3.1D),	as	well	as	other	variants	and	additional	non‐
telomeric	sequences	from	interstitial	or	subtelomeric	sites.	Interestingly,	the	percentage	and	abundance	of	
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numerous	variant	 sequences	within	 the	 telomeres	of	both	cell	 types	was	high	regardless	of	ALT	status	
suggesting	that	the	proximal	region	of	human	telomeres	may	contain	more	variant	repeats	in	terms	of	both	
diversity	and	abundance	than	previously	considered.	Variant	repeat	integration	along	the	entire	length	of	
ALT	telomeres	was	further	confirmed	by	telomere	and	variant	repeat‐specific	FISH	on	chromatin	fibres,	
demonstrating	that	the	C‐type	variant	repeats	are	not	restricted	to	the	proximal	region	of	the	telomere	
(Figure	3.1E).	G‐type	variant	repeats	were	not	detected	in	elongated	chromatin	fibres,	presumably	because	
of	their	low	abundance	in	WI38‐VA13/2RA	telomeres.		
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Figure	3.1	–	Variant	repeats	are	interspersed	throughout	the	telomeres	of	ALT	cells.	(A)	FISH	performed	on	interphase	nuclei	
using	both	a	Texas	Red‐conjugated	(TTAGGG)3	telomeric	probe	(red)	and	Alexa	488–OO‐(TCAGGG)3	or	(TGAGGG)3	variant	probe	
(green)	 counterstained	with	 4’,6‐diamidino‐2‐phenylindole	 (DAPI;	 blue).	 (B)	 Representative	metaphase	 spreads	 of	 the	WI38‐
VA13/2RA	ALT	cell	line	processed	for	FISH	as	described	in	A	showing	localisation	of	the	C‐	and	G‐type	variant	repeat	at	individual	
telomeres.	Magnified	examples	are	shown	to	the	lower	right.	(C)	Percentage	of	each	telomeric	repeat	type	generated	from	next	
generation	sequencing	analysis	of	WI38‐VA13/2RA	and	HeLa	cells.	Variant	repeats	were	counted	within	reads	containing	>6	non‐
consecutive	 TBAGGG	 telomeric	 repeats.	 Next	 generation	 sequencing	was	 carried	 out	 by	Mark	 Hills.	 (D)	 Examples	 of	 various	
telomeric	75	nucleotide	reads	from	sequencing	data	of	WI38‐VA13/2RA	cells.	(E)	Distribution	of	the	C‐	and	G‐type	variant	repeats	
along	the	length	of	the	telomere	in	the	WI38‐VA13/2RA	cell	line,	visualised	on	chromatin	fibres.	Scale	bars,	5	µm.		
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Figure	S3.1	–	Variant	repeats	are	present	within	the	telomeres	of	ALT	cells.	(A)	FISH	performed	on	interphase	nuclei	using	
both	a	Texas	Red‐conjugated	(TTAGGG)3	telomeric	probe	(red)	and	Alexa	488–OO‐(TCAGGG)3	or	(TGAGGG)3	variant	probe	(green)	
counterstained	with	4’,6‐diamidino‐2‐phenylindole	(DAPI;	blue).	(B)	Representative	metaphase	spread	of	the	HT1080	telomerase‐
positive	cell	line	processed	for	FISH	as	described	in	A	showing	no	localisation	of	the	C‐type	variant	repeat	at	individual	telomeres.	
Magnified	examples	are	shown	to	the	lower	right.	Scale	bars,	5	µm.	(C)	Quantitation	of	the	abundance	of	each	telomeric	repeat	type	
generated	from	next	generation	sequencing	analysis	of	WI38‐VA13/2RA	and	HeLa	cells.	Variant	repeats	were	counted	within	reads	
containing	>6	non‐consecutive	TBAGGG	telomeric	repeats.	(D)	Quantitation	of	total	telomeric	DNA	content	of	the	entire	panel	of	
cell	lines	relative	to	HeLa	by	telomere	dot	blot	analysis	(mean	±SD;	n	=	3	independent	experiments).		
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Table	3.1	–	Variant	repeats	and	nuclear	receptors	present	at	ALT	telomeres.		
Cell	line	 Cell	type	 Immortalisation	 C‐type	variant	
G‐type	
variant	 TR2	 TR4	 COUP‐TF1	 COUP‐TF2	 EAR‐2	
Telomere	
maintenance	
WI38	 Fibroblast;	lung	 n/a	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Mortal	
JFCF‐6	 Fibroblast;	jejunal	 n/a	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Mortal	
GM02063	 Fibroblast;	skin	 n/a	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Mortal	
HT1080	 Fibrosarcoma	 Tumour	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Telomerase	
HeLa	 Cervical	carcinoma	 Tumour	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Telomerase	
JFCF‐6/T.	1F	 Fibroblast;	jejunal	 SV40	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Telomerase	
GM639	 Fibroblast;	skin	 SV40	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 Telomerase	
WI38‐
VA13/2RA	
Fibroblast;	
lung	 SV40	 +	 +	 +	 +	 +	 +	 +	 ALT	
U‐2	OS	 Osteosarcoma	 Tumour	 +	 	APBs	only*	 +	 +	 ‐	 +	 ‐	 ALT	
IIICF/c	 Fibroblast;	breast,	LFS†	 Spontaneous	 +	
APBs	
only	 +	 +	 +	 +	 +	 ALT	
JFCF‐6/T.	
1M	
Fibroblast;	
jejunal	 SV40	 +	
APBs	
only	 +	 +	 +	 +	 +	 ALT	
JFCF‐6/T.	
1R	
Fibroblast;	
jejunal	 SV40	 +	
APBs	
only	 +	 +	 +	 +	 +	 ALT	
GM847	 Fibroblast,	skin	 SV40	 +	 APBs	only	 +	 +	 +	 +	 +	 ALT	
SUSM‐1	 Fibroblast;	liver	 Chemical	 +	
APBs	
only	 +	 +	 +	 +	 ‐	 ALT	
Saos‐2	 Osteosarcoma	 Tumour	 +	 APBs	only	 +	 +	 ‐	 +	 ‐	 ALT	
	
*Variant	repeat	only	detected	within	APBs,	not	at	individual	telomeres	by	FISH	analysis	performed	on	metaphase	spreads.		
†LFS,	Li‐Fraumeni	syndrome		
	
3.3	Nuclear	receptors	bind	preferentially	to	C‐type	variant	repeats	
Nuclear	receptors	have	the	ability	to	directly	bind	to	DNA	in	order	to	regulate	the	expression	of	adjacent	
genes.	These	proteins	 have	 vital	 functions	 in	 a	 large	number	 of	 biological	 and	physiological	 processes.	
Numerous	nuclear	receptors	have	been	identified	at	the	telomeres	of	ALT	cells	(Dejardin	and	Kingston,	
2009),	but	the	mechanism	by	which	these	proteins	are	recruited	to	telomeres	remains	to	be	determined.	
Using	indirect	immunofluorescence	against	five	nuclear	receptors	(TR2,	TR4,	COUP‐TF1,	COUP‐TF2	and	
EAR‐2)	 coupled	with	 telomere	 FISH	 on	 interphase	 nuclei	 of	 a	 variety	 of	 cell	 types,	we	 confirmed	 that	
nuclear	 receptor	 binding	 to	 telomeres	 is	 ALT‐specific	 (Table	 3.1).	 We	 chose	 to	 focus	 our	 further	
investigations	on	COUP‐TF2	and	TR4,	as	they	were	the	most	abundant	of	the	five	nuclear	receptors	at	ALT	
telomeres	 and	 were	 detectable	 at	 the	 telomeres	 of	 all	 ALT	 cell	 lines	 examined	 but	 not	 mortal	 and	
telomerase‐positive	cell	lines	(Figure	S3.2	and	Table	3.1).	As	with	the	variant	repeats,	we	identified	COUP‐
TF2	 and	 TR4	nuclear	 receptors	 both	 in	APBs	 (Figure	 3.2A)	 and	 at	 chromosome	 termini	 (Figure	 3.2B).	
Immunostaining	of	chromatin	fibres	further	demonstrated	the	nuclear	receptors	to	be	interspersed	along	
the	length	of	the	telomere	(Figure	3.2C).		
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Figure	3.2	–	Nuclear	receptors	are	detected	at	ALT	telomeres.	(A)	Indirect	immunofluorescence	staining	of	IIICF/c	nuclei	at	
interphase.	COUP‐TF2	or	TR4	(red)	and	PML	(purple)	coupled	with	telomere	FISH	(green)	and	DAPI	(blue)	counterstaining	shows	
that	nuclear	receptors	are	present	within	APBs	(indicated	by	arrowheads).	(B)	Representative	metaphase	spreads	of	the	GM847	
ALT	cell	line	stained	with	COUP‐TF2	or	TR4	(red)	and	TRF2	(green)	immunofluorescence	and	DAPI	(blue)	show	localisation	of	
nuclear	receptors	to	telomeres.	Magnified	examples	are	shown	to	the	lower	right.	(C)	Distribution	of	TR4	(red)	amongst	TRF2	
(green)	along	the	length	of	the	telomere	in	the	WI38‐VA13/2RA	cell	line	visualised	at	chromatin	fibres.	Scale	bars,	5	µm.		
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Figure	S3.2	–	COUP‐TF2	and	TR4	nuclear	receptors	detected	at	ALT	telomeres.	Indirect	immunofluorescence	against	COUP‐
TF2	or	TR4	(red)	coupled	with	telomere	FISH	(green)	performed	on	a	panel	of	telomerase‐positive	and	ALT	cell	lines.	Scale	bars,	
5	µm.		
	
Nuclear	receptors	are	predicted	to	bind	to	the	direct	repeat	5'‐RGGTCA‐3',	with	spacings	of	0‐8	nucleotides	
(Kato	et	al.,	1995;	Sandelin	and	Wasserman,	2005).	In	light	of	this,	and	the	abundance	of	the	C‐type	variant	
within	ALT	telomeres,	we	performed	electrophoretic	mobility	shift	assays	(EMSAs)	to	determine	whether	
nuclear	receptors	were	capable	of	binding	directly	to	variant	repeats	in	vitro.	TR4	was	capable	of	binding	
to	 both	 the	 C‐	 and	 G‐type	 variants	 as	well	 as	 the	 canonical	 telomeric	 repeat,	 and,	 as	 predicted,	 had	 a	
significantly	 higher	 affinity	 for	 the	 C‐type	 variant	 (Figures	 3.3A	 and	 C).	 We	 also	 conducted	 EMSAs	 to	
determine	the	binding	affinity	of	the	shelterin	component	TRF2	for	the	variant	repeats.	As	expected,	TRF2	
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displayed	a	considerably	higher	affinity	for	the	canonical	telomeric	repeat,	than	for	each	of	the	two	variant	
repeats	(Figures	3.3B	and	C).	We	found	no	significant	differences	in	global	nuclear	receptor	protein	levels	
in	 ALT	 versus	 telomerase‐positive	 cell	 lines	 by	 western	 blotting,	 which	 showed	 that	 nuclear	 receptor	
expression	was	not	elevated	in	ALT	cells,	nor	was	their	lack	of	recruitment	to	the	telomeres	of	telomerase‐
positive	cells	the	result	of	insufficient	expression	(Figure	S3.3).	We	then	used	the	telomeric	subset	of	reads	
described	in	the	previous	section	to	calculate	the	percentage	of	C‐type	repeats	that	are	present	in	pairs,	
forming	 the	 canonical	 nuclear	 receptor	 binding	 site	 (RGGTCA(n0‐8)RGGTCA,	where	 n	 is	 the	 number	 of	
nucleotide	spacers).	Nuclear	receptor	binding	sites	were	found	to	occur	at	89.5%	of	C‐type	repeats	in	WI38‐
VA13/2RA	telomeres	and	76.9%	of	C‐type	repeats	in	HeLa	telomeres,	demonstrating	that	nuclear	receptor	
binding	sites	are	enriched	following	C‐type	repeat	interspersion	in	ALT	telomeres.		
	
	
Figure	3.3	–	Binding	of	TR4	and	TRF2	to	variant	telomeric	repeat	sequences.	(A)	Electrophoretic	mobility	shift	assay	(EMSA)	
titration	experiments	conducted	using	double‐stranded	γ32P‐radiolabelled	C‐	and	G‐type	variant	and	canonical	telomeric	repeat	
probes,	incubated	with	purified	human	TR4.	A	binding	curve	generated	from	two	independent	titration	experiments	is	also	shown	
(mean	±	range).	(B)	EMSA	titration	experiments	and	binding	curve	for	human	TRF2.	(C)	Estimation	of	dissociation	constants	(Kd)	
obtained	from	titration	displayed	in	(A)	and	(B).	The	Kd	was	calculated	by	quantifying	the	disappearance	of	the	band	corresponding	
to	free	DNA	and	determining	the	concentration	at	which	50%	of	the	probe	is	bound	by	protein.		
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Figure	S3.3	–	Nuclear	receptor	expression	 is	not	altered	 in	ALT	cells.	Western	blot	 of	whole‐cell	 extracts	 (20	μg	protein	
equivalents)	showing	the	levels	of	COUP‐TF2	and	TR4	expression	in	a	panel	of	telomerase‐positive	and	ALT	cell	lines.		
	
3.4	Telomeric	localisation	of	nuclear	receptors	contributes	to	the	ALT	phenotype	
Nuclear	 receptors	 have	 high	 sequence	 homology	 to	 each	 other,	 bind	 to	 similar	 sequences,	 and	 are	
frequently	 found	 to	 have	 similar	 physiological	 and	 biochemical	 functions.	 In	 agreement	with	 previous	
observations	 (Dejardin	 and	 Kingston,	 2009),	 knockdown	 of	 COUP‐TF2	 resulted	 in	 an	 increase	 in	 TR4	
expression	in	WI38‐VA13/2RA	cells	(Figure	3.4A).	In	case	these	receptors	possess	redundant	functions,	we	
therefore	carried	out	knockdown	experiments	of	COUP‐TF2	and	TR4	individually	and	simultaneously	in	
the	WI38‐VA13/2RA	and	IIICF/c	ALT	cell	 lines,	 to	 investigate	the	extent	of	 their	connection	to	the	ALT	
mechanism	(Figure	3.4A).	These	cell	lines	were	selected	because	they	represent	the	two	extremes	of	both	
nuclear	receptor	recruitment	to	the	telomere	and	variant	repeat	content,	with	WI38‐VA13/2RA	having	the	
most,	and	 IIICF/c	having	 the	 least.	We	 then	 investigated	 the	effects	of	knockdown	on	a	variety	of	ALT‐
associated	characteristics.	Knockdown	of	COUP‐TF2	and	TR4	with	siRNA	caused	a	significant	reduction	in	
APBs	 after	 72	 h,	 both	 individually	 and	 in	 combination	 (Figure	 3.4B).	 In	 addition,	 depletion	 of	 nuclear	
receptors	led	to	a	decrease	in	partially	single‐stranded	C‐rich	telomere	circles	known	as	C‐circles	(Figure	
3.4C),	 which	 are	 a	 marker	 of	 cells	 that	 employ	 the	 ALT	 mechanism	 (Henson	 et	 al.,	 2009).	 Although	
knockdown	of	both	nuclear	receptors	led	to	a	reduction	in	C‐circles,	we	did	not	observe	a	decrease	in	WI38‐
VA13/2RA	 cells	 upon	 depletion	 of	 COUP‐TF2	 alone	 (Figure	 3.4C),	 which	 may	 be	 due	 to	 functional	
redundancy	of	these	receptors.	We	then	sought	to	establish	whether	removal	of	nuclear	receptors	from	the	
telomere	would	influence	telomere	capping.	However,	nuclear	receptor	depletion	did	not	affect	the	DDR	at	
ALT	telomeres	(Figure	S3.4A),	nor	the	rate	of	chromosome	end‐to‐end	fusions	(Figure	S3.4B).	Finally,	we	
determined	 whether	 depletion	 of	 nuclear	 receptor	 expression	 in	 ALT	 cells	 altered	 the	 frequency	 of	
telomere	exchange	events.	A	significant	reduction	in	the	levels	of	T‐SCEs	was	observed	by	CO‐FISH	analysis	
(Londono‐Vallejo	 et	 al.,	 2004)	 upon	 transient	 knockdown	 of	 COUP‐TF2	 and	 TR4	 individually	 and	 to	 a	
greater	 extent	 following	 simultaneous	 knockdown	 in	WI38‐VA13/2RA	 cells	 (Figure	 3.4D).	 These	 data	
demonstrate	that	nuclear	receptor	recruitment	to	the	telomere	contributes	to	the	ALT	phenotype.		
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Figure	3.4	–	Nuclear	receptor	depletion	results	in	suppression	of	ALT	phenotypic	characteristics.	(A)	Western	blot	analysis	
of	whole‐cell	extracts	(1	×	105	cell	equivalents)	from	WI38‐VA13/2RA	and	IIICF/c	cells	72	hrs	after	transfection	with	siRNA	against	
COUP‐TF2	and	TR4	shows	knockdown	of	proteins.	(B)	Quantitation	of	APBs	72	hrs	post‐transfection	of	WI38‐VA13/2RA	and	
IIICF/c	cells	with	siRNA	against	COUP‐TF2	and	TR4	via	indirect	immunofluorescence	against	the	PML	protein	and	telomere	FISH	
(mean	±SD;	n	=	3	independent	experiments,	quantifying	50	nuclei	per	replicate).	(C)	Quantitation	of	C‐circle	levels	72	hrs	post‐
transfection	of	WI38‐VA13/2RA	and	IIICF/c	cells	(mean	±SD;	n	=	3).	(D)	Quantitation	of	telomere‐sister	chromatid	exchanges	(T‐
SCEs)	observed	via	chromosome	orientation‐FISH	(CO‐FISH)	after	knockdown	of	nuclear	receptor	expression	in	WI38‐VA13/2RA	
cells	 (mean	 ±SD;	n	=	3,	 quantifying	 >2,000	 chromosome	 ends	 or	~20	metaphases	 per	 replicate).	 Quantitation	 of	 T‐SCEs	was	
restricted	to	chromosome	ends	with	clearly	distinguishable	sister	telomeres.		
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Figure	S3.4	–	Depletion	of	nuclear	receptors	does	not	affect	the	level	of	meta‐TIFs,	nor	the	rate	of	chromosomal	end‐to‐
end	fusions.	(A)	Quantitation	of	meta‐TIFs	conducted	72	hrs	after	transfection	of	WI38‐VA13/2RA	cells	with	siRNA	against	COUP‐
TF2	and	TR4	(mean	±SD;	n	=	3,	quantifying	>2,000	chromosome	ends	or	~20	metaphases	per	replicate).	(B)	Quantitation	of	the	
percentage	 of	 chromosomal	 end‐to‐end	 fusions	 observed	 72	 hrs	 after	 knockdown	 of	 nuclear	 receptors	 with	 siRNA	 in	WI38‐
VA13/2RA	cells	(mean	±SD;	n	=	3,	quantifying	>2,000	chromosome	ends	or	~20	metaphases	per	replicate).		
	
3.5	Telomeric	incorporation	of	C‐type	variant	repeats	results	in	nuclear	receptor	recruitment	
Exogenous	expression	of	a	human	telomerase	RNA	(hTR)	containing	mutations	in	the	template	sequence	
reconstitutes	active	telomerase	enzyme	in	vivo	that	is	capable	of	adding	mutant	telomeric	repeats	onto	the	
ends	of	chromosomes	(Marusic	et	al.,	1997).	Since	variant	telomeric	repeats	are	common	in	ALT	cells	and	
C‐type	variant	repeats	specifically	provide	preferential	binding	sites	for	nuclear	receptors,	we	adapted	this	
approach	to	determine	whether	incorporation	of	the	C‐	and	G‐type	variant	repeats	in	telomerase‐positive	
cells	directly	causes	nuclear	receptor	recruitment	to	the	telomere.	We	found	overexpression	of	both	C‐	and	
G‐type	hTR	to	be	detrimental	to	the	viability	of	numerous	telomerase‐positive	cell	types.	Indeed,	mutant	
hTR	expression	has	been	previously	shown	to	lead	to	the	formation	of	chromosomal	end‐to‐end	fusions,	
inhibit	cell	proliferation	and	induce	apoptosis	(Guiducci	et	al.,	2001;	Kim	et	al.,	2001;	Li	et	al.,	2004;	Stohr	
and	Blackburn,	2008).	In	order	to	both	circumvent	this	limitation,	and	to	emulate	the	variant	interspersion	
pattern	we	have	identified	in	ALT	telomeres,	we	exogenously	expressed	wild‐type	hTR	in	addition	to	wild‐
type,	C‐	or	G‐type	variant	hTR	in	the	telomerase‐positive	HT1080	cell	line	(referred	to	as	HT1080	hTR	wild‐
type,	HT1080	hTR	C‐type	and	HT1080	hTR	G‐type,	respectively).	Cells	were	passaged	for	more	than	150	
population	 doublings	 (pds)	 to	 achieve	 sufficient	 variant	 repeat	 incorporation,	 and	 potential	 cell	 line	
contamination	was	excluded	by	16‐locus	STR	profiling.		
We	first	confirmed	that	the	C‐	and	G‐type	variant	repeats	were	incorporated	into	the	telomere	by	terminal	
restriction	 fragment	 (TRF)	analysis	using	γ32P‐radiolabelled	probes	specific	 to	each	of	 the	 three	repeat	
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types	(Figure	S3.5A).	In	addition,	FISH	against	both	the	canonical	telomeric	repeat	and	either	the	C‐	or	G‐
type	 variant	 was	 conducted	 to	 confirm	 their	 incorporation	 specifically	 into	 telomeres	 (Figure	 3.5A).	
Indirect	immunofluorescence	performed	on	metaphase	spreads	showed	that	both	COUP‐TF2	and	TR4	were	
recruited	to	the	telomeres	as	a	result	of	the	addition	of	the	C‐type	repeat	(Figures	3.5B	and	C)	and	to	a	
considerably	lesser	extent	following	incorporation	of	either	the	wild‐type	or	G‐type	repeat	(Figure	3.5B	
and	S3.5B).		
	
	
Figure	3.5	–	Nuclear	receptor	recruitment	upon	variant	telomeric	repeat	incorporation.	(A)	FISH	performed	on	interphase	
nuclei	using	both	a	Texas	Red‐conjugated	(TTAGGG)3	telomeric	probe	(red)	and	Alexa	488–OO‐(TCAGGG)3	or	(TGAGGG)3	variant	
probe	(green)	counterstained	with	DAPI	(blue).	(B)	Quantitation	of	the	percentage	of	nuclear	receptor‐positive	chromosome	ends	
stained	with	either	COUP‐TF2	or	TR4	on	one	or	both	chromatids	(mean	±SD;	n	=	3,	quantifying	>2,000	chromosome	ends	or	~20	
metaphases	per	replicate).	(C)	Representative	metaphase	spreads	of	the	HT1080	hTR	C‐type	cell	line	stained	with	COUP‐TF2	or	
TR4	(red)	and	TRF2	(green)	immunofluorescence	and	DAPI	(blue).	Magnified	examples	are	shown	to	the	lower	right.	Scale	bars,	5	
µm.	Michael	D.	Stutz	generated	all	the	HT1080	hTR	cell	lines	with	variant	repeats.		
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Figure	S3.5	–	 Incorporation	of	variant	repeats	 into	 the	 telomeres	of	 telomerase‐positive	cells.	 (A)	 Terminal	 restriction	
fragment	(TRF)	analysis	conducted	to	visualise	telomere	lengths	using	γ32P‐radiolabelled	(CCCTAA)3,	(CCCTGA)3	and	(CCCTCA)3	
for	each	of	the	three	repeat	types.	(B)	Representative	metaphase	spreads	of	the	HT1080	hTR	wild‐type	and	HT1080	hTR	G‐type	
cell	lines	stained	with	COUP‐TF2	or	TR4	(red)	and	TRF2	(green)	immunofluorescence	and	DAPI	(blue).	Magnified	examples	are	
shown	to	the	lower	right.	Scale	bars,	5	µm.		
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3.6	Variant	 repeat	 incorporation	 induces	ALT‐associated	characteristics	but	not	 inter‐telomeric	
recombination		
As	insertion	of	mutant	repeats	into	the	telomere	would	be	expected	to	compromise	shelterin	binding,	we	
examined	 the	 DDR	 at	 the	 telomeres.	 Telomere	 dysfunction‐induced	 foci	 (TIFs)	 were	 detected	 at	 the	
telomere	 by	 combining	 telomere	 FISH	 with	 immunofluorescence	 against	 the	 DDR	 protein	 H2AX	
phosphorylated	 at	 serine	 139	 (γ‐H2AX)	 on	 metaphase	 spreads	 (meta‐TIFs)	 (Cesare	 et	 al.,	 2009).	
Introduction	of	either	C‐	or	G‐type	variant	repeats	into	the	telomeres	led	to	an	elevation	in	the	number	of	
meta‐TIFs	(Figure	3.6A).	This	is	in	contrast	to	the	HT1080	cells	expressing	only	wild‐type	hTR,	which	have	
previously	been	reported	to	show	decreased	meta‐TIFs,	presumably	due	to	a	reduction	in	the	number	of	
very	 short	 telomeres	 (Pickett	 et	 al.,	 2009).	Moreover,	 HT1080	 cells	 expressing	 either	 the	 C‐	 or	 G‐type	
variant	 hTR	 exhibited	 a	 marked	 increase	 in	 C‐circles	 (Figure	 3.6B).	 These	 cells	 also	 exhibited	
heterogeneous	telomeres	as	well	as	a	marked	increase	in	telomere	length	compared	to	those	expressing	
wild‐type	hTR	alone	as	demonstrated	by	TRF	analysis	(Figure	S3.5A).	Interestingly,	we	also	noticed	that	
the	amount	of	the	C‐type	variant	repeat	decreased	at	the	latest	time	point	(pd	+150)	suggesting	that	there	
may	be	some	selection	against	telomeric	incorporation	of	this	variant.	Most	ALT	cells	lack	functional	p53	
and	can	consequently	sustain	a	greater	level	of	DNA	damage	(Cesare	and	Reddel,	2008).	For	this	reason	we	
similarly	incorporated	C‐	and	G‐type	variant	repeats	into	the	HT1080‐6TG	cell	line	due	to	its	non‐functional	
p53	status	(Anderson	et	al.,	1994).	However,	despite	similar	telomere	lengths	(regardless	of	whether	the	
cells	were	expressing	wild‐type,	C‐	or	G‐type	hTR),	a	similar	effect	of	meta‐TIF	and	C‐circle	 levels	were	
obtained	in	the	absence	of	p53	(data	not	shown).		
Finally,	 we	 determined	 whether	 the	 incorporation	 of	 variant	 repeats	 could	 instigate	 inter‐telomeric	
recombination‐mediated	replication,	which	is	characteristic	of	ALT	cells	and	is	proposed	to	be	a	component	
of	 the	 ALT	 mechanism.	 We	 inserted	 a	 telomere‐targeting	 tag	 (Dunham	 et	 al.,	 2000),	 comprised	 of	 a	
neomycin	resistance	gene	(neoR)	cassette	flanked	on	either	side	by	800	bp	of	telomeric	DNA,	into	HT1080	
cells	containing	C‐	and	G‐type	variant	repeat	telomeres.	Single	locus	integration	of	the	telomeric	neoR	tag	
was	confirmed	by	FISH	in	two	clonal	populations	of	both	C‐	and	G‐type	variant	HT1080	cells;	however,	no	
copying	of	the	tag	was	detected	following	culture	for	a	further	60	pds	(Figure	3.6C),	which	has	previously	
been	 demonstrated	 to	 be	 sufficient	 to	 identify	 copying	 of	 the	 tag	 by	ALT	 (Dunham	 et	 al.,	 2000).	 Thus,	
integration	 of	 variant	 repeats	 in	 a	 telomerase‐positive	 cell	 line	 can	 elicit	 a	 number	 of	 ALT‐associated	
characteristics,	 but	 is	 not	 sufficient	 to	 activate	 detectable	 levels	 of	 the	 inter‐telomeric	 recombination‐
mediated	copying	that	is	a	hallmark	of	ALT.		
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Figure	3.6	–	Incorporation	of	variant	repeats	into	the	telomeres	induces	ALT‐associated	characteristics.	(A)	Quantitation	
of	meta‐TIF	analysis	showing	the	percentage	of	chromosome	ends	stained	with	γ‐H2AX	on	one	or	both	chromatids	in	HT1080	cells	
expressing	variant	hTR	compared	to	wild‐type	(mean	±SD;	n	=	3,	quantifying	>2,000	chromosome	ends	or	~20	metaphases	per	
replicate).	(B)	Quantitation	of	C‐circle	levels	in	HT1080	cells	expressing	wild‐type	and	variant	hTR	in	comparison	to	the	IIICF/c	
ALT	cell	line	(mean	±SD;	n	=	3)	plotted	on	a	logarithmic	scale.	(C)	Representative	metaphase	spreads	of	the	HT1080	hTR	C‐	and	G‐
type	cells	processed	for	neoR‐FISH	showing	no	copying	of	the	neoR	tag	at	early	and	late	pds.	NeoR‐FISH	was	performed	by	Hilda	A.	
Pickett.	Magnified	examples	are	shown	to	the	lower	right.	Scale	bars,	5	µm.		
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3.7	Conclusion	
In	this	chapter	we	investigated	whether	ALT	telomeres	contain	structural	abnormalities	that	contribute	to	
ALT	activity.	Here	we	used	next	generation	sequencing	to	analyse	the	DNA	content	of	ALT	telomeres.	We	
discovered	that	variant	repeats	were	interspersed	throughout	the	telomeres	of	ALT	cells.	We	found	that	
the	C‐type	variant	repeat	predominated	and	created	a	high‐affinity	binding	site	for	the	nuclear	receptors	
COUP‐TF2	 and	 TR4.	 Nuclear	 receptors	 were	 directly	 recruited	 to	 telomeres	 and	 ALT‐associated	
characteristics	were	induced	following	incorporation	of	the	C‐type	variant	repeat	by	a	mutant	telomerase.	
We	propose	that	the	presence	of	variant	repeats	throughout	ALT	telomeres	results	from	recombination‐
mediated	telomere	replication	and	spreading	of	variant	repeats	from	the	proximal	regions	of	the	telomeres,	
and	 that	 the	 consequent	 binding	 of	 nuclear	 receptors	 alters	 the	 architecture	 of	 telomeres	 to	 facilitate	
further	recombination.		
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Results	II		
		
4.1	Introduction	
Note,	 this	 chapter	 relates	 to	 a	 previous	 manuscript	 entitled	 “NuRD‐ZNF827	 recruitment	 to	 telomeres	
creates	a	molecular	scaffold	for	homologous	recombination”	published	in	the	Nature	Structural	&	Molecular	
Biology	(Conomos	et	al.,	2014).	All	figures	and	supplementary	data	have	subsequently	been	reformatted	to	
follow	University	of	Sydney	thesis	guidelines.		
Cells	which	utilise	ALT	have	alterations	both	in	telomeric	DNA	sequence	and	in	telomeric	binding	proteins	
(Dejardin	and	Kingston,	2009;	Conomos	et	al.,	2012;	Lee	et	al.,	2014).	In	addition,	a	strong	correlation	has	
been	 found	 between	 ALT	 status	 and	mutations	 in	 the	 SWI/SNF	 family	 ATP‐dependent	 helicase	 ATRX	
(Heaphy	et	al.,	2011a;	Schwartzentruber	et	al.,	2012;	Lovejoy	et	al.,	2012;	Bower	et	al.,	2012),	although	loss	
of	ATRX	is	insufficient	to	induce	ALT	(Lovejoy	et	al.,	2012).	Moreover,	depletion	of	both	paralogs	of	the	
anti‐silencing	factor	1	(ASF1),	which	disrupts	histone	transfer	at	replication	forks,	has	recently	been	shown	
to	 induce	 an	 ALT	 phenotype	 (O'Sullivan	 et	 al.,	 2014).	 These	 observations	 suggest	 the	 hypothesis	 that	
alterations	to	telomeric	chromatin	coupled	with	replicative	stress	at	telomeres	may	activate	and/or	maintain	
ALT	activity.		
Here	we	describe	evidence	that	the	nucleosome	remodelling	and	histone	deacetylation	(NuRD)	complex	
has	an	important	role	in	the	ALT	mechanism.	NuRD	has	previously	been	proposed	to	contribute	to	tumour	
biology,	 with	many	 of	 its	 protein	 constituents	 being	 found	 to	 be	 up‐regulated	 in	 human	 cancers,	 and	
inappropriate	localisation	of	NuRD	being	implicated	in	the	regulation	of	transcriptional	events	involved	in	
oncogenesis	and	cancer	progression	(reviewed	in	Lai	and	Wade,	2011).	In	this	study	we	find	that	NuRD	
localises	to	telomeres	in	an	ALT‐specific	manner,	via	binding	to	a	zinc	finger	protein	ZNF827	of	previously	
unknown	function,	and	that	this	is	dependent	on	an	RRK	motif	in	the	N‐terminus	of	ZNF827.	The	NuRD‐
ZNF827	 complex	 causes	 histone	 hypoacetylation	 at	 telomeres,	 which	 would	 be	 expected	 to	 cause	
compaction	of	telomeric	chromatin.	Experimental	manipulation	of	the	level	of	NuRD‐ZNF827	recruitment	
to	 telomeres	 demonstrated	 that	 binding	 of	 this	 complex	 correlates	 with	 markers	 of	 ALT	 activity.	 Of	
particular	 interest,	 NuRD‐ZNF827	 binding	 to	 ALT	 telomeres	 causes	 telomere‐telomere	 interactions,	
recruitment	 of	 the	 HR	 protein,	 BRIT1/Microcephalin‐1	 (MCPH1),	 and	 inhibition	 of	 shelterin,	 thus	
enhancing	HR	activity	at	ALT	telomeres.	Moreover,	we	 find	that	decreased	binding	of	NuRD‐ZNF827	to	
telomeres	causes	a	telomere‐specific	DDR	and	the	induction	of	senescence	and/or	apoptosis,	specifically	
in	ALT	cells.	Our	data	demonstrate	that	NuRD‐ZNF827	has	a	vital,	multi‐faceted	role	at	the	telomeres	of	
cells	 that	 utilise	 ALT,	 altering	 the	 telomeric	 chromatin	 conformation	 through	 partial	 displacement	 of	
shelterin	 and	 histone	 deacetylation,	 controlling	 the	 telomeric	 DDR,	 providing	 an	 HR‐permissive	
environment	and	actively	enhancing	interactions	of	telomeres	with	other	telomeres	and	APBs.		
4.2	NuRD	recruitment	to	ALT	telomeres	is	nuclear	receptor‐dependent	and	cell	cycle	regulated	
We	have	previously	demonstrated	ALT‐specific	nuclear	receptor	binding	to	telomeres,	and	postulated	that	
these	proteins	alter	the	telomere	architecture	to	facilitate	recombination	(Conomos	et	al.,	2012;	Conomos	
Results	II		 	
 
 
53 
et	 al.,	 2013).	 Given	 that	 the	 TR2	 and	 TR4	 nuclear	 receptors	 recruit	 the	 NuRD	 chromatin‐remodelling	
protein	complex	to	specific	promoters	in	mice	(Cui	et	al.,	2011),	we	investigated	whether	nuclear	receptors	
TR2,	 TR4	 and	 COUP‐TF2	 recruit	 NuRD	 to	 ALT	 telomeres.	 We	 carried	 out	 telomere‐chromatin	
immunoprecipitation	(telomere‐ChIP)	in	a	panel	of	cell	lines,	and	found	an	increase	in	the	binding	of	NuRD	
components	to	the	telomeres	of	ALT	cells	(WI38‐VA13/2RA,	JFCF‐6/T.	1M	and	JFCF‐6/T.	1R)	compared	to	
those	of	the	mortal	(MRC5)	and	telomerase‐positive	(HT1080	and	JFCF‐6/T.	1F)	cell	lines	(Figure	4.1A).	No	
significant	differences	in	global	protein	levels	of	NuRD	components	were	observed,	demonstrating	ALT‐
specific	 differences	 in	 NuRD	 recruitment	 rather	 than	 protein	 expression	 (Figure	 S4.1A).	 To	 determine	
whether	NuRD	recruitment	to	ALT	telomeres	is	cell	cycle	regulated,	we	treated	the	WI38‐VA13/2RA	ALT	
cell	line	with	cell	cycle	inhibitors	for	up	to	24	hrs	in	order	to	obtain	G1/S	(aphidicolin),	G2/M	(RO‐3306)	
and	M	(metaphase;	colcemid)	cell	populations	(Figure	4.1B).	NuRD	binding	to	ALT	telomeres	was	found	to	
be	cell	cycle	regulated,	with	maximum	binding	in	G1/S	phase,	and	least	binding	during	metaphase	(Figure	
4.1C).	This	trend	was	not	observed	for	any	of	the	three	nuclear	receptors	examined	(Figure	S4.1B),	and	
changes	in	NuRD	recruitment	were	not	the	result	of	altered	global	expression	of	nuclear	receptors	or	NuRD	
components	themselves	(Figure	S4.1C).	Interestingly,	a	shift	in	the	band	representing	TR4	was	detected	at	
metaphase	(Figure	S4.1C),	suggesting	that	a	post‐translational	modification	of	TR4	may	be	associated	with	
decreased	binding	of	NuRD	at	this	stage	of	the	cell	cycle.		
Depletion	of	the	nuclear	receptors	individually	via	transfection	with	siRNA	had	no	effect	on	global	levels	of	
NuRD	proteins	(Figure	4.1D)	but	resulted	in	a	significant	reduction	in	their	binding	to	telomeres	in	the	case	
of	TR4	and	COUP‐TF2	but	not	TR2,	as	analysed	by	ChIP	(Figure	4.1E).	This	demonstrated	a	role	for	both	
TR4	and	COUP‐TF2	but	not	TR2	 in	 the	recruitment	of	NuRD	to	ALT	telomeres.	To	 further	demonstrate	
NuRD	 recruitment	 to	 ALT	 telomeres	 by	 nuclear	 receptors	 we	 used	 the	 previously	 characterised	
telomerase‐positive	 cell	 line	 HT1080	 hTR	 TCA	 (Conomos	 et	 al.,	 2012;	 Lee	 et	 al.,	 2014).	 This	 cell	 line	
expresses	a	mutant	telomerase,	which	causes	the	nuclear	receptor	binding‐TCAGGG	variant	repeat	to	be	
incorporated	into	the	telomeres.	Telomere‐ChIP	was	used	to	confirm	nuclear	receptor	recruitment	(Figure	
S4.1D).	A	significant	increase	in	telomeric	recruitment	of	NuRD	components	was	observed	in	the	HT1080	
hTR	TCA	cell	 line	 compared	 to	 the	HT1080	hTR	 control	 cell	 line	expressing	only	wild‐type	 telomerase	
(Pickett	et	al.,	2009)	(Figure	4.1F),	without	any	change	in	global	expression	of	NuRD	components	(Figure	
S4.1E).	Overall,	this	demonstrates	TR4‐	and	COUP‐TF2‐dependent	recruitment	of	NuRD	specifically	to	ALT	
telomeres.		
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Figure	4.1	–	Nuclear	receptor	recruitment	of	NuRD	to	ALT	telomeres	is	cell	cycle	regulated.	(A)	Telomere‐ChIP	against	NuRD	
components	in	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	lines	showing	representative	blots	for	telomere	and	Alu‐specific	
DNA	content.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	is	presented	in	the	accompanying	graph	(mean	±	range;	
n	=	2	biological	replicates).	(B)	Schematic	representation	of	cell	cycle	synchronisation	protocol	showing	cell	cycle	profiles	of	the	
WI38‐VA13/2RA	ALT	cell	line	treated	with	either	aphidicolin	(1	µg/mL),	RO‐3306	(9	µM)	or	colcemid	(10	ng/mL)	for	24	hrs	to	
establish	G1/S,	G2/M	and	M	phase	populations,	respectively.	(C)	Telomere‐ChIP	against	NuRD	components	in	synchronised	WI38‐
VA13/2RA	cells.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	is	presented	in	the	accompanying	graph	(mean	±	
range;	n	=	2	biological	replicates).	(D)	Western	blot	analysis	of	whole‐cell	extracts	(1	×	105	cell	equivalents)	from	WI38‐VA13/2RA	
cells	72	hrs	after	transfection	with	siRNA	against	TR2,	TR4	and	COUP‐TF2.	Knockdown	of	proteins	as	well	as	global	expression	
levels	of	NuRD	components	are	 indicated.	(E)	Telomere‐ChIP	against	NuRD	components	 in	WI38‐VA13/2RA	cells	72	hrs	post‐
transfection	with	siRNA	targeting	nuclear	receptors.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	is	presented	in	
the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(F)	Telomere‐ChIP	against	NuRD	
components	in	HT1080	hTR	TCA	cells	and	the	HT1080	hTR	control	cell	line.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	
down	is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	and	**P<0.	005	by	two	tailed	t	
test).		
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Figure	S4.1	–	Cell	cycle	regulation	of	NuRD	recruitment	by	nuclear	receptors.	(A)	Western	blot	analysis	of	whole‐cell	extracts	
(20	μg	protein	equivalents)	 from	a	panel	of	mortal,	 telomerase‐positive	and	ALT	cell	 lines	showing	global	expression	 levels	of	
nuclear	receptors	and	NuRD	components.	(B)	Telomere‐ChIP	against	nuclear	receptors	in	synchronised	WI38‐VA13/2RA	cells.	
Quantitation	 of	 the	 percentage	 of	 telomeric	DNA	pulled	 down	 is	 presented	 in	 the	 accompanying	 graph	 (mean	±	 range;	n	=	2	
biological	 replicates).	 (C)	 Western	 blot	 analysis	 of	 whole‐cell	 extracts	 (1	 ×	 105	 cell	 equivalents)	 from	 synchronised	 WI38‐
VA13/2RA	cells	showing	global	expression	levels	of	nuclear	receptors	and	NuRD	components.	(D)	Telomere‐ChIP	against	nuclear	
receptors	in	HT1080	hTR	and	HT1080	hTR	TCA	cells.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	is	presented	
in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(E)	Western	blot	analysis	of	
whole‐cell	extracts	(1	×	105	cell	equivalents)	from	HT1080	hTR	and	HT1080	hTR	TCA	cells	showing	global	expression	levels	of	
nuclear	receptors	as	well	as	NuRD	components.		
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4.3	NuRD	recruitment	to	telomeres	requires	the	N‐terminal	RRK	motif	of	ZNF827	
Recent	proteomics	analysis	of	telomeres	identified	numerous	proteins	unique	to	ALT	telomeric	chromatin	
(Dejardin	 and	 Kingston,	 2009).	 Amongst	 these	 was	 a	 novel	 zinc‐finger	 protein	 ZNF827	 of	 unknown	
function.	Several	C2H2	zinc	finger	domain‐containing	proteins,	including	FOG‐1	(Hong	et	al.,	2005),	SALL1	
(Lauberth	and	Rauchman,	2006)	and	Bcl11b	(Cismasiu	et	al.,	2005;	Topark‐Ngarm	et	al.,	2006),	have	been	
shown	to	instigate	sequence‐specific	recruitment	of	NuRD.	This	recruitment	capability	has	been	attributed	
to	an	RRK	motif	situated	within	the	N‐terminal	region	(Lauberth	and	Rauchman,	2006),	which	we	found	to	
be	 present	within	 ZNF827	 (Figure	 4.2A).	 To	 determine	whether	 ZNF827	 fulfils	 a	 similar	 role	 in	NuRD	
recruitment	we	overexpressed	ZNF827	as	well	as	a	mutant	carrying	a	triple	amino	acid	substitution	in	the	
RRK	motif	(ZNF827	ΔRRK)	in	either	WI38‐VA13/2RA	ALT	cells	or	the	HT1080	hTR	telomerase‐positive	
cell	line	(Figures	4.2A	and	B).	The	HT1080	hTR	cell	line	has	elevated	telomerase	activity	due	to	increased	
expression	of	the	wild‐type	telomerase	RNA	subunit,	hTR,	and	was	included	as	a	control	because	these	cells	
contain	a	large	amount	of	telomeric	DNA,	comparable	to	ALT	cells.	We	identified	a	significant	increase	in	
NuRD	 recruitment	 to	 telomeric	DNA	 following	 overexpression	 of	 ZNF827,	 but	 not	 the	mutant	 ZNF827	
ΔRRK,	which	 itself	retains	 telomeric	binding	(Figure	4.2C).	Deletion	of	 the	RRK	motif	rather	 than	triple	
amino	 acid	 substitution	 had	 a	 slightly	 less	 severe	 effect,	whereby	 overexpression	 of	 ZNF827	with	 this	
mutation	resulted	in	only	a	small	increase	in	NuRD	recruitment	to	the	telomere	(data	not	shown).	Indirect	
immunofluorescent	detection	of	the	RBAP46	NuRD	component	and	Myc‐tagged	ZNF827	in	combination	
with	telomere‐fluorescence	in	situ	hybridisation	(telomere‐FISH),	corroborated	the	finding	that	ZNF827‐
mediated	NuRD	recruitment	is	specific	to	ALT	telomeres	and	requires	a	functional	RRK	motif	(Figure	4.2D).	
Interestingly,	 ZNF827	 overexpression	 caused	 an	 increase	 in	 the	 intensity	 of	 large	 telomeric	 foci	
(presumably	APBs)	in	the	ALT	cell	line.	An	increase	in	ZNF827	recruitment	was	also	found	to	accompany	
the	elevated	presence	of	NuRD	at	the	telomeres	of	HT1080	hTR	TCA	cells	compared	to	HT1080	hTR	cells	
(Figure	 S4.2A).	 Depletion	 of	 ZNF827	 by	 siRNA	 (Figure	 4.2E)	 resulted	 in	 a	 significant	 reduction	 in	 the	
recruitment	 of	 NuRD	 to	 ALT	 telomeres	 (Figure	 4.2F).	 Co‐immunoprecipitation	 (Co‐IP)	 with	 ZNF827	
confirmed	 interactions	 with	 many	 NuRD	 components,	 with	 the	 exception	 of	 LSD1	 (Figure	 4.2G).	 No	
interactions	 with	 shelterin	 components	 were	 detected.	 In	 the	 reverse	 experiments,	 using	 antibodies	
against	NuRD	and	shelterin	components	to	IP	the	complex,	we	confirmed	interactions	between	ZNF827	
and	NuRD,	but	not	between	ZNF827	and	shelterin	(Figure	S4.2B).	Again,	interactions	with	LSD1	were	not	
detected	indicating	that,	in	contrast	to	other	contexts	where	LSD1	is	an	integral	part	of	NuRD	(Wang	et	al.,	
2009),	the	telomeric	NuRD‐ZNF827	complex	is	independent	of	LSD1.		
ZNF827	recruitment	to	telomeres	was	abolished	by	knockdown	of	TR4	and	COUP‐TF2	but	not	TR2	(Figure	
4.2H),	 consistent	with	ZNF827‐mediated	NuRD	recruitment	specifically	 to	TR4	and	COUP‐TF2.	We	also	
identified	 an	 increase	 in	 ZNF827	 expression	 following	 TR4	 knockdown	 and,	 conversely,	 a	 decrease	 in	
ZNF827	expression	following	TR4	overexpression	(Figures	S4.2C	and	D),	indicating	that	TR4	is	a	negative	
regulator	of	ZNF827	expression.	ZNF827	recruitment	to	telomeres	was	specific	to	ALT	cells	(Figure	4.2I),	
and	was	not	due	to	elevated	levels	of	ZNF827	expression	(Figure	S4.2E).	Telomere‐ChIP	on	synchronised	
WI38‐VA13/2RA	cells	revealed	that	ZNF827	binding	throughout	the	cell	cycle	is	similar	to	NuRD	(but	not	
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nuclear	receptors)	(Figure	S4.2F),	consistent	with	other	evidence	that	binding	of	NuRD	to	the	telomere	is	
mediated	by	ZNF827.	However,	ZNF827	transcript	levels	throughout	the	cell	cycle	did	not	reflect	telomere‐
bound	NuRD‐ZNF827	(Figure	S4.2G).	Furthermore,	we	detected	an	inverse	correlation	between	ZNF827	
transcript	levels	and	the	abundance	of	NuRD‐ZNF827	at	the	telomeres.	This	was	particularly	striking	in	
HT1080	hTR	TCA	cells	compared	to	HT1080	hTR	cells	(Figure	S4.2H).	These	data	support	the	existence	of	
a	negative	feedback	mechanism	whereby	the	levels	of	ZNF827	are	tightly	regulated	to	prevent	excessive	
NuRD	recruitment	to	telomeres.	Collectively,	these	data	indicate	that	NuRD	recruitment	to	telomeres	in	
ALT	cells	requires	the	RRK	motif	of	ZNF827,	and	is	regulated	by	the	levels	of	ZNF827,	which	are	down‐
regulated	both	by	NuRD	binding	and	by	TR4.		
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Figure	4.2	–	The	N‐terminal	RRK	motif	of	ZNF827	is	required	for	nuclear	receptor‐dependent	NuRD	recruitment	to	ALT	
telomeres.	(A)	Schematic	representation	of	the	N‐terminal	amino	acid	sequence	of	zinc	finger	proteins	which	share	the	RRK	motif,	
and	the	triple	amino	acid	substitution	within	this	motif	(ZNF827	ΔRRK).	(B)	Western	blot	analysis	of	whole‐cell	extracts	(1	×	105	
cell	equivalents)	 from	HT1080	hTR	and	WI38‐VA13/2RA	cells	48	hrs	after	 transfection	with	Myc‐tagged	ZNF827	and	ZNF827	
ΔRRK.	(C)	Telomere‐ChIP	against	NuRD	components	in	WI38‐VA13/2RA	cells	48	hrs	after	overexpression	of	either	ZNF827	or	
ZNF827	ΔRRK.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	is	presented	in	the	accompanying	graph	(mean	±	
range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(D)	Four‐color	imaging	of	HT1080	hTR	and	WI38‐VA13/2RA	nuclei	
48	hrs	after	either	ZNF827	or	ZNF827	ΔRRK	overexpression.	Indirect	immunofluorescence	against	the	NuRD	component	RBAP46	
(red)	and	Myc‐tagged	ZNF827	(purple)	coupled	with	telomere‐FISH	(green)	and	DAPI	(blue)	counterstaining	shows	that	NuRD	is	
recruited	to	cells	overexpressing	ZNF827.	The	white	bar	is	equivalent	to	10	µm.	(E)	Real‐time	RT‐PCR	confirming	the	knockdown	
of	ZNF827	transcript	levels	72	hrs	post‐transfection	with	siRNA	(mean	±	SD;	n	=	3	technical	replicates;	***P<0.	0001	by	two	tailed	
t	test).	Real‐time	RT‐PCR	was	performed	by	Hilda	A.	Pickett.	(F)	Telomere‐ChIP	against	NuRD	components	in	WI38‐VA13/2RA	
cells	 72	 hrs	 after	 ZNF827	 knockdown.	 Quantitation	 of	 the	 percentage	 of	 telomeric	 DNA	 pulled	 down	 is	 presented	 in	 the	
accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).		
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Figure	4.2	Continued	–	 (G)	 Co‐immunoprecipitation	 (Co‐IP)	 of	 ZNF827	 from	WI38‐VA13/2RA	 cells	 overexpressing	 ZNF827,	
followed	by	western	blot	analysis	of	NuRD	and	shelterin	components.	(H)	Telomere‐ChIP	against	ZNF827	in	WI38‐VA13/2RA	cells	
72	hrs	post‐transfection	with	siRNA	against	TR2,	TR4	and	COUP‐TF2.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	
is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(I)	Telomere‐ChIP	
against	ZNF827	in	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	lines.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	
down	is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	**P<0.	005	by	two	tailed	t	test).		
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Figure	S4.2	–	ZNF827	binding	to	telomeres	is	cell	cycle	regulated	and	ALT‐specific.	(A)	Telomere‐ChIP	against	ZNF827	in	the	
HT1080	hTR	and	HT1080	hTR	TCA	cell	lines.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	is	presented	in	the	
accompanying	graph	(mean	±	range;	n	=	2	biological	replicates).	(B)	Reverse	Co‐IP	of	NuRD	and	shelterin	components	from	WI38‐
VA13/2RA	 cells	 overexpressing	 ZNF827	 followed	 by	western	 blot	 analysis	 to	 detect	 ZNF827.	 (C)	 Real‐time	 RT‐PCR	 showing	
ZNF827	transcript	levels	in	WI38‐VA13/2RA	cells	72	hrs	post‐transfection	with	siRNA	against	different	nuclear	receptors	(mean	
±	SD;	n	=	3	technical	replicates;	**P<0.	005	by	two	tailed	t	test).	(D)	Real‐time	RT‐PCR	showing	ZNF827	transcript	levels	in	WI38‐
VA13/2RA	cells	48	hrs	after	overexpression	of	different	nuclear	receptors	(mean	±	SD;	n	=	3	technical	replicates;	**P<0.	005	by	
two	tailed	t	test).	(E)	Real‐time	RT‐PCR	showing	ZNF827	transcript	levels	in	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	
lines	(mean	±	SD;	n	=	3	technical	replicates;	*P<0.	05	by	two	tailed	t	test).	
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Figure	 S4.2	 Continued	 –	 (F)	 Telomere‐ChIP	 against	 ZNF827	 in	 synchronised	 WI38‐VA13/2RA	 cells.	 Quantitation	 of	 the	
percentage	of	telomeric	DNA	pulled	down	is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates).	(G)	
Real‐time	RT‐PCR	showing	ZNF827	transcript	levels	in	synchronised	WI38‐VA13/2RA	cells	(mean	±	SD;	n	=	3	technical	replicates).	
(H)	Real‐time	RT‐PCR	showing	ZNF827	transcript	levels	in	HT1080	hTR	and	HT1080	hTR	TCA	cells	(mean	±	SD;	n	=	3	technical	
replicates;	***P<0.	0001	by	two	tailed	t	test).	All	real‐time	RT‐PCR	was	carried	out	by	Hilda	A.	Pickett.		
	
4.4	NuRD‐ZNF827	deacetylates	ALT	telomeric	chromatin	and	inhibits	shelterin	binding	
The	 NuRD	 complex	 is	 a	 chromatin	 remodeller,	 which	 has	 a	 regulatory	 role	 in	 gene	 transcription	
predominantly	 through	chromatin	compaction	via	 its	HDAC	activity	 (reviewed	 in	Lai	and	Wade,	2011).	
Having	 found	 that	 ZNF827	 recruits	 NuRD	 to	 nuclear	 receptors	 at	 telomeres	 in	 ALT	 cells,	 we	 used	
knockdown	and	overexpression	of	ZNF827	to	 investigate	the	 impact	on	NuRD	binding	to	telomeres.	To	
determine	whether	NuRD	recruitment	alters	the	chromatin	state	of	telomeres,	we	performed	telomere‐
ChIP	 against	 different	 epigenetic	 modifications	 or	 “histone	 marks”	 in	 WI38‐VA13/2RA	 cells	 72	 hrs	
following	 siRNA‐mediated	 depletion	 of	 ZNF827.	 We	 identified	 a	 significant	 increase	 in	 acetylation	 of	
telomeric	histone	H4	at	both	lysines	5	and	8	(designated	acetyl	H4K5	and	H4K8,	respectively)	following	
knockdown	(Figure	4.3A).	An	increase	in	telomeric	histone	acetylation	was	also	observed	following	double	
knockdown	of	nuclear	receptors	TR4	and	COUP‐TF2	(Figure	S4.3A).	Overexpression	of	ZNF827	but	not	
ZNF827	 ΔRRK	 resulted	 in	 histone	 deacetylation	 (Figure	 4.3B).	 HT1080	 hTR	 TCA	 cells	 also	 displayed	
histone	deacetylation	at	their	telomeres	compared	to	the	HT1080	hTR	control	cell	line	(Figure	4.3C).	This	
directly	 demonstrates	 histone	 deacetylation	 by	 NuRD,	 following	 its	 recruitment	 to	 telomeres	 through	
nuclear	receptor	binding	to	variant	repeats.		
We	next	asked	whether	histone	hypoacetylation	was	a	general	feature	of	ALT	telomeres.	We	observed	no	
global	differences	in	either	histone	acetylation	or	methylation	at	telomeres	in	ALT	versus	non‐ALT	cells	
(Figure	S4.3B),	suggesting	no	net	change	 in	histone	marks	at	ALT	telomeres.	 Interestingly,	a	significant	
decrease	in	the	heterochromatin	mark	H3K9me3	was	observed	at	the	telomeres	of	HT1080	hTR	TCA	cells	
compared	 to	 the	HT1080	 hTR	 control	 cell	 line	 (Figure	 4.3C),	which	may	 be	 attributed	 to	 inhibition	 of	
shelterin	binding	caused	by	the	presence	of	variant	repeats.	This	is	supported	by	a	recent	study	that	found	
TRF2	depletion	markedly	 reduced	methylation	of	H3K9	(Porro	et	 al.,	2014).	Thus	 the	HDAC	activity	of	
NuRD‐ZNF827	may	have	a	critical	 function	 in	counteracting	histone	demethylation	caused	by	shelterin	
undersaturation,	 by	 compacting	 telomeric	 chromatin	 through	 histone	 hypoacetylation.	 To	 confirm	 the	
function	of	NuRD‐ZNF827	in	deacetylating	ALT	telomeric	chromatin,	we	measured	levels	of	the	telomeric	
RNA,	TERRA	(Azzalin	et	al.,	2007).	We	found	a	small	increase	in	TERRA	levels	following	either	ZNF827	or	
nuclear	receptor	double	knockdown	(Figure	4.3D)	and	a	significant	decrease	 in	TERRA	levels	 following	
ZNF827	overexpression	(Figure	4.3E),	indicating	that	NuRD‐ZNF827	decreases	TERRA	transcription.		
Based	on	relative	binding	affinities,	we	have	previously	deduced	that	nuclear	receptor	binding	to	variant	
repeats	 competitively	 displaces	 shelterin	 (Conomos	 et	 al.,	 2012).	Here	we	 determined	whether	NuRD‐
mediated	 chromatin	 deacetylation	 could	 also	 diminish	 shelterin	 binding	 to	 telomeres.	 Both	 double	
knockdown	 of	 nuclear	 receptors	 and	 knockdown	 of	 ZNF827	 significantly	 elevated	 recruitment	 of	 the	
shelterin	 components	 TRF2	 and	 RAP1	 to	 WI38‐VA13/2RA	 telomeres	 (Figure	 4.3F),	 whereas	
overexpression	 of	 ZNF827	 caused	 a	 significant	 decrease	 in	 shelterin	 binding	 to	ALT	 telomeres	 (Figure	
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4.3G).	This	was	confirmed	via	indirect	immunofluorescence	against	TRF2	and	telomere‐FISH	to	illustrate	
partial	loss	of	shelterin	at	the	telomere	following	overexpression	of	ZNF827	but	not	ZNF827	ΔRRK	(Figure	
4.3H).	 These	data	 demonstrate	 the	 potential	 for	 telomeric	NuRD	 to	 both	deplete	 shelterin	 and	 restore	
chromatin	compaction	by	histone	hypoacetylation.		
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Figure	4.3	–	NuRD‐ZNF827	deacetylates	histones,	 inhibits	TERRA	 transcription	and	prevents	shelterin	binding	at	ALT	
telomeres.	 (A)	 Telomere‐ChIP	 against	 histones	 and	 histone	 marks	 in	 WI38‐VA13/2RA	 cells	 72	 hrs	 after	 siRNA‐mediated	
knockdown	of	ZNF827.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	normalised	to	the	appropriate	histone	(either	
H3	or	H4)	is	presented	in	the	two	accompanying	graphs	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	
(B)	Telomere‐ChIP	against	histone	H4	and	pan	acetyl	H4	in	WI38‐VA13/2RA	cells	48	hrs	after	overexpression	of	either	ZNF827	
wild‐type	or	ZNF827	ΔRRK.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	normalised	to	histone	H4	is	presented	
in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(C)	Telomere‐ChIP	against	
histones	and	histone	marks	in	HT1080	hTR	and	HT1080	hTR	TCA	cells.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	
down	normalised	to	the	appropriate	histone	(either	H3	or	H4)	is	presented	in	the	two	accompanying	graphs	(mean	±	range;	n	=	2	
biological	 replicates;	 *P<0.	 05	 by	 two	 tailed	 t	 test).	 (D)	 TERRA	RNA	 dot	 blot	 analysis	 on	WI38‐VA13/2RA	 cells	 72	 hrs	 post‐
transfection	with	siRNA	targeting	either	ZNF827	or	TR4	and	COUP‐TF2.	Quantitation	of	TERRA	transcript	levels	normalised	to	the	
scrambled	siRNA‐treated	control	is	presented	in	the	accompanying	graph	(mean	±	SD;	n	=	3	biological	replicates).	(E)	TERRA	RNA	
dot	 blot	 analysis	 on	 WI38‐VA13/2RA	 cells	 48	 hrs	 after	 overexpression	 of	 ZNF827.	 Quantitation	 of	 TERRA	 transcript	 levels	
normalised	to	the	empty	vector	control	is	presented	in	the	accompanying	graph	(mean	±	SD;	n	=	3	biological	replicates;	*P<0.	05	
by	two	tailed	t	test).	(F)	Telomere‐ChIP	against	shelterin	components	in	WI38‐VA13/2RA	cells	72	hrs	after	ZNF827	knockdown.	
Quantitation	 of	 the	 percentage	 of	 telomeric	DNA	pulled	 down	 is	 presented	 in	 the	 accompanying	 graph	 (mean	±	 range;	n	=	2	
biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(G)	Telomere‐ChIP	against	shelterin	components	in	WI38‐VA13/2RA	cells	48	
hrs	 after	 overexpression	 of	 ZNF827.	 Quantitation	 of	 the	 percentage	 of	 telomeric	 DNA	 pulled	 down	 is	 presented	 in	 the	
accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(H)	Four‐color	imaging	of	WI38‐
VA13/2RA	nuclei	48	hrs	after	overexpression	of	ZNF827	or	ZNF827	ΔRRK.	 Indirect	 immunofluorescence	against	 the	shelterin	
component	TRF2	(red)	and	Myc‐tagged	ZNF827	(purple)	coupled	with	telomere‐FISH	(green)	and	DAPI	(blue)	counterstaining	
shows	that	ALT	cells	overexpressing	ZNF827	but	not	ZNF827	ΔRRK	have	diminished	TRF2	recruitment	to	telomeres	(indicated	by	
white	arrows).	The	white	bar	is	equivalent	to	10	µm.		
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Figure	S4.3	–	NuRD‐ZNF827	remodels	ALT	telomeric	chromatin.	(A)	Telomere‐ChIP	against	histones	and	histone	marks	in	
WI38‐VA13/2RA	cells	72	hrs	after	simultaneous	siRNA‐mediated	knockdown	TR4	and	COUP‐TF2.	Quantitation	of	the	percentage	
of	telomeric	DNA	pulled	down	normalised	to	the	appropriate	histone	(either	H3	or	H4)	 is	presented	in	the	two	accompanying	
graphs	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(B)	Telomere‐ChIP	against	histones	and	histone	
marks	in	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	lines.	Quantitation	of	the	percentage	of	telomeric	DNA	pulled	down	
normalised	 to	 the	 appropriate	 histone	 (either	H3	or	H4)	 is	presented	 in	 the	 two	 accompanying	 graphs	 (mean	±	 range;	n	=	2	
biological	replicates).		
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4.5	NuRD‐ZNF827	drives	ALT	and	recruits	HR	proteins	
To	 determine	 whether	 recruitment	 of	 NuRD‐ZNF827	 to	 telomeres	 is	 required	 for	 ALT	 activity,	 we	
quantitated	APBs	(Yeager	et	al.,	1999),	which	are	robust	markers	of	ALT	activity	detected	by	colocalisation	
of	PML	protein	with	telomeric	DNA.	Depletion	of	ZNF827	(Figure	S4.4A)	caused	a	significant	reduction	in	
APBs	(Figures	4.4A	and	C),	whereas	overexpression	of	ZNF827	(Figure	S4.4B)	led	to	a	significant	increase	
in	APB	number	in	both	IIICF/c	and	WI38‐VA13/2RA	cell	lines	(Figures	4.4B	and	C).	In	addition,	ZNF827	
depletion	decreased	partially	single‐stranded	C‐rich	telomere	circles	known	as	C‐circles,	another	hallmark	
of	ALT	(Henson	et	al.,	2009).	Conversely,	overexpression	of	ZNF827	led	to	a	significant	increase	in	C‐circles	
(Figure	 4.4D).	 Elevated	 telomere‐sister	 chromatid	 exchange	 (T‐SCE)	 events	 are	 associated	 with	 ALT	
activity	 (Londono‐Vallejo	 et	 al.,	 2004;	 Bechter	 et	 al.,	 2004),	 and	 can	 be	 quantitated	 by	 chromosome	
orientation‐FISH	(CO‐FISH)	(see	Figure	4.4E).	We	observed	a	substantial	increase	in	T‐SCE	frequency	in	
WI38‐VA13/2RA	 ALT	 cells	 following	 ZNF827	 overexpression	 (Figures	 4.4F,	 G	 and	 H),	 which	 was	 not	
observed	 in	 the	HT1080	hTR	 telomerase‐positive	 cells	 (Figures	 S4.4C	 and	D).	 In	 contrast,	 depletion	of	
ZNF827	was	accompanied	by	a	decrease	in	T‐SCEs	(Figure	4.4H).	Other	telomeric	aberrations	were	also	
observed	following	ZNF827	overexpression	specifically	in	ALT	cells	(Figure	4.4F).	First,	we	identified	an	
increase	 in	 telomere	 exchange	 events	 involving	 only	 one	 sister	 chromatid,	 the	 great	majority	 of	which	
involved	duplication	of	the	leading	strand,	which	may	be	representative	of	inter‐telomeric	recombination	
(Figure	S4.4E).	Second,	we	observed	an	increase	in	fragile	telomeres	(Figure	S4.4F)	indicative	of	replication	
stress.	Third,	we	identified	a	significant	increase	in	the	percentage	of	chromosome	ends	associated	with	
large	 extra‐chromosomal	 telomeric	 repeat	 (ECTR)	 DNA	 signals	 (Figure	 S4.4G),	 which	 we	 have	 shown	
previously	to	be	consistent	with	APBs	in	both	size	and	signal	intensity	(Cesare	et	al.,	2009).		
The	observed	changes	to	ALT	phenotypic	characteristics	suggest	that	NuRD‐ZNF827	plays	an	important	
role	 in	 promoting	 telomeric	 recombination,	 but	 do	 not	 directly	 demonstrate	 HR‐primed	 telomere	
replication.	To	further	evaluate	whether	ALT‐mediated	telomere	synthesis	was	directly	affected	we	pulsed	
cells	with	BrdU	for	8	hrs	to	determine	whether	newly	synthesised	DNA	was	being	added	to	the	telomeres	
following	ZNF827	overexpression.	By	combining	indirect	immunofluorescence	against	both	BrdU	and	the	
Myc‐tagged	ZNF827	with	telomere‐FISH	we	observed	a	striking	increase	in	the	incorporation	of	BrdU	into	
telomeres	 following	 ZNF827	 overexpression	 in	 both	 WI38‐VA13/2RA	 and	 IIICF/c	 cells	 (Figure	 4.4I),	
indicating	that	ZNF827	promotes	ALT	activity.		
The	 ALT	 mechanism	 involves	 HR‐mediated	 strand	 invasion	 and	 template‐driven	 telomere	 synthesis,	
indicating	a	requirement	for	HR	proteins	(reviewed	in	Cesare	and	Reddel,	2010).	It	has	previously	been	
shown	that	the	NuRD	component	CHD4	is	able	to	recruit	the	early	DDR	protein,	BRIT1	(Pan	et	al.,	2012).	
BRIT1	 regulates	DNA	 repair	 through	 chromatin	 remodelling	 by	 allowing	 access	 of	DDR	 and	HR	 repair	
proteins	to	DNA	(Lin	et	al.,	2010).	We	investigated	whether	NuRD‐ZNF827	directly	recruits	BRIT1	to	ALT	
telomeres.	Using	indirect	immunofluorescence	coupled	with	telomere‐FISH	we	found	a	significant	increase	
in	 BRIT1	 localisation	 to	 WI38‐VA13/2RA	 telomeres	 following	 ZNF827	 overexpression.	 This	 was	
accompanied	by	an	increase	in	breast	cancer	type	1	susceptibility	protein	(BRCA1)	accrual	at	telomeres	
(Figure	4.4J).	BRCA1	plays	a	central	role	in	double‐strand	break	repair	by	HR	and	thus	its	accumulation	at	
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telomeres	may	facilitate	ALT‐associated	telomeric	recombination.	Indeed,	BRCA1	has	been	shown	to	be	
required	for	BrdU	incorporation	at	APBs	(Wu	et	al.,	2003).	BRIT1	and	BRCA1	localisation	at	large	telomeric	
foci	 is	 consistent	with	 their	presence	 in	APBs,	 and	 supports	 the	proposed	 role	of	APBs	as	 sites	 of	ALT	
activity	 (Yeager	 et	 al.,	 1999;	 Draskovic	 et	 al.,	 2009).	 Together	 these	 data	 suggest	 that	 NuRD‐ZNF827	
recruitment	to	ALT	telomeres	promotes	HR	and	ALT	activity.		
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Figure	4.4	–	NuRD‐ZNF827	recruitment	to	telomeres	promotes	ALT	activity.	(A)	Three‐color	 imaging	of	WI38‐VA13/2RA	
nuclei	at	interphase	72	hrs	after	ZNF827	knockdown.	Indirect	immunofluorescence	against	PML	(red)	coupled	with	telomere‐FISH	
(green)	and	DAPI	(blue)	counterstaining	illustrates	that	APBs	decrease	following	ZNF827	depletion.	The	white	bar	is	equivalent	to	
10	 µm.	 (B)	 Four‐color	 imaging	 of	WI38‐VA13/2RA	 nuclei	 48	 hrs	 after	 ZNF827	 overexpression.	 Indirect	 immunofluorescence	
against	PML	(red)	and	Myc‐tagged	ZNF827	(purple)	coupled	with	telomere‐FISH	(green)	and	DAPI	(blue)	counterstaining	shows	
that	ALT	cells	overexpressing	ZNF827	have	more	APBs	(indicated	by	white	arrows).	The	white	bar	is	equivalent	to	10	µm.	(C)	
Quantitation	of	the	number	of	APBs	in	WI38‐VA13/2RA	and	IIICF/c	cells	after	knockdown	(72	hrs)	and	overexpression	(48	hrs)	of	
ZNF827	(mean	±	SD;	n	=	50).	P	values	were	obtained	from	two‐tailed	Mann‐Whitney	tests.	Three	independent	experiments	yielded	
similar	 results	 in	 both	 ALT	 cell	 lines.	 (D)	 C‐circle	 assay	 on	WI38‐VA13/2RA	 and	 IIICF/c	 cells	 after	 knockdown	 (72	 hrs)	 and	
overexpression	(48	hrs)	of	ZNF827.	Quantitation	of	C‐circle	levels	relative	to	the	untransfected	sample	of	each	cell	line	is	displayed	
in	the	accompanying	graph	(mean	±	SD;	n	=	3	biological	replicates;	*P<0.	05	by	two	tailed	t	test).		
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Figure	4.4	Continued	–	(E)	Schematic	representation	of	 the	chromosome	orientation‐FISH	(CO‐FISH)	protocol	used	 to	detect	
telomere‐sister	chromatid	exchange	(T‐SCE)	events.	(F)	Examples	of	telomere	aberrations	observed	following	CO‐FISH	analysis	of	
WI38‐VA13/2RA	cells	48	hrs	post‐ZNF827	overexpression.	Leading‐	(red;	Texas	Red‐conjugated	(TTAGGG)3)	and	lagging‐	(green;	
Alexa	 Fluor	 488‐conjugated	 (CCCTAA)3)	 strand	 telomere‐FISH	 coupled	 with	 DAPI	 (blue)	 counterstaining.	 The	 white	 bar	 is	
equivalent	to	5	µm.	(G)	CO‐FISH	of	metaphases	from	WI38‐VA13/2RA	cells	48	hrs	post‐ZNF827	overexpression.	The	white	bar	is	
equivalent	to	10	µm.	(H)	Quantitation	of	T‐SCEs	observed	via	CO‐FISH	after	knockdown	(72	hrs)	and	overexpression	(48	hrs)	of	
ZNF827	in	WI38‐VA13/2RA	cells	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	>2,000	chromosome	ends	or	~20	metaphases	
per	replicate).	Quantitation	of	T‐SCEs	was	restricted	to	chromosome	ends	with	clearly	distinguishable	sister	telomeres.	(I)	Four‐
color	imaging	of	WI38‐VA13/2RA	nuclei	48	hrs	after	ZNF827	overexpression.	Indirect	immunofluorescence	against	BrdU	(red)	
and	Myc‐tagged	ZNF827	(purple)	coupled	with	telomere‐FISH	(green)	and	DAPI	(blue)	counterstaining	shows	an	increase	in	BrdU	
incorporation	at	telomeres	following	an	8	hr	pulse	in	cells	overexpressing	ZNF827	(colocalisations	indicated	by	white	arrows).	The	
white	 bar	 is	 equivalent	 to	 10	 µm.	 Quantitation	 of	 the	 percentage	 of	 cells	 with	 BrdU‐positive	 telomeres	 is	 displayed	 in	 the	
accompanying	graph	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	50	nuclei	per	replicate;	*P<0.	05	and	**P<0.	005	by	two	
tailed	t	test).	(J)	Four‐color	imaging	of	WI38‐VA13/2RA	nuclei	48	hrs	after	ZNF827	overexpression.	Indirect	immunofluorescence	
against	 BRIT1	 or	 BRCA1	 (red)	 and	 Myc‐tagged	 ZNF827	 (purple)	 coupled	 with	 telomere‐FISH	 (green)	 and	 DAPI	 (blue)	
counterstaining	shows	that	ALT	cells	overexpressing	ZNF827	have	considerably	more	of	these	proteins	localising	to	telomeres	
(colocalisations	 indicated	by	white	arrows).	The	white	bar	 is	equivalent	to	10	µm.	Quantitation	of	the	percentage	of	cells	with	
BRIT1	and	BRCA1	colocalising	with	telomeres	 is	displayed	 in	the	accompanying	graph	(mean	±	SD;	n	=	3	biological	replicates,	
quantifying	50	nuclei	per	replicate;	*P<0.	05	by	two	tailed	t	test).		
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Figure	 S4.4	 –	 ALT	 phenotypic	 characteristics	 are	 affected	 by	 ZNF827	 expression.	 (A)	 Real‐time	 RT‐PCR	 confirming	
knockdown	of	ZNF827	transcript	levels	72	hrs	post‐transfection	with	siRNA	in	WI38‐VA13/2RA	and	IIICF/c	cells	(mean	±	SD;	n	=	
3	technical	replicates;	**P<0.	005	and	***P<0.	0001	by	two	tailed	t	test).	Real‐time	RT‐PCR	was	performed	by	Hilda	A.	Pickett.	(B)	
Western	 blot	 analysis	 of	 whole‐cell	 extracts	 (1	 ×	 105	 cell	 equivalents)	 from	WI38‐VA13/2RA	 and	 IIICF/c	 cells	 48	 hrs	 after	
overexpression	of	ZNF827.	(C)	Western	blot	analysis	of	whole‐cell	extracts	(1	×	105	cell	equivalents)	from	HT1080	hTR	cells	48	
hrs	after	overexpression	of	ZNF827.	(D)	 CO‐FISH	of	metaphases	 from	HT1080	hTR	cells	48	hrs	post‐ZNF827	overexpression.	
Leading	 (red;	 Texas	 Red‐conjugated	 (TTAGGG)3)	 and	 lagging	 (green;	 Alexa	 Fluor	 488‐conjugated	 (CCCTAA)3)	 telomere‐FISH	
coupled	with	DAPI	(blue)	counterstaining.	The	white	bar	is	equivalent	to	10	µm.	(E)	Quantitation	of	the	percentage	of	chromosome	
ends	with	two	colors	on	only	one	sister	chromatid	observed	48	hrs	after	ZNF827	overexpression	in	WI38‐VA13/2RA	cells	via	CO‐
FISH	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	>2,000	chromosome	ends	or	~20	metaphases	per	replicate;	*P<0.	05	by	
two	tailed	t	test).	(F)	Quantitation	of	the	percentage	of	fragile	telomeres	observed	48	hrs	after	ZNF827	overexpression	in	WI38‐
VA13/2RA	cells	via	CO‐FISH	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	>2,000	chromosome	ends	or	~20	metaphases	per	
replicate;	*P<0.	05	by	two	tailed	t	test).		
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Figure	S4.4	Continued	–	(G)	Quantitation	of	the	percentage	of	chromosome	ends	associating	with	ECTR	foci	observed	48	hrs	after	
ZNF827	 overexpression	 in	 WI38‐VA13/2RA	 cells	 via	 CO‐FISH	 (mean	 ±	 SD;	 n	 =	 3	 biological	 replicates,	 quantifying	 >2,000	
chromosome	ends	or	~20	metaphases	per	replicate;	*P<0.	05	by	two	tailed	t	test).		
	
4.6	NuRD‐ZNF827	recruitment	causes	telomere‐telomere	interactions	
Overexpression	of	ZNF827	in	ALT	cells	resulted	in	a	striking	phenotype	visualised	as	long,	thin	fibres	of	
telomeric	DNA	connecting	telomeres	(Figure	4.5A).	These	structures	have	been	observed	previously	in	ALT	
cells,	and	were	termed	"telomere	bridges"	and	postulated	to	be	recombination	intermediates	(Draskovic	
et	al.,	2009).	Here,	telomere	bridges	were	identified	between	the	telomeres	of	sister	chromatids,	between	
homologous	and	non‐homologous	chromosomes,	and	among	multiple	chromosomes	(Figure	4.5B).	These	
structures	were	frequently	associated	with	large	aggregates	of	telomeric	material,	consistent	with	telomere	
bridges	connecting	with	APBs	that	then	dissipate	during	metaphase.	Quantitation	of	telomere	bridges	in	a	
panel	of	mortal,	telomerase‐positive	and	ALT	cell	lines	confirmed	that	these	structures	are	specific	to	cells	
which	use	the	ALT	mechanism	(Figure	4.5C).	ZNF827	and	nuclear	receptor	knockdown,	as	well	as	ZNF827	
and	 ZNF827	 ΔRRK	 overexpression	 demonstrated	 that	 the	 number	 of	 these	 structures	 correlated	with	
ZNF827‐mediated	recruitment	of	NuRD	to	the	telomere	(Figure	4.5D).	This	conclusion	was	corroborated	
by	the	presence	of	telomere	bridges	in	HT1080	hTR	TCA	cells	but	not	in	the	control	HT1080	hTR	cell	line	
(Figure	S4.5A).		
To	determine	whether	the	HDAC	activity	of	NuRD	was	required	for	telomere	bridge	formation	we	treated	
WI38‐VA13/2RA	 cells	 overexpressing	 ZNF827	with	HDAC	 inhibitors.	 Strikingly,	we	 found	 a	 significant	
increase	in	telomere	bridges	(Figure	S4.5B),	despite	a	slight	decrease	in	NuRD	recruitment	to	telomeres	
(Figure	 S4.5C),	 indicating	 that	 the	 HDAC	 activity	 of	 NuRD	 limits	 telomere	 bridge	 formation.	 Telomere	
bridges	were	not	seen	in	the	absence	of	the	hypotonic	swelling	and	high‐speed	cytocentrifugation	steps	
used	during	cytogenetic	preparation	(Figure	S4.5D),	indicating	that	the	DNA	is	stretched	as	result	of	cellular	
swelling.	We	postulate	 that	 the	 telomere	bridge	phenotype	observed	 following	ZNF827	overexpression	
results	from	telomere‐telomere	associations	caused	by	increased	NuRD,	which	promotes	protein‐protein	
interactions	among	multiple	NuRD	components	situated	on	different	telomeres,	and	that	the	DNA	which	is	
connected	in	this	way	becomes	stretched	by	cytogenetic	processing.		
To	investigate	these	telomere	associations	throughout	the	cell	cycle,	bridges	were	quantitated	following	
synchronisation	of	WI38‐VA13/2RA	cells	overexpressing	ZNF827.	Telomere	bridges	were	most	prevalent	
in	the	G2/M	population,	decreasing	in	M,	and	essentially	non‐detectable	within	the	G1/S	population	(Figure	
S4.5E).	This	was	confirmed	using	indirect	immunofluorescence	against	the	cell	cycle	markers	CDT1	(G1),	
geminin	 (S/G2),	 CENP‐F	 (G2)	 and	 H3	 phosphorylated	 at	 serine	 10	 (phospho‐H3;	 M)	 (Figure	 4.5E),	
indicating	 that	 telomere	 bridges	 are	 formed	 post‐replicatively	 and	 are	 largely	 resolved	 by	 the	 end	 of	
metaphase,	thus	facilitating	mitotic	chromosome	segregation	(Figure	4.5F).	Western	blot	analysis	of	cell	
cycle	proteins	showed	a	decrease	in	G2/M	markers	after	ZNF827	knockdown	and	an	increase	following	
ZNF827	overexpression	(Figure	S4.5F).	The	G1	marker,	CDT1,	mirrored	this	result.	An	accumulation	of	ALT	
cells	in	G2/M	in	response	to	ZNF827	overexpression,	and	a	reciprocal	decrease	of	cells	in	G2/M	following	
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knockdown	of	ZNF827	was	further	demonstrated	by	cell	cycle	analysis	(Figure	S4.5G).	This	suggests	that	
the	enhanced	telomere‐telomere	interactions	in	G2	delay	transit	of	cells	through	G2/M.	These	data	thus	
indicate	 that	 NuRD‐ZNF827‐mediated	 telomere‐telomere	 interactions	 occur	 post‐replicatively	 and	 that	
their	resolution	is	rate‐limiting	for	cell	cycle	progression.		
	
Figure	 4.5	 –	 ALT‐specific	 telomere‐telomere	 interactions	 are	 caused	 by	NuRD‐ZNF827.	 (A)	 Representative	 metaphase	
spread	of	the	WI38‐VA13/2RA	cell	line	stained	with	TR4	(red)	and	Myc‐tagged	ZNF827	(green)	immunofluorescence	and	DAPI	
(blue)	demonstrating	extensive	telomere	bridge	formation	48	hrs	after	ZNF827	overexpression.	Aggregates	of	telomeric	material	
frequently	found	on	telomere	bridges	are	indicated	by	white	arrows.	The	white	bar	is	equivalent	to	10	µm.	(B)	Magnified	examples	
of	telomere	bridges	shown	in	(A).	The	white	bar	is	equivalent	to	5	µm.	(C)	Quantitation	of	the	percentage	of	(pro)metaphases	with	
telomere	bridges	in	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	lines	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	
~50	(pro)metaphases	per	replicate).		
Results	II		 	
 
 
72 
Figure	4.5	Continued	–	(D)	Quantitation	of	the	percentage	of	(pro)metaphases	with	telomere	bridges	in	WI38‐VA13/2RA	cells	
following	siRNA‐mediated	knockdown	(72	hrs)	of	ZNF827	and	nuclear	receptors	as	well	as	overexpression	(48	hrs)	of	ZNF827	and	
ZNF827	ΔRRK	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	~50	(pro)metaphases	per	replicate;	*P<0.	05	and	**P<0.	005	by	
two	tailed	t	test).	(E)	Quantitation	of	the	percentage	of	WI38‐VA13/2RA	cells	with	telomere	bridges	and	specific	cell	cycle	markers	
48	hrs	after	ZNF827	overexpression.	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	~50	cells	per	replicate;	*P<0.	05	and	**P<0.	
005	by	two	tailed	t	test).	(F)	Schematic	representation	of	telomere	bridge	formation	throughout	the	cell	cycle	in	WI38‐VA13/2RA	
cells	48	hrs	after	ZNF827	overexpression.	Indirect	immunofluorescence	against	cell	cycle	markers	(multiple	colors)	coupled	with	
telomere‐FISH	(white)	and	DAPI	(blue)	counterstaining	shows	that	telomere	bridges	form	during	S/G2	phase	and	are	resolved	by	
metaphase.	The	white	bar	is	equivalent	to	10	µm.		
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Figure	S4.5	–	ALT‐specific	telomere	bridges	caused	by	the	NuRD‐ZNF827	complex	lead	to	prolonged	prometaphase.	(A)	
Quantitation	of	the	percentage	of	(pro)metaphases	with	telomere	bridges	in	the	HT1080	hTR	and	HT1080	hTR	TCA	cell	lines	(mean	
±	SD;	n	=	3,	quantifying	~50	(pro)metaphases	per	replicate;	***P<0.	0001	by	two	tailed	t	test).	(B)	Quantitation	of	the	percentage	
of	WI38‐VA13/2RA	cells	with	telomere	bridges	48	hrs	after	ZNF827	overexpression	and	24	hrs	after	treatment	with	various	HDAC	
inhibitors	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	~50	cells	per	replicate;	*P<0.	05	by	two	tailed	t	test).	(C)	Telomere‐
ChIP	against	NuRD	components	in	WI38‐VA13/2RA	cells	24	hrs	after	TSA	treatment.	Quantitation	of	the	percentage	of	telomeric	
DNA	pulled	down	is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	
(D)	Quantitation	of	the	percentage	of	WI38‐VA13/2RA	cells	with	telomere	bridges	with	or	without	the	use	of	standard	cytogenetic	
methods	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	~50	cells	per	replicate;	***P<0.	0001	by	two	tailed	t	test).	
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Figure	S4.5	Continued	–	(E)	Quantitation	of	the	percentage	of	cells	with	telomere	bridges	48	hrs	after	ZNF827	overexpression	in	
synchronised	WI38‐VA13/2RA	cells	(mean	±	SD;	n	=	3	biological	replicates,	quantifying	~50	cells	per	replicate;	*P<0.	05	and	**P<0.	
005	by	two	tailed	t	test).	(F)	Western	blot	analysis	of	whole‐cell	extracts	(1	×	105	cell	equivalents)	from	WI38‐VA13/2RA	cells	
following	siRNA‐mediated	knockdown	(72	hrs)	and	overexpression	(48	hrs)	of	ZNF827	showing	the	global	expression	of	cell	cycle	
markers.	(G)	Quantitation	of	 the	percentage	of	HT1080	hTR,	WI38‐VA13/2RA	and	 IIICF/c	 cells	 in	each	 stage	of	 the	 cell	 cycle	
following	siRNA‐mediated	knockdown	(72	hrs)	and	overexpression	(48	hrs)	of	ZNF827	(mean	±	SD;	n	=	3	biological	replicates).		
	
4.7	NuRD‐ZNF827	loss	causes	senescence	and	apoptosis	in	ALT	cells	
To	investigate	the	role	of	telomeric	NuRD‐ZNF827	in	ALT	cell	proliferation,	we	knocked	down	ZNF827	with	
siRNA	every	72	hrs	over	the	course	of	9	days	in	a	panel	of	cell	 lines	(Figure	S4.6A).	The	growth	rate	of	
mortal	 and	 telomerase‐positive	 cells	 was	 not	 significantly	 altered,	 however	 ZNF827	 depletion	 had	 a	
variable	but	detrimental	effect	on	the	growth	rate	of	ALT	cells	(Figure	4.6A).	A	slight	increase	in	the	growth	
rate	of	ALT	cells	was	observed	during	the	first	72	hrs,	consistent	with	ZNF827	depletion	allowing	cells	to	
bypass	stalling	in	G2/M	caused	by	telomere‐telomere	interactions.	However,	by	day	6‐9	the	growth	rate	of	
all	 the	 ALT	 cell	 lines	 was	 significantly	 diminished.	 We	 used	 a	 combination	 of	 trypan‐blue	 and	 β‐
galactosidase	staining	to	assess	cell	viability	and	detect	senescence,	respectively.	A	significant	increase	in	
both	senescent	and	non‐viable	cells	was	observed	following	ZNF827	depletion	in	ALT	cells	(Figures	4.6B	
and	C).	WI38‐VA13/2RA	cells	exhibited	the	most	severe	effects,	with	a	significant	increase	in	both	non‐
viable	and	senescent	cells,	whilst	the	reduction	in	growth	rate	of	IIICF/c	cells	was	predominantly	reflective	
of	 the	 onset	 of	 senescence	 within	 approximately	 38%	 of	 the	 population	 (Figure	 4.6C).	 Indirect	
immunofluorescence	against	cleaved	caspase‐3	was	used	to	detect	activation	of	apoptosis.	A	significant	
increase	in	cleaved	caspase‐3‐positive	cells	was	observed	in	WI38‐VA13/2RA	cells	but	not	the	HT1080	hTR	
or	 IIICF/c	 cell	 lines	 (Figure	 4.6D),	 indicating	 that	 ZNF827	 depletion	 can	 initiate	 senescence	 and/or	
apoptosis	 in	ALT	 cells.	 The	 differences	 in	 response	may	 reflect	 differences	 in	 the	 checkpoints	 that	 are	
retained	by	different	immortalised	cell	lines.	Alternatively,	increased	NuRD	binding	to	the	telomeres	of	the	
WI38‐VA13/2RA	cell	line	compared	to	IIICF/c	cells	may	exacerbate	the	effects	of	ZNF827	depletion.		
Given	growing	evidence	that	heterochromatin	can	shield	DNA	from	damage	and	that	NuRD	components	
can	prevent	spontaneous	DNA	damage	(Smeenk	et	al.,	2010),	we	investigated	whether	ZNF827	depletion	
and	 the	 subsequent	 loss	 of	 NuRD	 recruitment	 to	 telomeres	 could	 increase	 the	 DDR	 at	 ALT	 telomeres.	
Telomere‐ChIP	revealed	that	knockdown	of	ZNF827	for	6	days	caused	a	significant	increase	in	γ‐H2AX	at	
telomeric	 repeats	 but	 not	 at	 Alu	 repeats	 in	 WI38‐VA13/2RA	 cells,	 which	 was	 not	 observed	 in	 the	
telomerase‐positive	HT1080	hTR	cell	line	(Figure	4.6E).	In	contrast,	overexpression	of	ZNF827	led	to	an	
ALT‐specific	 decrease	 in	 telomere‐specific	 γ‐H2AX	 (Figure	 4.6F)	 suggesting	 that	 NuRD‐ZNF827	 can	
decrease	DDR	at	ALT	 telomeres,	 either	by	preventing	DNA	damage	or	by	 inhibiting	 the	DDR.	 It	 is	 also	
possible	 that	 removal	 of	 NuRD‐ZNF827	 from	 telomeres	 disrupts	 ALT	 activity,	 thus	 compounding	 the	
telomere‐specific	DDR.	These	data	implicate	a	protective	role	for	NuRD‐ZNF827	at	ALT	telomeres,	which	
is	vital	for	ALT	activity	and	the	sustained	proliferation	of	ALT	cells.		
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Figure	4.6	–	ZNF827	knockdown	increases	the	telomeric	DDR	and	causes	senescence/apoptosis	in	ALT	cells.	(A)	Growth	
curves	of	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	lines	transfected	with	ZNF827	siRNA	every	72	hrs	over	the	course	of	
9	days.	(B)	Phase‐contrast	(left	panel)	and	bright‐field	(right	panel)	microscopy	of	HT1080	hTR,	WI38‐VA13/2RA	and	IIICF/c	cells	
after	 9	 days	 of	 ZNF827	 knockdown	 showing	 senescent	 cells	 with	 β‐galactosidase	 activity	 (blue)	 at	 pH	 6.0.	 The	 white	 bar	 is	
equivalent	 to	 40	 µm.	 (C)	 Quantitation	 of	 the	 percentage	 of	 viable	 (trypan	 blue‐negative),	 senescent	 (β‐galactosidase‐
positive/trypan	blue‐negative)	and	non‐viable	(trypan	blue‐positive)	cells	in	a	panel	of	mortal,	telomerase‐positive	and	ALT	cell	
lines	after	9	days	of	ZNF827	knockdown.	IIICF/c	cells	48	hrs	after	a	5	Gy	dose	of	ionising	radiation	(IR)	is	also	shown.	(D)	Two‐
color	imaging	of	WI38‐VA13/2RA	nuclei	72	hrs	after	ZNF827	knockdown	and	48	hrs	after	5	Gy	IR.	Indirect	immunofluorescence	
against	cleaved	caspase‐3	(red)	and	DAPI	(blue)	counterstaining	was	used	to	identify	apoptotic	cells.	The	white	bar	is	equivalent	
to	10	µm.	Quantitation	of	the	percentage	of	cleaved	caspase‐3	(apoptotic)	cells	is	displayed	in	the	accompanying	graph	(mean	±	
SD;	n	=	3,	quantifying	50	nuclei	per	replicate;	**P<0.	005	and	***P<0.	0001	by	two	tailed	t	test).	(E)	Telomere‐ChIP	against	γ‐H2AX	
in	HT1080	hTR	and	WI38‐VA13/2RA	cells	after	6	days	of	ZNF827	knockdown.	Quantitation	of	the	percentage	of	telomeric	DNA	
pulled	down	is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	05	by	two	tailed	t	test).	(F)	
Telomere‐ChIP	against	γ‐H2AX	in	HT1080	hTR	and	WI38‐VA13/2RA	cells	48	hrs	after	ZNF827	overexpression.	Quantitation	of	the	
percentage	of	telomeric	DNA	pulled	down	is	presented	in	the	accompanying	graph	(mean	±	range;	n	=	2	biological	replicates;	*P<0.	
05	by	two	tailed	t	test).		
	
Figure	S4.6	–	Validation	of	ZNF827	knockdown	in	cell	line	panel.	Real‐time	RT‐PCR	confirming	the	knockdown	of	ZNF827	
transcript	 levels	72	hrs	post‐transfection	with	 siRNA	 in	 the	entire	panel	of	 cell	 lines	 shown	 in	Figure	4.6A	 (mean	±	SD;	n	=	3	
technical	replicates;	*P<0.	05	by	two	tailed	t	test).	Real‐time	RT‐PCR	was	performed	by	Hilda	A.	Pickett.		
	
4.8	Conclusion	
In	 the	previous	chapter	we	have	shown	that	nuclear	receptors	are	bound	to	 the	 telomeres	of	cells	 that	
utilise	ALT.	Here	we	demonstrate	that	nuclear	receptors	recruit	ZNF827,	a	zinc	finger	protein	of	unknown	
function,	which	recruits	the	NuRD	complex	via	binding	to	an	N‐terminal	RRK	motif	within	ZNF827.	This	
results	 in	 hypoacetylation	 of	 telomeric	 chromatin,	 decreased	 shelterin	 binding,	 a	 diminished	 telomeric	
DDR	as	well	as	enhanced	telomere‐telomere	interactions	and	recruitment	of	HR	proteins,	and	is	critically	
important	 for	 cell	 viability	 and	proliferation.	We	propose	 that	NuRD‐ZNF827	 recruitment	 to	 telomeres	
establishes	a	molecular	platform	which	remodels	telomeric	chromatin	and	creates	an	environment	which	
promotes	telomere‐telomere	recombination,	and	integrates	and	controls	multiple	mechanistic	elements	of	
ALT	activity.		
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Discussion	
		
5.1	Discussion	of	Results	I	
In	this	study,	we	have	described	telomeric	structural	abnormalities	associated	with	ALT	cells,	and	provided	
evidence	for	their	role	in	the	ALT	pathway.	The	data	presented	here	demonstrate	for	the	first	time	that	ALT	
telomeres	 are	 enriched	 with	 variant	 telomeric	 repeats	 that	 differ	 from	 the	 canonical	 form,	 the	 most	
common	 of	 which	 is	 the	 C‐type	 variant.	 In	 mortal	 and	 telomerase‐positive	 cells,	 variant	 repeats	 are	
restricted	to	the	proximal	2	kb	of	the	telomere	where	they	evolve	along	haploid	lineages	by	intra‐allelic	
mutational	mechanisms	such	as	replication	errors	and	slippage,	and	persist	as	a	result	of	 low	selective	
pressure	and	 inaccessibility	 to	 telomerase	 (Baird	et	 al.,	 1995;	Coleman	et	 al.,	 1999;	Baird	et	 al.,	 2000).	
However,	in	ALT	cells,	telomeres	engage	in	complex	HR‐mediated	replication	events	(Varley	et	al.,	2002;	
Dunham	 et	 al.,	 2000),	 which	 presumably	 result	 in	 the	 dispersion	 of	 proximal	 repeats	 throughout	 the	
telomeres	that	we	have	observed	here.	The	specific	location	and	percentage	(relative	to	telomere	length)	
of	these	variant	repeats	within	the	telomere	may	determine	whether	they	contribute	to	the	ALT	phenotype.	
We	have	demonstrated	that	the	C‐type	variant	repeat	is	highly	abundant	within	ALT	telomeres,	existing	in	
small	interspersed	blocks	of	variant	sequences	throughout	the	entire	canonical	repeat	arrays.	It	is	unclear	
why	 the	 C‐type	 repeat	 specifically	 dominates.	 Presumably	 any	 variant	 repeat	 present	 in	 the	 proximal	
telomere	region	can	be	copied	and	spread	throughout	the	telomeres	by	ALT	activity,	but	the	functional	
properties	of	some	variants	may	provide	a	selective	advantage.	We	therefore	investigated	potential	binding	
partners	of	telomeric	variant	repeats,	and	found	that	the	interspersion	of	C‐type	repeats	through	telomere	
repeat	arrays	provides	frequent	high	affinity	binding	sites	for	nuclear	receptors.		
While	the	variant	repeat	content	and	corresponding	extent	of	nuclear	receptor	recruitment	to	the	telomere	
were	found	to	vary	considerably	between	cell	lines,	we	have	demonstrated	that	this	phenomenon	is	specific	
to	ALT	cells,	as	both	variant	repeats	and	nuclear	receptors	were	not	detectable	at	the	telomeres	of	mortal	
or	 telomerase‐positive	 cell	 lines.	 Subsequently,	we	 demonstrated	 that	 nuclear	 receptors	 have	 a	 higher	
affinity	 for	 the	C‐type	variant	 repeat	 than	 the	canonical	 and	G‐type	repeats,	whereas	TRF2	binds	more	
strongly	than	TR4	to	the	canonical	telomeric	repeat.	Also,	the	DNA	binding	domain	of	its	shelterin	partner	
TRF1	 is	 known	 to	 hold	 an	 even	 greater	 affinity	 for	 double‐stranded	 telomeric	 DNA	 than	 that	 of	 TRF2	
(Hanaoka	et	al.,	2005).	This	suggests	that	recruitment	of	nuclear	receptors	to	canonical	telomeric	repeats	
is	 hindered	 by	 robust	 shelterin	 binding;	 however,	 upon	 the	 introduction	 of	 variant	 repeats,	 nuclear	
receptors	preferentially	bind	to	the	C‐type	repeat,	altering	the	protein	stoichiometry	at	the	telomere.		
Nuclear	receptor	depletion	was	shown	to	substantially	diminish	numerous	ALT	phenotypic	characteristics,	
including	the	formation	of	APBs,	generation	of	extrachromosomal	C‐circles	and	T‐SCE	events,	indicating	
that	the	recruitment	of	these	proteins	to	the	telomeres	significantly	contributes	to	the	ALT	mechanism.	In	
view	of	 their	many	known	biological	 functions,	 the	 effect	of	 nuclear	 receptor	depletion	upon	ALT	may	
possibly	be	indirect.	However,	in	further	support	of	the	hypothesis	that	it	is	due	to	lack	of	their	recruitment	
to	the	telomere,	nuclear	receptor	knockdown	had	a	greater	effect	on	the	ALT	phenotype	within	the	WI38‐
Discussion		 	
 
 
78 
VA13/2RA	 cell	 line	 compared	 to	 IIICF/c	which	 is	 in	 accordance	with	 our	 observations	 that	 the	 C‐type	
variants	(and	nuclear	receptors)	are	more	abundant	at	WI38‐VA13/2RA	telomeres.	Knockdown	of	nuclear	
receptors	did	not,	however,	affect	the	number	of	meta‐TIFs	or	rate	of	chromosome	fusions,	implicating	the	
inability	of	shelterin	to	bind	to	variant	repeats,	rather	than	the	presence	of	nuclear	receptors	themselves,	
as	the	primary	source	of	these	telomeric	abnormalities.	Alternatively,	nuclear	receptor	redundancy	may	
require	the	removal	of	more	than	two	nuclear	receptors	to	affect	the	DDR	at	the	telomere,	or	the	level	of	
chromosomal	end‐to‐end	fusions.		
Notably,	we	have	shown	that	insertion	of	the	C‐type	variant	into	the	telomeres	of	telomerase‐positive	cells	
resulted	 in	 the	 recruitment	 of	 nuclear	 receptors	 to	 the	 telomere.	 This	 directly	 demonstrates	 sequence	
specific	telomeric	binding	of	nuclear	receptors.	In	addition,	both	C‐	and	G‐type	variant	repeat	incorporation	
led	 to	 the	 induction	 of	 ALT‐associated	 characteristics	 such	 as	 telomere	 lengthening,	 telomere	 length	
heterogeneity,	meta‐TIFs	and	C‐circles.	These	observations	are	comparable	to	previous	studies	in	which	
mutant	telomeric	repeat	incorporation	was	found	to	produce	an	ALT‐like	phenotype	in	yeast	(Bechard	et	
al.,	2009)	and	recently,	insertion	of	TTTGGG	mutant	repeats	into	the	telomeres	of	a	telomerase‐positive	
human	 breast	 cancer	 cell	 line	 with	 non‐functional	 p53	 induced	 several	 ALT‐associated	 characteristics	
(Brault	 and	 Autexier,	 2011).	 However,	 we	 were	 unable	 to	 detect	 inter‐telomeric	 replication‐mediated	
copying	of	an	individual	telomere‐inserted	tag	to	multiple	chromosome	ends,	indicating	that	the	insertion	
of	variant	repeats	and	the	recruitment	of	nuclear	receptors	is	insufficient	to	activate	an	ALT	mechanism	in	
an	 immortalised	 telomerase‐positive	 cell	 line.	 Nonetheless,	 it	 remains	 possible	 that	 nuclear	 receptor	
recruitment	contributes	to	ALT	activation	within	mortal	cell	lines.	Telomerase‐positive	cells	already	have	
a	TMM	and	may	not	possess	the	genetic	changes	that	are	fully	permissive	for	the	activation	of	ALT.	For	
instance,	 further	genetic	alterations	such	as	 loss	of	ATRX,	which	has	recently	been	shown	to	be	widely	
mutated	in	ALT	tumours	and	immortalised	cell	lines	(Heaphy	et	al.,	2011a;	Schwartzentruber	et	al.,	2012;	
Lovejoy	et	al.,	2012),	may	be	required	for	complete	ALT	activation.	Furthermore,	the	variant	repeat	content	
and	 distal	 arrangement	 of	 artificially	 generated	 repeats	 may	 be	 insufficient	 to	 initiate	 HR‐mediated	
telomeric	replication.		
In	summary,	we	have	demonstrated	that	ALT	telomeres	display	high	levels	of	interspersed	variant	repeats,	
which	have	profound	implications	for	telomere	architecture	and	function.	We	propose	that	the	presence	of	
variant	sequences	throughout	the	telomeres	of	ALT	cells,	and	the	consequent	binding	of	nuclear	receptors,	
destabilise	telomeres	by	attenuating	shelterin	binding	(Figure	5.1).	In	addition,	incorporation	of	variant	
repeats	and	nuclear	receptor	recruitment	may	cause	the	telomeric	chromatin	structure	to	become	more	
permissive	to	recombination,	creating	a	positive	feedback	loop	which	leads	to	the	incorporation	of	more	
variant	repeats	and	further	destabilisation	of	the	telomere.	While	the	prevalence	of	the	C‐type	variant	at	
ALT	telomeres	may	be	more	functionally	relevant	in	certain	cell	lines	than	in	others,	it	is	possible	that	the	
telomeres	of	 these	 cells	 are	 enriched	with	other	 variant	 repeat	 sequences	 that	 could	 similarly	prevent	
shelterin	 binding	 and	 cause	 recruitment	 of	 nuclear	 receptors	 as	 well	 as	 other	 proteins	 not	 generally	
associated	with	 the	telomere.	The	presence	of	variant	repeats	may	also	result	 in	replication‐dependent	
defects	such	as	stalled	replication	forks,	and	may	disrupt	strand	invasion	and	the	formation	of	the	T‐loop	
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by	means	 of	 both	 sequence	 disruption	 and	 protein	 binding	 affinity.	 Furthermore,	 the	 interspersion	 of	
variant	repeats	may	influence	telomeric	heterochromatin	and	nucleosome	positioning.	Nuclear	receptors	
have	 been	 shown	 to	 be	 capable	 of	 altering	 expression	 of	 target	 genes	 via	 recruitment	 of	 chromatin	
remodelling	complexes	(Cui	et	al.,	2011),	so	we	speculate	that	recruitment	of	such	factors	may	also	change	
the	heterochromatic	state	of	ALT	telomeres,	thus	contributing	to	derepression	of	telomeric	recombination.	
Alternatively,	nuclear	receptors	may	cause	telomeres	to	interact	with	one	another	and/or	APBs	via	their	
oligomerisation	 or	 recruitment	 of	 common	 binding	 partners	 (Dejardin,	 2012),	 thus	 facilitating	 HR‐
dependent	telomere	elongation	by	the	ALT	mechanism.		
	
Figure	5.1	–	Model	of	alterations	in	telomere	architecture	during	ALT	activation.	Dispersal	of	variant	sequences	amongst	
distal	telomeric	repeats	leads	to	changes	in	telomere	structure	such	as	removal	of	shelterin,	recruitment	of	nuclear	receptors	and	
elicitation	 of	 a	 DDR	which	 facilitates	 telomere	 elongation	 via	 HR.	 Nuclear	 receptors	may	 also	 recruit	 chromatin	 remodelling	
complexes	capable	of	altering	the	heterochromatic	state	of	ALT	telomeres.	Although	this	schematic	shows	only	COUP‐TF2	and	TR4,	
additional	nuclear	receptors	are	likely	recruited	to	the	telomeres	as	either	homo‐	or	heterodimers	or	even	monomers.		
	
5.2	Discussion	of	Results	II	
ALT	telomeres	contain	many	variant	repeats	originating	from	proximal	telomeric	regions,	which	become	
interspersed	throughout	telomeres	by	HR‐mediated	telomere	extension	(Conomos	et	al.,	2012;	Conomos	
et	al.,	2013;	Lee	et	al.,	2014).	Variant	repeat	interspersion	causes	displacement	of	shelterin	and	sequence‐
specific	recruitment	of	nuclear	receptors	(Conomos	et	al.,	2012).	Here,	we	demonstrate	that	in	ALT	cells	
the	NuRD	chromatin	remodelling	complex	is	recruited	to	the	nuclear	receptors	TR4	and	COUP‐TF2	by	a	
zinc	finger	protein,	ZNF827.	ZNF827	is	a	previously	uncharacterised	protein,	which	shares	a	conserved	N‐
terminal	RRK	motif	with	 other	 zinc	 finger	 proteins	 that	 have	 been	 identified	 to	 recruit	NuRD	 in	 other	
contexts.	Consistent	with	findings	regarding	NuRD	binding	to	FOG‐1,	where	recruitment	of	NuRD	to	GATA‐
1	is	optimal	when	multiple	FOG‐1	molecules	are	present	and	thus	several	points	of	contact	with	NuRD	can	
be	made	(Lejon	et	al.,	2011),	we	demonstrate	that	NuRD	recruitment	to	telomeres	is	increased	following	
ZNF827	overexpression.	Our	 results	 also	 reveal	 a	potential	negative	 feedback	mechanism	whereby	 the	
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recruitment	 of	NuRD	 to	ALT	 telomeres	 is	 limited	by	 the	 total	 ZNF827	 level,	 and	ZNF827	expression	 is	
limited	and	regulated	at	the	transcriptional	level	by	TR4.	Negative	feedback	control	of	NuRD	binding	may	
prevent	potentially	detrimental	effects	of	excess	NuRD	recruitment	to	telomeres.		
NuRD‐ZNF827	binding	to	telomeres	was	associated	with	increased	ALT	activity,	as	manifest	by	an	increase	
in	T‐SCEs,	markers	of	telomeric	HR	which	are	greatly	increased	in	ALT	cells	(Londono‐Vallejo	et	al.,	2004),	
and	also	an	increase	in	APBs	and	C‐circles,	both	markers	of	ALT	activity	(Yeager	et	al.,	1999;	Henson	et	al.,	
2009).	Consistent	with	this	observation,	telomeric	recruitment	of	NuRD‐ZNF827	peaks	at	G2,	which	is	the	
cell	cycle	phase	in	which	HR	and	hence	ALT	activity	is	most	likely	to	occur.	NuRD‐ZNF827	increases	ALT	
activity	 via	 multiple	 mechanisms,	 including	 increased	 associations	 among	 telomeres	 either	 on	 sister	
chromatids	or	on	different	chromosomes.	This	is	consistent	with	the	findings	that	the	copy	template	for	
ALT‐mediated	telomere	extension	can	be	either	the	same	chromosome	end	(Muntoni	et	al.,	2009)	or	the	
telomere	of	a	different	chromosome	(Dunham	et	al.,	2000).	Because	of	the	evidence	that	there	are	multiple	
sites	with	the	NuRD	complex	which	can	interact	with	an	RRK	motif	(Lejon	et	al.,	2011),	we	propose	that	
NuRD	 can	 simultaneously	 interact	 with	 several	 ZNF827	 molecules,	 and	 therefore	 that,	 if	 the	 ZNF827	
molecules	are	on	different	telomeres,	these	protein‐protein	interactions	will	connect	them	and	be	detected	
as	telomere	bridges	in	cytogenetic	preparations.	Similarly,	ZNF827	molecules	bound	to	ECTR	DNA	within	
APBs	would	enable	protein‐protein	connections	between	telomeres	and	APBs,	which	have	been	proposed	
to	be	sites	of	ALT	activity	(Yeager	et	al.,	1999;	Draskovic	et	al.,	2009).		
We	demonstrate	that	increased	formation	of	telomere	bridges	is	associated	with	increased	time	taken	to	
transit	 through	G2/M,	which	may	 also	 increase	 the	probability	 that	ALT‐associated	HR	activity	 occurs.	
However,	there	needs	to	be	a	mechanism	to	resolve	these	telomere‐telomere	interactions	so	that	cell	cycle	
progression	can	continue.	Our	data	do	not	directly	address	the	nature	of	this	mechanism,	but	it	is	possible	
that	proteins	within,	or	recruited	to	 the	 large	NuRD‐ZNF827	complex	have	this	capacity,	or	that	one	or	
more	components	of	NuRD‐ZNF827	undergo	post‐translational	modification	such	as	sumoylation	within	
APBs.	 Alternatively,	 the	 nuclear	 receptors	 on	 ALT	 telomeres	 to	which	NuRD‐ZNF827	 is	 recruited	may	
undergo	sumoylation	in	APBs,	consistent	with	the	evidence	that	nuclear	receptors	undergo	sumoylation	
inside	PML	bodies	(Park	et	al.,	2007),	and	our	evidence	that	TR4	is	present	in	a	higher	molecular	weight	
form	in	M	phase	(Figure	S4.1C).		
Another	mechanism	whereby	NuRD‐ZNF827	increases	ALT	activity	is	through	recruitment	of	HR	proteins.	
We	demonstrate	that	NuRD‐ZNF827	is	able	to	recruit	the	DDR	protein	BRIT1,	which	is	accompanied	by	the	
HR	protein	BRCA1,	and	that	there	is	an	increase	in	BrdU	incorporation	at	ALT	telomeres	following	NuRD‐
ZNF827	recruitment.	This	raises	the	question	whether	NuRD‐ZNF827	may	have	a	role	in	HR‐mediated	DNA	
repair	 elsewhere	 in	 the	 genome.	NuRD‐mediated	 protein‐protein	 interactions	 similar	 to	 those	 that	we	
postulate	 to	 be	 involved	 in	 connecting	 telomeres	 to	 each	 other	 could	 potentially	 be	 involved	 in	 HR‐
mediated	repair	at	sites	of	DNA	damage.	It	is	also	possible	that	NuRD‐ZNF827	localisation	to	telomeres	may	
sequester	NuRD	from	other	genomic	sites.	NuRD	components	exhibit	transcription‐independent	functions	
in	 the	 maintenance	 of	 genomic	 stability,	 including	 roles	 in	 cell	 cycle	 progression	 (Polo	 et	 al.,	 2010),	
chromatin	 assembly	 during	 replication	 (Sims	 and	Wade,	 2011),	 as	well	 as	 in	 DNA	 damage	 and	 repair	
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(Smeenk	et	 al.,	2010;	Chou	et	 al.,	2010;	Pan	et	al.,	2012).	Thus,	displacement	of	NuRD	away	 from	non‐
telomeric	sites	could	potentially	contribute	to	genomic	instability,	driving	progression	of	ALT	cancers.		
A	 further	 mechanism	 by	 which	 NuRD‐ZNF827	 increases	 ALT	 activity	 is	 displacement	 of	 shelterin.	
Decreased	telomeric	binding	of	shelterin	has	been	found	to	disrupt	T‐loop	formation	and	telomere	length	
homeostasis	 in	telomerase‐positive	cells	(Wang	et	al.,	2004;	Doksani	et	al.,	2013),	as	well	as	promoting	
replication	 defects	 at	 telomeres	 (Sfeir	 et	 al.,	 2009;	 Martinez	 et	 al.,	 2009).	 Previous	 studies	 have	
demonstrated	a	strong	correlation	between	ATRX	loss	and	the	ALT	mechanism,	and	it	has	also	been	shown	
that	depletion	of	both	ASF1	isoforms,	ASF1a	and	ASF1b,	can	initiate	hallmarks	of	the	ALT	mechanism	in	
cells	which	already	have	long	telomeres.	Depletion	of	either	ATRX	or	ASF1	can	cause	replicative	stress,	so	
these	data	suggest	that	replicative	stress	may	contribute	to,	but	 is	 insufficient	 for	activation	of	 the	ALT	
mechanism.	We	show	that	NuRD‐ZNF827	causes	telomeric	replication	defects,	manifest	by	an	increase	in	
telomeric	fragile	sites,	which	would	be	expected	to	promote	HR‐mediated	repair.	We	therefore	propose	
that	 depletion	 of	 shelterin	 binding	 by	NuRD‐ZNF827	 increases	 ALT	 activity	 by	 a	 two‐fold	mechanism:	
replication	stress	culminating	in	fork	collapse	and	HR‐mediated	repair,	and	decreased	shelterin‐mediated	
repression	of	HR	at	the	telomere	(Figure	5.2).		
	
	
Figure	5.2	–	NuRD‐ZNF827	recruitment	to	telomeres	drives	HR	and	protects	against	the	DDR	in	ALT	cells.	Model	depicting	
alterations	to	the	telomere	architecture	that	occur	during	ALT	activation	to	maintain	a	HR‐permissive	environment	and	prevent	
the	onset	of	senescence	and/or	apoptosis	via	the	telomeric	DDR.		
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Strikingly,	despite	recruitment	of	HR	proteins	and	partial	depletion	of	shelterin,	we	find	that	NuRD‐ZNF827	
represses	the	overall	DDR	at	telomeres,	and	therefore	that	it	fulfils	a	role	in	the	maintenance	of	telomere	
capping	 function.	This	 is	 in	agreement	with	our	previous	 finding	that	 incorporation	 into	 telomeres	of	a	
variant	 repeat	 sequence	which	 is	 incapable	 of	 recruiting	NuRD‐ZNF827	caused	 an	 increased	 telomere‐
specific	DDR	compared	to	a	variant	which	is	capable	of	recruitment	(Figure	3.6A).	We	demonstrate	that	the	
HDAC	activity	of	NuRD‐ZNF827	at	ALT	telomeres	causes	histone	hypoacetylation,	a	marker	of	chromatin	
compaction,	even	 though	ALT	 telomeres	were	not	hypoacetylated	overall.	We	propose	 that	 the	histone	
deacetylase	activity	of	NuRD	contributes	to	the	capping	effect,	compensating,	at	least	in	part,	for	the	DDR‐
promoting	effect	of	displacing	shelterin.	The	epigenetic	state	of	 telomeric	chromatin	most	 likely	results	
from	 the	 interplay	 of	 a	 complex	 set	 of	 modifiers,	 and	 evidence	 has	 recently	 been	 presented	 that	 the	
telomeres	of	ALT	cells	are	decompacted	compared	to	telomerase‐positive	cells	(Episkopou	et	al.,	2014).		
Regardless	 of	 the	 mechanism,	 our	 data	 indicate	 that	 NuRD‐ZNF827	 can	 substitute	 for	 some	 shelterin	
functions	in	ALT	cells	by	maintaining	a	partially	capped	telomeric	state,	whilst	simultaneously	creating	an	
HR‐permissive	conformation,	as	has	been	demonstrated	in	other	contexts	where	telomeric	chromatin	is	
altered	(Benetti	et	al.,	2007b;	Gonzalo	et	al.,	2006;	Benetti	et	al.,	2007a;	Episkopou	et	al.,	2014).	ALT	cells	
contain	large	numbers	of	telomeres	in	a	partially	capped,	or	intermediate	state	(Cesare	et	al.,	2009),	which	
presumably	makes	them	vulnerable	to	further	uncapping.	Acute	loss	of	NuRD‐ZNF827	capping	function	
most	likely	accounts	for	the	loss	of	viability	and/or	senescence	which	we	find	occurs	after	rapid	depletion	
of	ZNF827.		
NuRD‐ZNF827	therefore	has	a	critically	important	role	in	ALT	telomeres,	which	makes	it	a	potential	target	
for	development	of	therapeutics	for	cancers	that	depend	on	ALT.	Types	of	cancers	that	commonly	utilise	
ALT	include	osteosarcomas,	various	subtypes	of	soft	tissue	sarcomas,	and	astrocytic	brain	tumours,	many	
of	which	are	currently	difficult	to	treat	and	have	a	poor	prognosis	(Henson	and	Reddel,	2010).	Our	finding	
that	 telomeric	 recruitment	of	NuRD	can	be	abrogated	by	depleting	ZNF827	suggests	 that	a	drug	which	
prevents	 ZNF827	 interacting	with	 NuRD,	 perhaps	 by	 targeting	 its	 RRK	motif,	 would	 disrupt	 the	 ALT‐
promoting	effects	of	the	whole	complex.		
	
References		 	
 
 
84 
References			
Allshire,	R.	C.,	M.	Dempster,	and	N.	D.	Hastie.	1989.	Human	telomeres	contain	at	 least	three	types	of	G‐rich	repeat	
distributed	non‐randomly.	Nucleic	Acids	Res.	17:4611‐4627.		
Anderson,	M.	J.,	G.	Casey,	C.	L.	Fasching,	and	E.	J.	Stanbridge.	1994.	Evidence	that	wild‐type	TP53,	and	not	genes	on	
either	 chromosome	 I	 or	 II,	 controls	 the	 tumorigenic	 phenotype	 of	 the	 human	 fibrosarcoma	 HT1080.	 Genes	
Chromosomes	Cancer	9:266‐281.		
Atkinson,	S.	P.,	S.	F.	Hoare,	R.	M.	Glasspool,	and	W.	N.	Keith.	2005.	Lack	of	telomerase	gene	expression	in	alternative	
lengthening	of	telomere	cells	is	associated	with	chromatin	remodeling	of	the	hTR	and	hTERT	gene	promoters.	Cancer	
Res.	65:7585‐7590.		
Azzalin,	C.	M.,	P.	Reichenbach,	L.	Khoriauli,	E.	Giulotto,	and	J.	Lingner.	2007.	Telomeric	repeat	containing	RNA	and	RNA	
surveillance	factors	at	mammalian	chromosome	ends.	Science	318:798‐801.		
Bachor,	C.,	O.	A.	Bachor,	and	P.	Boukamp.	1999.	Telomerase	is	active	in	normal	gastrointestinal	mucosa	and	not	up‐
regulated	in	precancerous	lesions.	J.	Cancer	Res.	Clin.	Oncol.	125:453‐460.		
Bailey,	S.	M.,	M.	A.	Brenneman,	and	E.	H.	Goodwin.	2004a.	Frequent	recombination	in	telomeric	DNA	may	extend	the	
proliferative	life	of	telomerase‐negative	cells.	Nucleic	Acids	Res.	32:3743‐3751.		
Bailey,	S.	M.,	E.	H.	Goodwin,	and	M.	N.	Cornforth.	2004b.	Strand‐specific	fluorescence	in	situ	hybridization:	the	CO‐
FISH	family.	Cytogenet.	Genome	Res.	107:14‐17.		
Baird,	 D.	 M.,	 J.	 Coleman,	 Z.	 H.	 Rosser,	 and	 N.	 J.	 Royle.	 2000.	 High	 levels	 of	 sequence	 polymorphism	 and	 linkage	
disequilibrium	at	 the	 telomere	of	12q:	 implications	 for	 telomere	biology	and	human	evolution.	Am.	 J.	Hum.	Genet.	
66:235‐250.		
Baird,	 D.	 M.,	 A.	 J.	 Jeffreys,	 and	 N.	 J.	 Royle.	 1995.	 Mechanisms	 underlying	 telomere	 repeat	 turnover,	 revealed	 by	
hypervariable	variant	repeat	distribution	patterns	in	the	human	Xp/Yp	telomere.	EMBO	J.	14:5433‐5443.		
Baumann,	 P.,	 and	T.	R.	 Cech.	 2001.	 Pot1,	 the	putative	 telomere	 end‐binding	protein	 in	 fission	 yeast	 and	humans.	
Science	292:1171‐1175.		
Baur,	J.	A.,	Y.	Zou,	J.	W.	Shay,	and	W.	E.	Wright.	2001.	Telomere	position	effect	in	human	cells.	Science	292:2075‐2077.		
Bechard,	L.	H.,	B.	D.	Butuner,	G.	Masologites,	W.	McRae,	Z.	Topcu,	and	M.	J.	McEachern.	2009.	Mutant	telomeric	repeats	
in	yeast	can	disrupt	the	negative	regulation	of	recombination‐mediated	telomere	maintenance	and	create	an	ALT‐like	
phenotype.	Mol.	Cell.	Biol.	29:626‐639.		
Bechter,	O.	E.,	Y.	Zou,	J.	W.	Shay,	and	W.	E.	Wright.	2003.	Homologous	recombination	in	human	telomerase‐positive	
and	ALT	cells	occurs	with	the	same	frequency.	EMBO	Rep.	4:1138‐1143.		
Bechter,	O.	E.,	Y.	Zou,	W.	Walker,	W.	E.	Wright,	and	J.	W.	Shay.	2004.	Telomeric	recombination	in	mismatch	repair	
deficient	human	colon	cancer	cells	after	telomerase	inhibition.	Cancer	Res.	64:3444‐3451.		
Benetti,	R.,	M.	Garcia‐Cao,	and	M.	A.	Blasco.	2007a.	Telomere	 length	regulates	the	epigenetic	status	of	mammalian	
telomeres	and	subtelomeres.	Nat.	Genet.	39:243‐250.		
References		 	
 
 
85 
Benetti,	R.,	S.	Gonzalo,	I.	 Jaco,	P.	Munoz,	S.	Gonzalez,	S.	Schoeftner,	E.	Murchison,	T.	Andl,	T.	Chen,	P.	Klatt,	E.	Li,	M.	
Serrano,	S.	Millar,	G.	Hannon,	and	M.	A.	Blasco.	2008a.	A	mammalian	microRNA	cluster	controls	DNA	methylation	and	
telomere	recombination	via	Rbl2‐dependent	regulation	of	DNA	methyltransferases.	Nat.	Struct.	Mol.	Biol.	15:268‐279.		
Benetti,	R.,	S.	Gonzalo,	I.	Jaco,	G.	Schotta,	P.	Klatt,	T.	Jenuwein,	and	M.	A.	Blasco.	2007b.	Suv4‐20h	deficiency	results	in	
telomere	elongation	and	derepression	of	telomere	recombination.	J.	Cell	Biol.	178:925‐936.		
Benetti,	R.,	S.	Schoeftner,	P.	Munoz,	and	M.	A.	Blasco.	2008b.	Role	of	TRF2	in	the	assembly	of	telomeric	chromatin.	Cell	
Cycle	7:3461‐3468.		
Bernardi,	R.,	I.	Guernah,	D.	Jin,	S.	Grisendi,	A.	Alimonti,	J.	Teruya‐Feldstein,	C.	Cordon‐Cardo,	M.	C.	Simon,	S.	Rafii,	and	
P.	 P.	 Pandolfi.	 2006.	 PML	 inhibits	 HIF‐1a	 translation	 and	 neoangiogenesis	 through	 repression	 of	 mTOR.	Nature	
442:779‐785.		
Bernardi,	R.,	and	P.	P.	Pandolfi.	2003.	Role	of	PML	and	the	PML‐nuclear	body	in	the	control	of	programmed	cell	death.	
Oncogene	22:9048‐9057.		
Bernardi,	R.,	and	P.	P.	Pandolfi.	2007.	Structure,	dynamics	and	functions	of	promyelocytic	leukaemia	nuclear	bodies.	
Nat.	Rev.	Mol.	Cell	Biol.	8:1006‐1016.		
Bilaud,	T.,	C.	Brun,	K.	Ancelin,	C.	E.	Koering,	T.	Laroche,	and	E.	Gilson.	1997.	Telomeric	localization	of	TRF2,	a	novel	
human	telobox	protein.	Nat.	Genet.	17:236‐239.		
Bischof,	O.,	O.	Kirsh,	M.	Pearson,	K.	Itahana,	P.	G.	Pelicci,	and	A.	Dejean.	2002.	Deconstructing	PML‐induced	premature	
senescence.	EMBO	J.	21:3358‐3369.		
Blagoev,	K.	B.,	and	E.	H.	Goodwin.	2008.	Telomere	exchange	and	asymmetric	segregation	of	chromosomes	can	account	
for	the	unlimited	proliferative	potential	of	ALT	cell	populations.	DNA	Repair	(Amst.	)	7:199‐204.		
Blasco,	 M.	 A.	 2004.	 Telomere	 epigenetics:	 a	 higher‐order	 control	 of	 telomere	 length	 in	 mammalian	 cells.	
Carcinogenesis	25:1083‐1087.		
Blasco,	M.	A.	2007.	The	epigenetic	regulation	of	mammalian	telomeres.	Nat.	Rev.	Genet.	8:299‐309.		
Blasco,	M.	A.,	H.	W.	Lee,	M.	P.	Hande,	E.	Samper,	P.	M.	Lansdorp,	R.	A.	DePinho,	and	C.	W.	Greider.	1997.	Telomere	
shortening	and	tumor	formation	by	mouse	cells	lacking	telomerase	RNA.	Cell	91:25‐34.		
Bodnar,	A.	G.,	M.	Ouellette,	M.	Frolkis,	S.	E.	Holt,	C.	P.	Chiu,	G.	B.	Morin,	C.	B.	Harley,	J.	W.	Shay,	S.	Lichtsteiner,	and	W.	
E.	Wright.	1998.	Extension	of	life‐span	by	introduction	of	telomerase	into	normal	human	cells.	Science	279:349‐352.		
Bower,	K.,	C.	E.	Napier,	S.	L.	Cole,	R.	A.	Dagg,	L.	M.	Lau,	E.	L.	Duncan,	E.	L.	Moy,	and	R.	R.	Reddel.	2012.	Loss	of	wild‐type	
ATRX	expression	in	somatic	cell	hybrids	segregates	with	activation	of	Alternative	Lengthening	of	Telomeres.	PLoS	One	
7:e50062.		
Brault,	M.	 E.,	 and	 C.	 Autexier.	 2011.	 Telomeric	 recombination	 induced	 by	 dysfunctional	 telomeres.	Mol.	Biol.	Cell	
22:179‐188.		
Broccoli,	D.,	A.	Smogorzewska,	L.	Chong,	and	T.	de	Lange.	1997.	Human	telomeres	contain	two	distinct	Myb‐related	
proteins,	TRF1	and	TRF2.	Nat.	Genet.	17:231‐235.		
Bryan,	T.	M.,	A.	Englezou,	L.	Dalla‐Pozza,	M.	A.	Dunham,	and	R.	R.	Reddel.	1997.	Evidence	for	an	alternative	mechanism	
for	maintaining	telomere	length	in	human	tumors	and	tumor‐derived	cell	lines.	Nat.	Med.	3:1271‐1274.		
References		 	
 
 
86 
Bryan,	T.	M.,	A.	Englezou,	J.	Gupta,	S.	Bacchetti,	and	R.	R.	Reddel.	1995.	Telomere	elongation	in	immortal	human	cells	
without	detectable	telomerase	activity.	EMBO	J.	14:4240‐4248.		
Bryan,	T.	M.,	and	R.	R.	Reddel.	1997.	Telomere	dynamics	and	telomerase	activity	in	in	vitro	immortalised	human	cells.	
Eur.	J.	Cancer	33:767‐773.		
Cabuy,	E.,	C.	Newton,	T.	Roberts,	R.	Newbold,	and	P.	Slijepcevic.	2004.	Identification	of	subpopulations	of	cells	with	
differing	telomere	lengths	in	mouse	and	human	cell	lines	by	flow	FISH.	Cytometry	A	62:150‐161.		
Cao,	Y.,	T.	M.	Bryan,	and	R.	R.	Reddel.	2008a.	Increased	copy	number	of	the	TERT	and	TERC	telomerase	subunit	genes	
in	cancer	cells.	Cancer	Sci.	99:1092‐1099.		
Cao,	Y.,	L.	I.	Huschtscha,	A.	S.	Nouwens,	H.	A.	Pickett,	A.	A.	Neumann,	A.	C.	Chang,	C.	D.	Toouli,	T.	M.	Bryan,	and	R.	R.	
Reddel.	 2008b.	 Amplification	 of	 telomerase	 reverse	 transcriptase	 gene	 in	 human	mammary	 epithelial	 cells	 with	
limiting	telomerase	RNA	expression	levels.	Cancer	Res.	68:3115‐3123.		
Celli,	 G.	 B.,	 E.	 L.	 Denchi,	 and	 T.	 de	 Lange.	 2006.	 Ku70	 stimulates	 fusion	 of	 dysfunctional	 telomeres	 yet	 protects	
chromosome	ends	from	homologous	recombination.	Nat.	Cell	Biol.	8:885‐890.		
Cenci,	G.,	G.	Siriaco,	G.	D.	Raffa,	R.	Kellum,	and	M.	Gatti.	2003.	The	Drosophila	HOAP	protein	is	required	for	telomere	
capping.	Nat.	Cell	Biol.	5:82‐84.		
Cerone,	M.	A.,	C.	Autexier,	J.	A.	Londono‐Vallejo,	and	S.	Bacchetti.	2005.	A	human	cell	line	that	maintains	telomeres	in	
the	absence	of	telomerase	and	of	key	markers	of	ALT.	Oncogene	24:7893‐7901.		
Cesare,	 A.	 J.,	 and	 J.	 D.	 Griffith.	 2004.	 Telomeric	 DNA	 in	 ALT	 cells	 is	 characterized	 by	 free	 telomeric	 circles	 and	
heterogeneous	t‐loops.	Mol.	Cell.	Biol.	24:9948‐9957.		
Cesare,	A.	 J.,	 Z.	 Kaul,	 S.	 B.	 Cohen,	 C.	 E.	Napier,	H.	A.	 Pickett,	A.	A.	Neumann,	 and	R.	R.	Reddel.	 2009.	 Spontaneous	
occurrence	of	telomeric	DNA	damage	response	in	the	absence	of	chromosome	fusions.	Nat.	Struct.	Mol.	Biol.	16:1244‐
1251.		
Cesare,	A.	J.,	and	R.	R.	Reddel.	2008.	Telomere	uncapping	and	alternative	lengthening	of	telomeres.	Mech.	Ageing	Dev.	
129:99‐108.		
Cesare,	A.	J.,	and	R.	R.	Reddel.	2010.	Alternative	lengthening	of	telomeres:	models,	mechanisms	and	implications.	Nat.	
Rev.	Genet.	11:319‐330.		
Chen,	Q.,	A.	Ijpma,	and	C.	W.	Greider.	2001.	Two	survivor	pathways	that	allow	growth	in	the	absence	of	telomerase	are	
generated	by	distinct	telomere	recombination	events.	Mol.	Cell.	Biol.	21:1819‐1827.		
Chen,	Y.	J.,	V.	Hakin‐Smith,	M.	Teo,	G.	E.	Xinarianos,	D.	A.	Jellinek,	T.	Carroll,	D.	McDowell,	M.	R.	MacFarlane,	R.	Boet,	B.	
C.	 Baguley,	 A.	 W.	 Braithwaite,	 R.	 R.	 Reddel,	 and	 J.	 A.	 Royds.	 2006.	 Association	 of	 mutant	 TP53	 with	 alternative	
lengthening	of	telomeres	and	favorable	prognosis	in	glioma.	Cancer	Res.	66:6473‐6476.		
Cheok,	C.	F.,	C.	Z.	Bachrati,	K.	L.	Chan,	C.	Ralf,	L.	Wu,	and	I.	D.	Hickson.	2005.	Roles	of	the	Bloom's	syndrome	helicase	in	
the	maintenance	of	genome	stability.	Biochem.	Soc.	Trans.	33:1456‐1459.		
Chin,	L.,	S.	E.	Artandi,	Q.	Shen,	A.	Tam,	S.	L.	Lee,	G.	J.	Gottlieb,	C.	W.	Greider,	and	R.	A.	DePinho.	1999.	p53	deficiency	
rescues	the	adverse	effects	of	telomere	loss	and	cooperates	with	telomere	dysfunction	to	accelerate	carcinogenesis.	
Cell	97:527‐538.		
References		 	
 
 
87 
Chong,	L.,	B.	van	Steensel,	D.	Broccoli,	H.	Erdjument‐Bromage,	J.	Hanish,	P.	Tempst,	and	T.	de	Lange.	1995.	A	human	
telomeric	protein.	Science	270:1663‐1667.		
Chou,	D.	M.,	B.	Adamson,	N.	E.	Dephoure,	X.	Tan,	A.	C.	Nottke,	K.	E.	Hurov,	S.	P.	Gygi,	M.	P.	Colaiacovo,	and	S.	J.	Elledge.	
2010.	A	chromatin	localization	screen	reveals	poly	(ADP	ribose)‐regulated	recruitment	of	the	repressive	polycomb	
and	NuRD	complexes	to	sites	of	DNA	damage.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	107:18475‐18480.		
Chung,	Y.	L.,	and	T.	Y.	Tsai.	2009.	Promyelocytic	leukemia	nuclear	bodies	link	the	DNA	damage	repair	pathway	with	
hepatitis	B	virus	replication:	implications	for	hepatitis	B	virus	exacerbation	during	chemotherapy	and	radiotherapy.	
Mol.	Cancer	Res.	7:1672‐1685.		
Cismasiu,	V.	B.,	K.	Adamo,	J.	Gecewicz,	J.	Duque,	Q.	Lin,	and	D.	Avram.	2005.	BCL11B	functionally	associates	with	the	
NuRD	complex	in	T	lymphocytes	to	repress	targeted	promoter.	Oncogene	24:6753‐6764.		
Coggins,	L.	W.,	M.	O'Prey,	and	S.	Akhter.	1992.	 Intrahelical	pseudoknots	and	 interhelical	associations	mediated	by	
mispaired	human	minisatellite	DNA	sequences	in	vitro.	Gene	121:279‐285.		
Cohen,	S.	B.,	M.	E.	Graham,	G.	O.	Lovrecz,	N.	Bache,	P.	 J.	Robinson,	and	R.	R.	Reddel.	2007.	Protein	composition	of	
catalytically	active	human	telomerase	from	immortal	cells.	Science	315:1850‐1853.		
Cohen,	S.	B.,	and	R.	R.	Reddel.	2008.	A	sensitive	direct	human	telomerase	activity	assay.	Nat.	Methods	5:355‐360.		
Coleman,	J.,	D.	M.	Baird,	and	N.	J.	Royle.	1999.	The	plasticity	of	human	telomeres	demonstrated	by	a	hypervariable	
telomere	repeat	array	that	is	located	on	some	copies	of	16p	and	16q.	Hum.	Mol.	Genet.	8:1637‐1646.	meter	
Colgin,	L.	M.,	and	R.	R.	Reddel.	1999.	Telomere	maintenance	mechanisms	and	cellular	 immortalization.	Curr.	Opin.	
Genet.	Dev.	9:97‐103.		
Compton,	S.	A.,	J.	H.	Choi,	A.	J.	Cesare,	S.	Ozgur,	and	J.	D.	Griffith.	2007.	Xrcc3	and	Nbs1	are	required	for	the	production	
of	extrachromosomal	telomeric	circles	in	human	alternative	lengthening	of	telomere	cells.	Cancer	Res.	67:1513‐1519.		
Cong,	Y.	S.,	W.	E.	Wright,	and	J.	W.	Shay.	2002.	Human	telomerase	and	its	regulation.	Microbiol.	Mol.	Biol.	Rev.	66:407‐
425.		
Conomos,	D.,	H.	A.	Pickett,	and	R.	R.	Reddel.	2013.	Alternative	 lengthening	of	 telomeres:	 remodeling	 the	 telomere	
architecture.	Front.	Oncol.	3:27.		
Conomos,	D.,	M.	D.	Stutz,	M.	Hills,	A.	A.	Neumann,	T.	M.	Bryan,	R.	R.	Reddel,	and	H.	A.	Pickett.	2012.	Variant	repeats	are	
interspersed	throughout	the	telomeres	and	recruit	nuclear	receptors	in	ALT	cells.	J.	Cell	Biol.	199:893‐906.		
Conomos,	D.,	R.	R.	Reddel,	and	H.	A.	Pickett.	2014.	NuRD‐ZNF827	recruitment	to	telomeres	creates	a	molecular	scaffold	
for	homologous	recombination.	Nat.	Struct.	Mol.	Biol.	21:760‐770.		
Costa,	A.,	M.	G.	Daidone,	L.	Daprai,	R.	Villa,	S.	Cantu,	S.	Pilotti,	L.	Mariani,	A.	Gronchi,	J.	D.	Henson,	R.	R.	Reddel,	and	N.	
Zaffaroni.	 2006.	 Telomere	 maintenance	 mechanisms	 in	 liposarcomas:	 association	 with	 histologic	 subtypes	 and	
disease	progression.	Cancer	Res.	66:8918‐8924.		
Counter,	C.	M.,	A.	A.	Avilion,	C.	E.	LeFeuvre,	N.	G.	Stewart,	C.	W.	Greider,	C.	B.	Harley,	and	S.	Bacchetti.	1992.	Telomere	
shortening	associated	with	chromosome	instability	is	arrested	in	immortal	cells	which	express	telomerase	activity.	
EMBO	J.	11:1921‐1929.		
Cristofari,	G.,	and	J.	Lingner.	2006.	Telomere	length	homeostasis	requires	that	telomerase	levels	are	limiting.	EMBO	J.	
25:565‐574.		
References		 	
 
 
88 
Cui,	S.,	K.	E.	Kolodziej,	N.	Obara,	A.	Amaral‐Psarris,	J.	Demmers,	L.	Shi,	J.	Douglas	Engel,	F.	Grosveld,	J.	Strouboulis,	and	
O.	 Tanabe.	 2011.	 Nuclear	 receptors	 TR2	 and	 TR4	 recruit	 multiple	 epigenetic	 transcriptional	 corepressors	 that	
associate	specifically	with	the	embryonic	b‐type	globin	promoters	in	differentiated	adult	erythroid	cells.	Mol.	Cell.	Biol.	
31:3298‐3311.		
d'Adda	di	Fagagna,	F.,	P.	M.	Reaper,	L.	Clay‐Farrace,	H.	Fiegler,	P.	Carr,	T.	von	Zglinicki,	G.	Saretzki,	N.	P.	Carter,	and	S.	
P.	Jackson.	2003.	A	DNA	damage	checkpoint	response	in	telomere‐initiated	senescence.	Nature	426:194‐198.		
de	Lange,	T.	2004.	T‐loops	and	the	origin	of	telomeres.	Nat.	Rev.	Mol.	Cell	Biol.	5:323‐329.		
de	Lange,	T.	2009.	How	telomeres	solve	the	end‐protection	problem.	Science	326:948‐952.		
de	Lange,	T.,	L.	Shiue,	R.	M.	Myers,	D.	R.	Cox,	S.	L.	Naylor,	A.	M.	Killery,	and	H.	E.	Varmus.	1990.	Structure	and	variability	
of	human	chromosome	ends.	Mol.	Cell.	Biol.	10:518‐527.		
Dejardin,	J.	2012.	How	chromatin	prevents	genomic	rearrangements:	locus	colocalization	induced	by	transcription	
factor	binding.	BioEssays	34:90‐93.		
Dejardin,	J.,	and	R.	E.	Kingston.	2009.	Purification	of	proteins	associated	with	specific	genomic	loci.	Cell	136:175‐186.		
Dellaire,	G.,	and	D.	P.	Bazett‐Jones.	2004.	PML	nuclear	bodies:	dynamic	sensors	of	DNA	damage	and	cellular	stress.	
BioEssays	26:963‐977.		
Dellaire,	 G.,	 R.	W.	 Ching,	 K.	 Ahmed,	 F.	 Jalali,	 K.	 C.	 Tse,	 R.	 G.	 Bristow,	 and	D.	 P.	 Bazett‐Jones.	 2006.	 Promyelocytic	
leukemia	nuclear	bodies	behave	as	DNA	damage	sensors	whose	response	to	DNA	double‐strand	breaks	is	regulated	
by	NBS1	and	the	kinases	ATM,	Chk2,	and	ATR.	J.	Cell	Biol.	175:55‐66.		
Denchi,	E.	L.,	and	T.	de	Lange.	2007.	Protection	of	telomeres	through	independent	control	of	ATM	and	ATR	by	TRF2	
and	POT1.	Nature	448:1068‐1071.		
Deng,	Z.,	 J.	Norseen,	A.	Wiedmer,	H.	Riethman,	and	P.	M.	Lieberman.	2009.	TERRA	RNA	binding	to	TRF2	facilitates	
heterochromatin	formation	and	ORC	recruitment	at	telomeres.	Mol.	Cell	35:403‐413.		
Doksani,	Y.,	J.	Y.	Wu,	T.	de	Lange,	and	X.	Zhuang.	2013.	Super‐resolution	fluorescence	imaging	of	telomeres	reveals	
TRF2‐dependent	T‐loop	formation.	Cell	155:345‐356.		
Downs,	 J.	 A.,	 E.	 Kosmidou,	 A.	Morgan,	 and	 S.	 P.	 Jackson.	 2003.	 Suppression	 of	 homologous	 recombination	 by	 the	
Saccharomyces	cerevisiae	linker	histone.	Mol.	Cell	11:1685‐1692.		
Draskovic,	I.,	N.	Arnoult,	V.	Steiner,	S.	Bacchetti,	P.	Lomonte,	and	A.	Londono‐Vallejo.	2009.	Probing	PML	body	function	
in	ALT	cells	reveals	spatiotemporal	requirements	for	telomere	recombination.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	106:15726‐
15731.		
Dunham,	M.	A.,	A.	A.	Neumann,	C.	L.	Fasching,	and	R.	R.	Reddel.	2000.	Telomere	maintenance	by	recombination	in	
human	cells.	Nat.	Genet.	26:447‐450.		
Episkopou,	H.,	I.	Draskovic,	A.	van	Beneden,	G.	Tilman,	M.	Mattiussi,	M.	Gobin,	N.	Arnoult,	A.	Londono‐Vallejo,	and	A.	
Decottignies.	 2014.	 Alternative	 Lengthening	 of	 Telomeres	 is	 characterized	 by	 reduced	 compaction	 of	 telomeric	
chromatin.	Nucleic	Acids	Res.		
Eskiw,	C.	H.,	G.	Dellaire,	J.	S.	Mymryk,	and	D.	P.	Bazett‐Jones.	2003.	Size,	position	and	dynamic	behavior	of	PML	nuclear	
bodies	following	cell	stress	as	a	paradigm	for	supramolecular	trafficking	and	assembly.	J.	Cell	Sci.	116:4455‐4466.		
References		 	
 
 
89 
Esteller,	M.	2006.	Epigenetics	provides	a	new	generation	of	oncogenes	and	tumour‐suppressor	genes.	Br.	J.	Cancer	
94:179‐183.		
Falconer,	E.,	E.	A.	Chavez,	A.	Henderson,	S.	S.	Poon,	S.	McKinney,	L.	Brown,	D.	G.	Huntsman,	and	P.	M.	Lansdorp.	2010.	
Identification	of	sister	chromatids	by	DNA	template	strand	sequences.	Nature	463:93‐97.		
Fan,	Q.,	F.	Zhang,	B.	Barrett,	K.	Ren,	and	P.	R.	Andreassen.	2009.	A	role	for	monoubiquitinated	FANCD2	at	telomeres	in	
ALT	cells.	Nucleic	Acids	Res.	37:1740‐1754.		
Fasching,	C.	L.,	K.	Bower,	and	R.	R.	Reddel.	2005.	Telomerase‐independent	telomere	length	maintenance	in	the	absence	
of	alternative	lengthening	of	telomeres‐associated	promyelocytic	leukemia	bodies.	Cancer	Res.	65:2722‐2729.		
Fasching,	C.	L.,	A.	A.	Neumann,	A.	Muntoni,	T.	R.	Yeager,	 and	R.	R.	Reddel.	2007.	DNA	damage	 induces	alternative	
lengthening	of	telomeres	(ALT)	associated	promyelocytic	leukemia	bodies	that	preferentially	associate	with	linear	
telomeric	DNA.	Cancer	Res.	67:7072‐7077.		
Feng,	J.,	W.	D.	Funk,	S.	S.	Wang,	S.	L.	Weinrich,	A.	A.	Avilion,	C.	P.	Chiu,	R.	R.	Adams,	E.	Chang,	R.	C.	Allsopp,	J.	H.	Yu,	S.	Y.	
Le,	M.	D.	West,	C.	B.	Harley,	W.	H.	Andrews,	C.	W.	Greider,	and	B.	Villeponteau.	1995.	The	RNA	component	of	human	
telomerase.	Science	269:1236‐1241.		
Ferbeyre,	G.,	E.	De	Stanchina,	E.	Querido,	N.	Baptiste,	C.	Prives,	and	S.	W.	Lowe.	2000.	PML	is	induced	by	oncogenic	ras	
and	promotes	premature	senescence.	Genes	Dev.	14:2015‐2027.		
Fouche,	N.,	A.	J.	Cesare,	S.	Willcox,	S.	Ozgur,	S.	A.	Compton,	and	J.	D.	Griffith.	2006.	The	basic	domain	of	TRF2	directs	
binding	to	DNA	junctions	irrespective	of	the	presence	of	TTAGGG	repeats.	J.	Biol.	Chem.	281:37486‐37495.		
Fraga,	M.	F.,	E.	Ballestar,	A.	Villar‐Garea,	M.	Boix‐Chornet,	J.	Espada,	G.	Schotta,	T.	Bonaldi,	C.	Haydon,	S.	Ropero,	K.	
Petrie,	N.	G.	Iyer,	A.	Perez‐Rosado,	E.	Calvo,	J.	A.	Lopez,	A.	Cano,	M.	J.	Calasanz,	D.	Colomer,	M.	A.	Piris,	N.	Ahn,	A.	Imhof,	
C.	Caldas,	T.	Jenuwein,	and	M.	Esteller.	2005.	Loss	of	acetylation	at	Lys16	and	trimethylation	at	Lys20	of	histone	H4	is	
a	common	hallmark	of	human	cancer.	Nat.	Genet.	37:391‐400.		
Fraga,	M.	F.,	and	M.	Esteller.	2005.	Towards	the	human	cancer	epigenome:	a	first	draft	of	histone	modifications.	Cell	
Cycle	4:1377‐1381.		
Garcia‐Cao,	M.,	S.	Gonzalo,	D.	Dean,	and	M.	A.	Blasco.	2002.	A	role	for	the	Rb	family	of	proteins	in	controlling	telomere	
length.	Nat.	Genet.	32:415‐419.		
Garcia‐Cao,	M.,	R.	O'Sullivan,	A.	H.	Peters,	T.	Jenuwein,	and	M.	A.	Blasco.	2004.	Epigenetic	regulation	of	telomere	length	
in	mammalian	cells	by	the	Suv39h1	and	Suv39h2	histone	methyltransferases.	Nat.	Genet.	36:94‐99.		
Girardi,	A.	J.,	F.	C.	Jensen,	and	H.	Koprowski.	1965.	SV40‐induced	transformation	of	human	diploid	cells:	crisis	and	
recovery.	J.	Cell.	Comp.	Physiol.	65:69‐84.		
Goldberg,	A.	D.,	L.	A.	Banaszynski,	K.	M.	Noh,	P.	W.	Lewis,	S.	J.	Elsaesser,	S.	Stadler,	S.	Dewell,	M.	Law,	X.	Guo,	X.	Li,	D.	
Wen,	A.	Chapgier,	R.	C.	DeKelver,	J.	C.	Miller,	Y.	L.	Lee,	E.	A.	Boydston,	M.	C.	Holmes,	P.	D.	Gregory,	J.	M.	Greally,	S.	Rafii,	
C.	Yang,	P.	J.	Scambler,	D.	Garrick,	R.	J.	Gibbons,	D.	R.	Higgs,	I.	M.	Cristea,	F.	D.	Urnov,	D.	Zheng,	and	C.	D.	Allis.	2010.	
Distinct	factors	control	histone	variant	H3.3	localization	at	specific	genomic	regions.	Cell	140:678‐691.		
Gonzalo,	S.,	and	M.	A.	Blasco.	2005.	Role	of	Rb	family	in	the	epigenetic	definition	of	chromatin.	Cell	Cycle	4:e10‐e13.		
References		 	
 
 
90 
Gonzalo,	S.,	M.	Garcia‐Cao,	M.	F.	Fraga,	G.	Schotta,	A.	H.	Peters,	S.	E.	Cotter,	R.	Eguia,	D.	C.	Dean,	M.	Esteller,	T.	Jenuwein,	
and	M.	A.	Blasco.	2005.	Role	of	the	RB1	family	in	stabilizing	histone	methylation	at	constitutive	heterochromatin.	Nat.	
Cell	Biol.	7:420‐428.		
Gonzalo,	S.,	 I.	 Jaco,	M.	F.	Fraga,	T.	Chen,	E.	Li,	M.	Esteller,	and	M.	A.	Blasco.	2006.	DNA	methyltransferases	control	
telomere	length	and	telomere	recombination	in	mammalian	cells.	Nat.	Cell	Biol.	8:416‐424.		
Gottschling,	D.	E.,	O.	M.	Aparicio,	B.	L.	Billington,	and	V.	A.	Zakian.	1990.	Position	effect	at	S.	cerevisiae	 telomeres:	
reversible	repression	of	Pol	II	transcription.	Cell	63:751‐762.		
Grafi,	G.,	H.	Ben‐Meir,	Y.	Avivi,	M.	Moshe,	Y.	Dahan,	and	A.	Zemach.	2007.	Histone	methylation	controls	telomerase‐
independent	telomere	lengthening	in	cells	undergoing	dedifferentiation.	Dev.	Biol.	306:838‐846.		
Grewal,	S.	I.,	and	S.	Jia.	2007.	Heterochromatin	revisited.	Nat.	Rev.	Genet.	8:35‐46.		
Griffith,	J.	D.,	L.	Comeau,	S.	Rosenfield,	R.	M.	Stansel,	A.	Bianchi,	H.	Moss,	and	T.	de	Lange.	1999.	Mammalian	telomeres	
end	in	a	large	duplex	loop.	Cell	97:503‐514.		
Grobelny,	 J.	V.,	A.	K.	Godwin,	and	D.	Broccoli.	2000.	ALT‐associated	PML	bodies	are	present	 in	viable	cells	and	are	
enriched	in	cells	in	the	G2/M	phase	of	the	cell	cycle.	J.	Cell	Sci.	113:4577‐4585.		
Grudic,	A.,	A.	Jul‐Larsen,	S.	J.	Haring,	M.	S.	Wold,	P.	E.	Lonning,	R.	Bjerkvig,	and	S.	O.	Boe.	2007.	Replication	protein	A	
prevents	accumulation	of	single‐stranded	telomeric	DNA	in	cells	that	use	alternative	lengthening	of	telomeres.	Nucleic	
Acids	Res.	35:7267‐7278.		
Guiducci,	C.,	M.	A.	Cerone,	and	S.	Bacchetti.	2001.	Expression	of	mutant	telomerase	in	immortal	telomerase‐negative	
human	cells	 results	 in	cell	 cycle	deregulation,	nuclear	and	chromosomal	abnormalities	and	rapid	 loss	of	viability.	
Oncogene	20:714‐725.		
Guo,	 X.,	 Y.	Deng,	 Y.	 Lin,	W.	 Cosme‐Blanco,	 S.	 Chan,	H.	He,	G.	 Yuan,	E.	 J.	 Brown,	 and	 S.	 Chang.	 2007.	Dysfunctional	
telomeres	activate	an	ATM‐ATR‐dependent	DNA	damage	response	to	suppress	tumorigenesis.	EMBO	J.	26:4709‐4719.		
Hagemann,	C.,	J.	Anacker,	S.	Gerngras,	S.	Kuhnel,	H.	M.	Said,	R.	Patel,	U.	Kammerer,	D.	Vordermark,	K.	Roosen,	and	G.	
H.	Vince.	2008.	Expression	analysis	of	the	autosomal	recessive	primary	microcephaly	genes	MCPH1	(microcephalin)	
and	MCPH5	(ASPM,	abnormal	spindle‐like,	microcephaly	associated)	in	human	malignant	gliomas.	Oncol.	Rep.	20:301‐
308.		
Hakin‐Smith,	V.,	D.	A.	Jellinek,	D.	Levy,	T.	Carroll,	M.	Teo,	W.	R.	Timperley,	M.	J.	McKay,	R.	R.	Reddel,	and	J.	A.	Royds.	
2003.	Alternative	lengthening	of	telomeres	and	survival	in	patients	with	glioblastoma	multiforme.	Lancet	361:836‐
838.		
Hanaoka,	S.,	A.	Nagadoi,	and	Y.	Nishimura.	2005.	Comparison	between	TRF2	and	TRF1	of	their	telomeric	DNA‐bound	
structures	and	DNA‐binding	activities.	Protein	Sci.	14:119‐130.		
Harle‐Bachor,	C.,	and	P.	Boukamp.	1996.	Telomerase	activity	in	the	regenerative	basal	layer	of	the	epidermis	in	human	
skin	and	in	immortal	and	carcinoma‐derived	skin	keratinocytes.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	93:6476‐6481.		
Harley,	C.	B.	1991.	Telomere	loss:	mitotic	clock	or	genetic	time	bomb?	Mutat.	Res.	256:271‐282.		
Harley,	C.	B.,	A.	B.	Futcher,	and	C.	W.	Greider.	1990.	Telomeres	shorten	during	ageing	of	human	fibroblasts.	Nature	
345:458‐460.		
References		 	
 
 
91 
Hastie,	N.	D.,	M.	Dempster,	M.	G.	Dunlop,	A.	M.	Thompson,	D.	K.	Green,	and	R.	C.	Allshire.	1990.	Telomere	reduction	in	
human	colorectal	carcinoma	and	with	ageing.	Nature	346:866‐868.		
He,	D.	L.,	Z.	M.	Mu,	X.	F.	Le,	J.	T.	Hsieh,	R.	C.	Pong,	L.	W.	Chung,	and	K.	S.	Chang.	1997.	Adenovirus‐mediated	expression	
of	PML	suppresses	growth	and	tumorigenicity	of	prostate	cancer	cells.	Cancer	Res.	57:1868‐1872.		
He,	 H.,	 A.	 S.	Multani,	W.	 Cosme‐Blanco,	 H.	 Tahara,	 J.	Ma,	 S.	 Pathak,	 Y.	 Deng,	 and	 S.	 Chang.	 2006.	 POT1b	 protects	
telomeres	from	end‐to‐end	chromosomal	fusions	and	aberrant	homologous	recombination.	EMBO	J.	25:5180‐5190.		
Heaphy,	C.	M.,	R.	F.	de	Wilde,	Y.	Jiao,	A.	P.	Klein,	B.	H.	Edil,	C.	Shi,	C.	Bettegowda,	F.	J.	Rodriguez,	C.	G.	Eberhart,	S.	Hebbar,	
G.	J.	Offerhaus,	R.	McLendon,	B.	A.	Rasheed,	Y.	He,	H.	Yan,	D.	D.	Bigner,	S.	M.	Oba‐Shinjo,	S.	K.	Marie,	G.	J.	Riggins,	K.	W.	
Kinzler,	B.	Vogelstein,	R.	H.	Hruban,	A.	Maitra,	N.	Papadopoulos,	and	A.	K.	Meeker.	2011a.	Altered	telomeres	in	tumors	
with	ATRX	and	DAXX	mutations.	Science	333:425.		
Heaphy,	C.	M.,	A.	P.	Subhawong,	S.	M.	Hong,	M.	G.	Goggins,	E.	A.	Montgomery,	E.	Gabrielson,	G.	J.	Netto,	J.	I.	Epstein,	T.	
L.	Lotan,	W.	H.	Westra,	I.	M.	Shih,	C.	A.	Iacobuzio‐Donahue,	A.	Maitra,	Q.	K.	Li,	C.	G.	Eberhart,	J.	M.	Taube,	D.	Rakheja,	R.	
J.	Kurman,	T.	C.	Wu,	R.	B.	Roden,	P.	Argani,	A.	M.	De	Marzo,	L.	Terracciano,	M.	Torbenson,	and	A.	K.	Meeker.	2011b.	
Prevalence	of	the	alternative	lengthening	of	telomeres	telomere	maintenance	mechanism	in	human	cancer	subtypes.	
Am.	J.	Pathol.	179:1608‐1615.		
Helt,	A.	M.,	and	D.	A.	Galloway.	2003.	Mechanisms	by	which	DNA	tumor	virus	oncoproteins	target	the	Rb	family	of	
pocket	proteins.	Carcinogenesis	24:159‐169.		
Henson,	J.	D.	The	role	of	Alternative	Lengthening	of	Telomeres	in	human	cancer.	2006.	University	of	Sydney.		
Ref	Type:	Thesis/Dissertation	
Henson,	 J.	D.,	Y.	Cao,	L.	 I.	Huschtscha,	A.	C.	Chang,	A.	Y.	Au,	H.	A.	Pickett,	and	R.	R.	Reddel.	2009.	DNA	C‐circles	are	
specific	and	quantifiable	markers	of	alternative‐lengthening‐of‐telomeres	activity.	Nat.	Biotechnol.	27:1181‐1185.		
Henson,	J.	D.,	J.	A.	Hannay,	S.	W.	McCarthy,	J.	A.	Royds,	T.	R.	Yeager,	R.	A.	Robinson,	S.	B.	Wharton,	D.	A.	Jellinek,	S.	M.	
Arbuckle,	J.	Yoo,	B.	G.	Robinson,	D.	L.	Learoyd,	P.	D.	Stalley,	S.	F.	Bonar,	D.	Yu,	R.	E.	Pollock,	and	R.	R.	Reddel.	2005.	A	
robust	assay	for	alternative	lengthening	of	telomeres	in	tumors	shows	the	significance	of	alternative	lengthening	of	
telomeres	in	sarcomas	and	astrocytomas.	Clin.	Cancer	Res.	11:217‐225.		
Henson,	J.	D.,	A.	A.	Neumann,	T.	R.	Yeager,	and	R.	R.	Reddel.	2002.	Alternative	lengthening	of	telomeres	in	mammalian	
cells.	Oncogene	21:598‐610.		
Henson,	 J.	D.,	and	R.	R.	Reddel.	2010.	Assaying	and	 investigating	Alternative	Lengthening	of	Telomeres	activity	 in	
human	cells	and	cancers.	FEBS	Lett.	584:3800‐3811.		
Herrera,	E.,	C.	Martinez,	and	M.	A.	Blasco.	2000.	Impaired	germinal	center	reaction	in	mice	with	short	telomeres.	EMBO	
J.	19:472‐481.		
Hickson,	I.	D.	2003.	RecQ	helicases:	caretakers	of	the	genome.	Nat.	Rev.	Cancer	3:169‐178.		
Hockemeyer,	D.,	W.	Palm,	T.	Else,	J.	P.	Daniels,	K.	K.	Takai,	J.	Z.	Ye,	C.	E.	Keegan,	T.	de	Lange,	and	G.	D.	Hammer.	2007.	
Telomere	protection	by	mammalian	Pot1	requires	interaction	with	Tpp1.	Nat.	Struct.	Mol.	Biol.	14:754‐761.		
Hockemeyer,	D.,	A.	J.	Sfeir,	J.	W.	Shay,	W.	E.	Wright,	and	T.	de	Lange.	2005.	POT1	protects	telomeres	from	a	transient	
DNA	damage	response	and	determines	how	human	chromosomes	end.	EMBO	J.	24:2667‐2678.		
References		 	
 
 
92 
Hong,	W.,	M.	Nakazawa,	Y.	Y.	Chen,	R.	Kori,	C.	R.	Vakoc,	C.	Rakowski,	and	G.	A.	Blobel.	2005.	FOG‐1	recruits	the	NuRD	
repressor	complex	to	mediate	transcriptional	repression	by	GATA‐1.	EMBO	J.	24:2367‐2378.		
Jensen,	K.,	C.	Shiels,	and	P.	S.	Freemont.	2001.	PML	protein	isoforms	and	the	RBCC/TRIM	motif.	Oncogene	20:7223‐
7233.		
Jeyapalan,	 J.	 N.,	 A.	Mendez‐Bermudez,	 N.	 Zaffaroni,	 Y.	 E.	 Dubrova,	 and	N.	 J.	 Royle.	 2008.	 Evidence	 for	 alternative	
lengthening	of	telomeres	in	liposarcomas	in	the	absence	of	ALT‐associated	PML	bodies.	Int.	J.	Cancer	122:2414‐2421.		
Jeyapalan,	 J.	N.,	H.	Varley,	 J.	 L.	 Foxon,	R.	E.	Pollock,	A.	 J.	 Jeffreys,	 J.	D.	Henson,	R.	R.	Reddel,	 and	N.	 J.	Royle.	2005.	
Activation	of	the	ALT	pathway	for	telomere	maintenance	can	affect	other	sequences	in	the	human	genome.	Hum.	Mol.	
Genet.	14:1785‐1794.		
Jiang,	W.	Q.,	and	N.	Ringertz.	1997.	Altered	distribution	of	the	promyelocytic	leukemia‐associated	protein	is	associated	
with	cellular	senescence.	Cell	Growth	Differ.	8:513‐522.		
Jiang,	W.	Q.,	Z.	H.	Zhong,	J.	D.	Henson,	A.	A.	Neumann,	A.	C.	Chang,	and	R.	R.	Reddel.	2005.	Suppression	of	alternative	
lengthening	of	telomeres	by	Sp100‐mediated	sequestration	of	MRE11/RAD50/NBS1	complex.	Mol.	Cell.	Biol.	25:2708‐
2721.		
Jiang,	W.	Q.,	Z.	H.	Zhong,	J.	D.	Henson,	and	R.	R.	Reddel.	2007.	Identification	of	candidate	alternative	lengthening	of	
telomeres	genes	by	methionine	restriction	and	RNA	interference.	Oncogene	26:4635‐4647.		
Jiang,	W.	Q.,	Z.	H.	Zhong,	A.	Nguyen,	J.	D.	Henson,	C.	D.	Toouli,	A.	W.	Braithwaite,	and	R.	R.	Reddel.	2009.	Induction	of	
alternative	lengthening	of	telomeres‐associated	PML	bodies	by	p53/p21	requires	HP1	proteins.	J.	Cell	Biol.	185:797‐
810.		
Jones,	B.,	H.	Su,	A.	Bhat,	H.	Lei,	J.	Bajko,	S.	Hevi,	G.	A.	Baltus,	S.	Kadam,	H.	Zhai,	R.	Valdez,	S.	Gonzalo,	Y.	Zhang,	E.	Li,	and	
T.	 Chen.	 2008.	 The	 histone	 H3K79	 methyltransferase	 Dot1L	 is	 essential	 for	 mammalian	 development	 and	
heterochromatin	structure.	PLoS	Genet.	4:e1000190.		
Jones,	P.	A.,	and	S.	B.	Baylin.	2002.	The	fundamental	role	of	epigenetic	events	in	cancer.	Nat.	Rev.	Genet.	3:415‐428.		
Kato,	S.,	H.	Sasaki,	M.	Suzawa,	S.	Masushige,	L.	Tora,	P.	Chambon,	and	H.	Gronemeyer.	1995.	Widely	spaced,	directly	
repeated	PuGGTCA	elements	act	as	promiscuous	enhancers	for	different	classes	of	nuclear	receptors.	Mol.	Cell.	Biol.	
15:5858‐5867.		
Kim,	M.	M.,	M.	A.	Rivera,	I.	L.	Botchkina,	R.	Shalaby,	A.	D.	Thor,	and	E.	H.	Blackburn.	2001.	A	low	threshold	level	of	
expression	of	mutant‐template	telomerase	RNA	inhibits	human	tumor	cell	proliferation.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	
98:7982‐7987.		
Kim,	S.	H.,	C.	Beausejour,	A.	R.	Davalos,	P.	Kaminker,	S.	J.	Heo,	and	J.	Campisi.	2004.	TIN2	mediates	functions	of	TRF2	
at	human	telomeres.	J.	Biol.	Chem.	279:43799‐43804.		
Kim,	S.	H.,	P.	Kaminker,	and	J.	Campisi.	1999.	TIN2,	a	new	regulator	of	telomere	length	in	human	cells.	Nat.	Genet.	
23:405‐412.		
Koering,	C.	E.,	A.	Pollice,	M.	P.	Zibella,	S.	Bauwens,	A.	Puisieux,	M.	Brunori,	C.	Brun,	L.	Martins,	L.	Sabatier,	J.	F.	Pulitzer,	
and	E.	Gilson.	2002.	Human	telomeric	position	effect	is	determined	by	chromosomal	context	and	telomeric	chromatin	
integrity.	EMBO	Rep.	3:1055‐1061.		
References		 	
 
 
93 
Lachner,	M.,	D.	O'Carroll,	 S.	Rea,	K.	Mechtler,	 and	T.	 Jenuwein.	2001.	Methylation	of	histone	H3	 lysine	9	creates	a	
binding	site	for	HP1	proteins.	Nature	410:116‐120.		
Lai,	A.	Y.,	and	P.	A.	Wade.	2011.	Cancer	biology	and	NuRD:	a	multifaceted	chromatin	remodelling	complex.	Nat.	Rev.	
Cancer	11:588‐596.		
Lansdorp,	P.	M.,	S.	Poon,	E.	Chavez,	V.	Dragowska,	M.	Zijlmans,	T.	Bryan,	R.	Reddel,	M.	Egholm,	S.	Bacchetti,	and	U.	
Martens.	1997.	Telomeres	in	the	hematopoietic	system.	In	Ciba	Found.	Symp.	D.	J.	Chadwick,	and	G.	Cardew,	editors.	
John	Wiley	&	Sons	Ltd.,	West	Sussex,	U.	K.	209‐218.		
Lauberth,	S.	M.,	and	M.	Rauchman.	2006.	A	conserved	12‐amino	acid	motif	in	Sall1	recruits	the	nucleosome	remodeling	
and	deacetylase	corepressor	complex.	J.	Biol.	Chem.	281:23922‐23931.		
Law,	M.	J.,	K.	M.	Lower,	H.	P.	Voon,	J.	R.	Hughes,	D.	Garrick,	V.	Viprakasit,	M.	Mitson,	M.	De	Gobbi,	M.	Marra,	A.	Morris,	
A.	Abbott,	S.	P.	Wilder,	S.	Taylor,	G.	M.	Santos,	J.	Cross,	H.	Ayyub,	S.	Jones,	J.	Ragoussis,	D.	Rhodes,	I.	Dunham,	D.	R.	Higgs,	
and	R.	J.	Gibbons.	2010.	ATR‐X	syndrome	protein	targets	tandem	repeats	and	influences	allele‐specific	expression	in	
a	size‐dependent	manner.	Cell	143:367‐378.		
Lee,	J.	H.,	and	T.	T.	Paull.	2007.	Activation	and	regulation	of	ATM	kinase	activity	in	response	to	DNA	double‐strand	
breaks.	Oncogene	26:7741‐7748.		
Lee,	M.,	M.	Hills,	D.	Conomos,	M.	D.	Stutz,	R.	A.	Dagg,	L.	M.	Lau,	R.	R.	Reddel,	and	H.	A.	Pickett.	2014.	Telomere	extension	
by	telomerase	and	ALT	generates	variant	repeats	by	mechanistically	distinct	processes.	Nucleic	Acids	Res.	42:1733‐
1736.		
Lejnine,	S.,	V.	L.	Makarov,	and	J.	P.	Langmore.	1995.	Conserved	nucleoprotein	structure	at	the	ends	of	vertebrate	and	
invertebrate	chromosomes.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	92:2393‐2397.		
Lejon,	S.,	S.	Y.	Thong,	A.	Murthy,	S.	AlQarni,	N.	V.	Murzina,	G.	A.	Blobel,	E.	D.	Laue,	and	J.	P.	Mackay.	2011.	Insights	into	
association	of	the	NuRD	complex	with	FOG‐1	from	the	crystal	structure	of	an	RbAp48.	FOG‐1	complex.	J.	Biol.	Chem.	
286:1196‐1203.		
Lewis,	P.	W.,	S.	J.	Elsaesser,	K.	M.	Noh,	S.	C.	Stadler,	and	C.	D.	Allis.	2010.	Daxx	is	an	H3.3‐specific	histone	chaperone	
and	cooperates	with	ATRX	in	replication‐independent	chromatin	assembly	at	telomeres.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	
107:14075‐14080.		
Li,	B.,	 S.	Oestreich,	 and	T.	de	Lange.	2000.	 Identification	of	human	Rap1:	 implications	 for	 telomere	evolution.	Cell	
101:471‐483.		
Li,	H.,	and	R.	Durbin.	2009.	Fast	and	accurate	short	read	alignment	with	Burrows‐Wheeler	transform.	Bioinformatics	
25:1754‐1760.		
Li,	H.,	B.	Handsaker,	A.	Wysoker,	T.	Fennell,	J.	Ruan,	N.	Homer,	G.	Marth,	G.	Abecasis,	and	R.	Durbin.	2009.	The	sequence	
alignment/map	format	and	SAMtools.	Bioinformatics	25:2078‐2079.		
Li,	S.,	J.	E.	Rosenberg,	A.	A.	Donjacour,	I.	L.	Botchkina,	Y.	K.	Hom,	G.	R.	Cunha,	and	E.	H.	Blackburn.	2004.	Rapid	inhibition	
of	cancer	cell	growth	 induced	by	 lentiviral	delivery	and	expression	of	mutant‐template	 telomerase	RNA	and	anti‐
telomerase	short‐interfering	RNA.	Cancer	Res.	64:4833‐4840.		
Lin,	S.	Y.,	Y.	Liang,	and	K.	Li.	2010.	Multiple	roles	of	BRIT1/MCPH1	in	DNA	damage	response,	DNA	repair,	and	cancer	
suppression.	Yonsei	Med.	J.	51:295‐301.		
References		 	
 
 
94 
Liu,	K.,	M.	M.	Schoonmaker,	B.	L.	Levine,	C.	H.	 June,	R.	 J.	Hodes,	 and	N.	P.	Weng.	1999.	Constitutive	and	regulated	
expression	of	telomerase	reverse	transcriptase	(hTERT)	in	human	lymphocytes.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	96:5147‐
5152.		
Loayza,	D.,	H.	Parsons,	J.	Donigian,	K.	Hoke,	and	T.	de	Lange.	2004.	DNA	binding	features	of	human	POT1:	a	nonamer	
5'‐TAGGGTTAG‐3'	minimal	binding	site,	sequence	specificity,	and	internal	binding	to	multimeric	sites.	J.	Biol.	Chem.	
279:13241‐13248.		
Londono‐Vallejo,	 J.	 A.,	H.	Der‐Sarkissian,	 L.	 Cazes,	 S.	 Bacchetti,	 and	R.	R.	Reddel.	 2004.	Alternative	 lengthening	of	
telomeres	is	characterized	by	high	rates	of	telomeric	exchange.	Cancer	Res.	64:2324‐2327.		
Lovejoy,	C.	A.,	W.	Li,	 S.	Reisenweber,	S.	Thongthip,	 J.	Bruno,	T.	de	Lange,	S.	De,	 J.	H.	Petrini,	P.	A.	Sung,	M.	 Jasin,	 J.	
Rosenbluh,	Y.	Zwang,	B.	A.	Weir,	C.	Hatton,	E.	Ivanova,	L.	Macconaill,	M.	Hanna,	W.	C.	Hahn,	N.	F.	Lue,	R.	R.	Reddel,	Y.	
Jiao,	K.	Kinzler,	B.	Vogelstein,	N.	Papadopoulos,	 and	A.	K.	Meeker.	2012.	Loss	of	ATRX,	genome	 instability,	and	an	
altered	 DNA	 damage	 response	 are	 hallmarks	 of	 the	 Alternative	 Lengthening	 of	 Telomeres	 pathway.	 PLoS	Genet.	
8:e1002772.		
Luciani,	J.	J.,	D.	Depetris,	Y.	Usson,	C.	Metzler‐Guillemain,	C.	Mignon‐Ravix,	M.	J.	Mitchell,	A.	Megarbane,	P.	Sarda,	H.	
Sirma,	A.	Moncla,	J.	Feunteun,	and	M.	G.	Mattei.	2006.	PML	nuclear	bodies	are	highly	organised	DNA‐protein	structures	
with	a	function	in	heterochromatin	remodelling	at	the	G2	phase.	J.	Cell	Sci.	119:2518‐2531.		
Luke,	B.,	and	J.	Lingner.	2009.	TERRA:	telomeric	repeat‐containing	RNA.	EMBO	J.	28:2503‐2510.		
Lundblad,	 V.,	 and	 E.	 H.	 Blackburn.	 1993.	 An	 alternative	 pathway	 for	 yeast	 telomere	 maintenance	 rescues	 est1‐	
senescence.	Cell	73:347‐360.		
Makarov,	V.	L.,	Y.	Hirose,	and	J.	P.	Langmore.	1997.	Long	G	tails	at	both	ends	of	human	chromosomes	suggest	a	C	strand	
degradation	mechanism	for	telomere	shortening.	Cell	88:657‐666.		
Marciniak,	R.	A.,	D.	Cavazos,	R.	Montellano,	Q.	Chen,	L.	Guarente,	and	F.	B.	Johnson.	2005.	A	novel	telomere	structure	
in	human	alternative	lengthening	of	telomeres	cell	line.	Cancer	Res.	65:2730‐2737.		
Martens,	U.	M.,	E.	A.	Chavez,	S.	S.	Poon,	C.	Schmoor,	and	P.	M.	Lansdorp.	2000.	Accumulation	of	short	telomeres	in	
human	fibroblasts	prior	to	replicative	senescence.	Exp.	Cell	Res.	256:291‐299.		
Martinez,	P.,	M.	Thanasoula,	P.	Munoz,	C.	Liao,	A.	Tejera,	C.	McNees,	J.	M.	Flores,	O.	Fernandez‐Capetillo,	M.	Tarsounas,	
and	M.	A.	Blasco.	2009.	Increased	telomere	fragility	and	fusions	resulting	from	TRF1	deficiency	lead	to	degenerative	
pathologies	and	increased	cancer	in	mice.	Genes	Dev.	23:2060‐2075.		
Marusic,	L.,	M.	Anton,	A.	Tidy,	P.	Wang,	B.	Villeponteau,	 and	S.	Bacchetti.	 1997.	Reprogramming	of	 telomerase	by	
expression	of	mutant	telomerase	RNA	template	in	human	cells	leads	to	altered	telomeres	that	correlate	with	reduced	
cell	viability.	Mol.	Cell.	Biol.	17:6394‐6401.		
Mason,	J.	M.,	and	H.	Biessmann.	1995.	The	unusual	telomeres	of	Drosophila.	Trends	Genet.	11:58‐62.		
Mattern,	K.	A.,	S.	J.	Swiggers,	A.	L.	Nigg,	B.	Lowenberg,	A.	B.	Houtsmuller,	and	J.	M.	Zijlmans.	2004.	Dynamics	of	protein	
binding	to	telomeres	in	living	cells:	implications	for	telomere	structure	and	function.	Mol.	Cell.	Biol.	24:5587‐5594.		
Mattsson,	 K.,	 K.	 Pokrovskaja,	 C.	 Kiss,	 G.	 Klein,	 and	 L.	 Szekely.	 2001.	 Proteins	 associated	 with	 the	 promyelocytic	
leukemia	 gene	 product	 (PML)‐containing	 nuclear	 body	 move	 to	 the	 nucleolus	 upon	 inhibition	 of	 proteasome‐
dependent	protein	degradation.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	98:1012‐1017.		
References		 	
 
 
95 
Meeker,	A.	K.,	W.	R.	Gage,	J.	L.	Hicks,	I.	Simon,	J.	R.	Coffman,	E.	A.	Platz,	G.	E.	March,	and	A.	M.	De	Marzo.	2002.	Telomere	
length	 assessment	 in	 human	 archival	 tissues:	 combined	 telomere	 fluorescence	 in	 situ	 hybridization	 and	
immunostaining.	Am.	J.	Pathol.	160:1259‐1268.		
Meyne,	J.,	E.	H.	Goodwin,	and	R.	K.	Moyzis.	1994.	Chromosome	localization	and	orientation	of	the	simple	sequence	
repeat	of	human	satellite	I	DNA.	Chromosoma	103:99‐103.		
Michishita,	E.,	R.	A.	McCord,	E.	Berber,	M.	Kioi,	H.	Padilla‐Nash,	M.	Damian,	P.	Cheung,	R.	Kusumoto,	T.	L.	Kawahara,	J.	
C.	Barrett,	H.	Y.	Chang,	V.	A.	Bohr,	T.	Ried,	O.	Gozani,	and	K.	F.	Chua.	2008.	SIRT6	is	a	histone	H3	lysine	9	deacetylase	
that	modulates	telomeric	chromatin.	Nature	452:492‐496.		
Molenaar,	C.,	K.	Wiesmeijer,	N.	P.	Verwoerd,	S.	Khazen,	R.	Eils,	H.	J.	Tanke,	and	R.	W.	Dirks.	2003.	Visualizing	telomere	
dynamics	in	living	mammalian	cells	using	PNA	probes.	EMBO	J.	22:6631‐6641.		
Morin,	G.	B.	1989.	The	human	telomere	terminal	transferase	enzyme	is	a	ribonucleoprotein	that	synthesizes	TTAGGG	
repeats.	Cell	59:521‐529.		
Moyzis,	R.	K.,	J.	M.	Buckingham,	L.	S.	Cram,	M.	Dani,	L.	L.	Deaven,	M.	D.	Jones,	J.	Meyne,	R.	L.	Ratliff,	and	J.	R.	Wu.	1988.	
A	highly	conserved	repetitive	DNA	sequence,	(TTAGGG)n,	present	at	the	telomeres	of	human	chromosomes.	Proc.	Natl.	
Acad.	Sci.	U.	S.	A.	85:6622‐6626.		
Muntoni,	 A.,	 A.	 A.	 Neumann,	M.	Hills,	 and	R.	 R.	 Reddel.	 2009.	 Telomere	 elongation	 involves	 intra‐molecular	DNA	
replication	in	cells	utilizing	Alternative	Lengthening	of	Telomeres.	Hum.	Mol.	Genet.	18:1017‐1027.		
Muntoni,	A.,	and	R.	R.	Reddel.	2005.	The	first	molecular	details	of	ALT	in	human	tumor	cells.	Hum.	Mol.	Genet.	14	Suppl	
2:R191‐R196.		
Muratani,	 M.,	 D.	 Gerlich,	 S.	 M.	 Janicki,	 M.	 Gebhard,	 R.	 Eils,	 and	 D.	 L.	 Spector.	 2002.	 Metabolic‐energy‐dependent	
movement	of	PML	bodies	within	the	mammalian	cell	nucleus.	Nat.	Cell	Biol.	4:106‐110.		
Murnane,	J.	P.,	L.	Sabatier,	B.	A.	Marder,	and	W.	F.	Morgan.	1994.	Telomere	dynamics	in	an	immortal	human	cell	line.	
EMBO	J.	13:4953‐4962.		
Nabetani,	A.,	and	F.	Ishikawa.	2009.	Unusual	telomeric	DNAs	in	human	telomerase‐negative	immortalized	cells.	Mol.	
Cell.	Biol.	29:703‐713.		
Nabetani,	A.,	O.	Yokoyama,	and	F.	 Ishikawa.	2004.	Localization	of	hRad9,	hHus1,	hRad1	and	hRad17,	and	caffeine‐
sensitive	DNA	replication	at	the	alternative	lengthening	of	telomeres‐associated	promyelocytic	leukemia	body.	J.	Biol.	
Chem.	279:25849‐25857.		
Natarajan,	S.,	C.	Groff‐Vindman,	and	M.	J.	McEachern.	2003.	Factors	influencing	the	recombinational	expansion	and	
spread	of	telomeric	tandem	arrays	in	Kluyveromyces	lactis.	Eukaryot.	Cell	2:1115‐1127.		
Natarajan,	S.,	and	M.	J.	McEachern.	2002.	Recombinational	telomere	elongation	promoted	by	DNA	circles.	Mol.	Cell.	
Biol.	22:4512‐4521.		
Neumann,	A.	A.,	C.	M.	Watson,	J.	R.	Noble,	H.	A.	Pickett,	P.	P.	Tam,	and	R.	R.	Reddel.	2013.	Alternative	lengthening	of	
telomeres	in	normal	mammalian	somatic	cells.	Genes	Dev.	27:18‐23.		
Ng,	L.	J.,	J.	E.	Cropley,	H.	A.	Pickett,	R.	R.	Reddel,	and	C.	M.	Suter.	2009.	Telomerase	activity	is	associated	with	an	increase	
in	 DNA	 methylation	 at	 the	 proximal	 subtelomere	 and	 a	 reduction	 in	 telomeric	 transcription.	Nucleic	 Acids	 Res.	
37:1152‐1159.		
References		 	
 
 
96 
O'Sullivan,	R.	J.,	N.	Arnoult,	D.	H.	Lackner,	L.	Oganesian,	C.	Haggblom,	A.	Corpet,	G.	Almouzni,	and	J.	Karlseder.	2014.	
Rapid	induction	of	alternative	lengthening	of	telomeres	by	depletion	of	the	histone	chaperone	ASF1.	Nat.	Struct.	Mol.	
Biol.	21:167‐174.		
Ogino,	H.,	K.	Nakabayashi,	M.	Suzuki,	E.	I.	Takahashi,	M.	Fujii,	T.	Suzuki,	and	D.	Ayusawa.	1998.	Release	of	telomeric	
DNA	 from	 chromosomes	 in	 immortal	 human	 cells	 lacking	 telomerase	 activity.	 Biochem.	 Biophys.	 Res.	 Commun.	
248:223‐227.		
Olovnikov,	A.	M.	1973.	A	theory	of	marginotomy.	The	incomplete	copying	of	template	margin	in	enzymic	synthesis	of	
polynucleotides	and	biological	significance	of	the	phenomenon.	J.	Theor.	Biol.	41:181‐190.		
Opitz,	O.	G.,	Y.	Suliman,	W.	C.	Hahn,	H.	Harada,	H.	E.	Blum,	and	A.	K.	Rustgi.	2001.	Cyclin	D1	overexpression	and	p53	
inactivation	immortalize	primary	oral	keratinocytes	by	a	telomerase‐independent	mechanism.	J.	Clin.	Invest.	108:725‐
732.		
Palm,	W.,	D.	Hockemeyer,	T.	Kibe,	and	T.	de	Lange.	2009.	Functional	dissection	of	human	and	mouse	POT1	proteins.	
Mol.	Cell.	Biol.	29:471‐482.		
Pan,	M.	R.,	H.	 J.	Hsieh,	H.	Dai,	W.	C.	Hung,	K.	Li,	G.	Peng,	and	S.	Y.	Lin.	2012.	Chromodomain	helicase	DNA‐binding	
protein	4	(CHD4)	regulates	homologous	recombination	DNA	repair,	and	its	deficiency	sensitizes	cells	to	poly(ADP‐
ribose)	polymerase	(PARP)	inhibitor	treatment.	J.	Biol.	Chem.	287:6764‐6772.		
Park,	S.	W.,	X.	Hu,	P.	Gupta,	Y.	P.	Lin,	S.	G.	Ha,	and	L.	N.	Wei.	2007.	SUMOylation	of	Tr2	orphan	receptor	involves	Pml	
and	fine‐tunes	Oct4	expression	in	stem	cells.	Nat.	Struct.	Mol.	Biol.	14:68‐75.		
Perrem,	K.,	T.	M.	Bryan,	A.	Englezou,	T.	Hackl,	E.	L.	Moy,	and	R.	R.	Reddel.	1999.	Repression	of	an	alternative	mechanism	
for	lengthening	of	telomeres	in	somatic	cell	hybrids.	Oncogene	18:3383‐3390.		
Perrem,	K.,	L.	M.	Colgin,	A.	A.	Neumann,	T.	R.	Yeager,	and	R.	R.	Reddel.	2001.	Coexistence	of	alternative	lengthening	of	
telomeres	and	telomerase	in	hTERT‐transfected	GM847	cells.	Mol.	Cell.	Biol.	21:3862‐3875.		
Peters,	A.	H.,	D.	O'Carroll,	H.	Scherthan,	K.	Mechtler,	S.	Sauer,	C.	Schofer,	K.	Weipoltshammer,	M.	Pagani,	M.	Lachner,	A.	
Kohlmaier,	 S.	Opravil,	M.	Doyle,	M.	 Sibilia,	 and	T.	 Jenuwein.	 2001.	 Loss	of	 the	 Suv39h	histone	methyltransferases	
impairs	mammalian	heterochromatin	and	genome	stability.	Cell	107:323‐337.		
Pickett,	H.	A.,	A.	 J.	Cesare,	R.	L.	 Johnstone,	A.	A.	Neumann,	and	R.	R.	Reddel.	2009.	Control	of	telomere	 length	by	a	
trimming	mechanism	that	involves	generation	of	t‐circles.	EMBO	J.	28:799‐809.		
Polo,	S.	E.,	A.	Kaidi,	L.	Baskcomb,	Y.	Galanty,	and	S.	P.	Jackson.	2010.	Regulation	of	DNA‐damage	responses	and	cell‐
cycle	progression	by	the	chromatin	remodelling	factor	CHD4.	EMBO	J.	29:3130‐3139.		
Porro,	A.,	S.	Feuerhahn,	and	J.	Lingner.	2014.	TERRA‐reinforced	association	of	LSD1	with	MRE11	promotes	processing	
of	uncapped	telomeres.	Cell	Rep.		
Potts,	P.	R.,	and	H.	Yu.	2007.	The	SMC5/6	complex	maintains	telomere	length	in	ALT	cancer	cells	through	SUMOylation	
of	telomere‐binding	proteins.	Nat.	Struct.	Mol.	Biol.	14:581‐590.		
Poulet,	 A.,	 R.	 Buisson,	 C.	 Faivre‐Moskalenko,	 M.	 Koelblen,	 S.	 Amiard,	 F.	 Montel,	 S.	 Cuesta‐Lopez,	 O.	 Bornet,	 F.	
Guerlesquin,	T.	Godet,	J.	Moukhtar,	F.	Argoul,	A.	C.	Declais,	D.	M.	Lilley,	S.	C.	Ip,	S.	C.	West,	E.	Gilson,	and	M.	J.	Giraud‐
Panis.	2009.	TRF2	promotes,	remodels	and	protects	telomeric	Holliday	junctions.	EMBO	J.	28:641‐651.		
References		 	
 
 
97 
Ramirez,	R.	D.,	W.	E.	Wright,	 J.	W.	Shay,	and	R.	S.	Taylor.	1997.	Telomerase	activity	concentrates	 in	the	mitotically	
active	segments	of	human	hair	follicles.	J.	Invest.	Dermatol.	108:113‐117.		
Reddel,	R.	R.	2000.	The	role	of	senescence	and	immortalization	in	carcinogenesis.	Carcinogenesis	21:477‐484.		
Roth,	C.	W.,	F.	Kobeski,	M.	F.	Walter,	and	H.	Biessmann.	1997.	Chromosome	end	elongation	by	recombination	in	the	
mosquito	Anopheles	gambiae.	Mol.	Cell.	Biol.	17:5176‐5183.		
Saharia,	A.,	 and	S.	A.	 Stewart.	2009.	FEN1	contributes	 to	 telomere	 stability	 in	ALT‐positive	 tumor	cells.	Oncogene	
28:1162‐1167.		
Saharia,	A.,	D.	C.	Teasley,	J.	P.	Duxin,	B.	Dao,	K.	B.	Chiappinelli,	and	S.	A.	Stewart.	2010.	FEN1	ensures	telomere	stability	
by	facilitating	replication	fork	re‐initiation.	J.	Biol.	Chem.	285:27057‐27066.		
Sampl,	S.,	S.	Pramhas,	C.	Stern,	M.	Preusser,	C.	Marosi,	and	K.	Holzmann.	2012.	Expression	of	telomeres	in	astrocytoma	
WHO	Grade	2	to	4:	TERRA	level	correlates	with	telomere	length,	telomerase	activity,	and	advanced	clinical	grade.	
Transl.	Oncol.	5:56‐65.		
Sandelin,	A.,	and	W.	W.	Wasserman.	2005.	Prediction	of	nuclear	hormone	receptor	response	elements.	Mol.	Endocrinol.	
19:595‐606.		
Savitsky,	M.,	O.	Kravchuk,	L.	Melnikova,	and	P.	Georgiev.	2002.	Heterochromatin	protein	1	is	involved	in	control	of	
telomere	elongation	in	Drosophila	melanogaster.	Mol.	Cell.	Biol.	22:3204‐3218.		
Schoeftner,	S.,	and	M.	A.	Blasco.	2008.	Developmentally	regulated	transcription	of	mammalian	telomeres	by	DNA‐
dependent	RNA	polymerase	II.	Nat.	Cell	Biol.	10:228‐236.		
Schoeftner,	S.,	and	M.	A.	Blasco.	2010.	Chromatin	regulation	and	non‐coding	RNAs	at	mammalian	telomeres.	Semin.	
Cell	Dev.	Biol.	21:186‐193.		
Schwartzentruber,	J.,	A.	Korshunov,	X.	Y.	Liu,	D.	T.	Jones,	E.	Pfaff,	K.	Jacob,	D.	Sturm,	A.	M.	Fontebasso,	D.	A.	Quang,	M.	
Tonjes,	V.	Hovestadt,	S.	Albrecht,	M.	Kool,	A.	Nantel,	C.	Konermann,	A.	Lindroth,	N.	Jager,	T.	Rausch,	M.	Ryzhova,	J.	O.	
Korbel,	T.	Hielscher,	P.	Hauser,	M.	Garami,	A.	Klekner,	L.	Bognar,	M.	Ebinger,	M.	U.	Schuhmann,	W.	Scheurlen,	A.	Pekrun,	
M.	 C.	 Fruhwald,	 W.	 Roggendorf,	 C.	 Kramm,	 M.	 Durken,	 J.	 Atkinson,	 P.	 Lepage,	 A.	 Montpetit,	 M.	 Zakrzewska,	 K.	
Zakrzewski,	P.	P.	Liberski,	Z.	Dong,	P.	Siegel,	A.	E.	Kulozik,	M.	Zapatka,	A.	Guha,	D.	Malkin,	J.	Felsberg,	G.	Reifenberger,	
A.	von	Deimling,	K.	Ichimura,	V.	P.	Collins,	H.	Witt,	T.	Milde,	O.	Witt,	C.	Zhang,	P.	Castelo‐Branco,	P.	Lichter,	D.	Faury,	U.	
Tabori,	 C.	 Plass,	 J.	Majewski,	 S.	M.	 Pfister,	 and	N.	 Jabado.	 2012.	 Driver	mutations	 in	 histone	H3.3	 and	 chromatin	
remodelling	genes	in	paediatric	glioblastoma.	Nature	482:226‐231.		
Sfeir,	 A.,	 S.	 T.	 Kosiyatrakul,	 D.	 Hockemeyer,	 S.	 L.	 MacRae,	 J.	 Karlseder,	 C.	 L.	 Schildkraut,	 and	 T.	 de	 Lange.	 2009.	
Mammalian	telomeres	resemble	fragile	sites	and	require	TRF1	for	efficient	replication.	Cell	138:90‐103.		
Shay,	J.	W.,	and	S.	Bacchetti.	1997.	A	survey	of	telomerase	activity	in	human	cancer.	Eur.	J.	Cancer	33:787‐791.		
Shay,	J.	W.,	O.	M.	Pereira‐Smith,	and	W.	E.	Wright.	1991a.	A	role	for	both	RB	and	p53	in	the	regulation	of	human	cellular	
senescence.	Exp.	Cell	Res.	196:33‐39.		
Shay,	J.	W.,	W.	E.	Wright,	and	H.	Werbin.	1991b.	Defining	the	molecular	mechanisms	of	human	cell	immortalization.	
Biochim.	Biophys.	Acta	1072:1‐7.		
Sims,	 J.	 K.,	 and	 P.	 A.	Wade.	 2011.	Mi‐2/NuRD	 complex	 function	 is	 required	 for	 normal	 S	 phase	 progression	 and	
assembly	of	pericentric	heterochromatin.	Mol.	Biol.	Cell	22:3094‐3102.		
References		 	
 
 
98 
Smeenk,	 G.,	W.	W.	Wiegant,	 H.	 Vrolijk,	 A.	 P.	 Solari,	 A.	 Pastink,	 and	 H.	 van	 Attikum.	 2010.	 The	 NuRD	 chromatin‐
remodeling	complex	regulates	signaling	and	repair	of	DNA	damage.	J.	Cell	Biol.	190:741‐749.		
Smogorzewska,	A.,	and	T.	de	Lange.	2002.	Different	telomere	damage	signaling	pathways	in	human	and	mouse	cells.	
EMBO	J.	21:4338‐4348.		
Smogorzewska,	A.,	J.	Karlseder,	H.	Holtgreve‐Grez,	A.	Jauch,	and	T.	de	Lange.	2002.	DNA	ligase	IV‐dependent	NHEJ	of	
deprotected	mammalian	telomeres	in	G1	and	G2.	Curr.	Biol.	12:1635‐1644.		
Smyth,	C.	M.,	M.	A.	Helmer,	L.	Dalla‐Pozza,	and	P.	B.	Rowe.	1993.	Flow	cytometric	DNA	analyses	of	frozen	samples	from	
children's	solid	tumors.	Pathology	25:388‐393.		
Stansel,	R.	M.,	T.	 de	Lange,	 and	 J.	D.	Griffith.	 2001.	T‐loop	assembly	 in	vitro	 involves	binding	of	TRF2	near	 the	3'	
telomeric	overhang.	EMBO	J.	20:5532‐5540.		
Stansel,	 R.	 M.,	 D.	 Subramanian,	 and	 J.	 D.	 Griffith.	 2002.	 p53	 binds	 telomeric	 single	 strand	 overhangs	 and	 t‐loop	
junctions	in	vitro.	J.	Biol.	Chem.	277:11625‐11628.		
Stern,	J.	L.,	K.	G.	Zyner,	H.	A.	Pickett,	S.	B.	Cohen,	and	T.	M.	Bryan.	2012.	Telomerase	recruitment	requires	both	TCAB1	
and	Cajal	bodies	independently.	Mol.	Cell.	Biol.	32:2384‐2395.		
Stohr,	B.	A.,	and	E.	H.	Blackburn.	2008.	ATM	mediates	cytotoxicity	of	a	mutant	telomerase	RNA	in	human	cancer	cells.	
Cancer	Res.	68:5309‐5317.		
Subhawong,	A.	P.,	C.	M.	Heaphy,	P.	Argani,	Y.	Konishi,	N.	Kouprina,	H.	Nassar,	R.	Vang,	and	A.	K.	Meeker.	2009.	The	
alternative	lengthening	of	telomeres	phenotype	in	breast	carcinoma	is	associated	with	HER‐2	overexpression.	Mod.	
Pathol.	22:1423‐1431.		
Sullivan,	B.	A.	2010.	Optical	mapping	of	protein‐DNA	complexes	on	chromatin	fibers.	Methods	Mol.	Biol.	659:99‐115.		
Takai,	H.,	A.	Smogorzewska,	and	T.	de	Lange.	2003.	DNA	damage	foci	at	dysfunctional	telomeres.	Curr.	Biol.	13:1549‐
1556.		
Temime‐Smaali,	N.,	L.	Guittat,	T.	Wenner,	E.	Bayart,	C.	Douarre,	D.	Gomez,	M.	J.	Giraud‐Panis,	A.	Londono‐Vallejo,	E.	
Gilson,	M.	Amor‐Gueret,	and	J.	F.	Riou.	2008.	Topoisomerase	IIIa	is	required	for	normal	proliferation	and	telomere	
stability	in	alternative	lengthening	of	telomeres.	EMBO	J.	27:1513‐1524.		
Teng,	S.	C.,	 and	V.	A.	Zakian.	1999.	Telomere‐telomere	recombination	 is	an	efficient	bypass	pathway	 for	 telomere	
maintenance	in	Saccharomyces	cerevisiae.	Mol.	Cell.	Biol.	19:8083‐8093.		
Tilman,	 G.,	 A.	 Loriot,	 A.	 van	 Beneden,	 N.	 Arnoult,	 J.	 A.	 Londono‐Vallejo,	 C.	 De	 Smet,	 and	 A.	 Decottignies.	 2009.	
Subtelomeric	DNA	hypomethylation	is	not	required	for	telomeric	sister	chromatid	exchanges	in	ALT	cells.	Oncogene	
28:1682‐1693.		
Tokutake,	 Y.,	 T.	Matsumoto,	 T.	Watanabe,	 S.	Maeda,	H.	 Tahara,	 S.	 Sakamoto,	H.	Niida,	M.	 Sugimoto,	 T.	 Ide,	 and	Y.	
Furuichi.	1998.	Extra‐chromosome	 telomere	 repeat	DNA	 in	 telomerase‐negative	 immortalized	 cell	 lines.	Biochem.	
Biophys.	Res.	Commun.	247:765‐772.		
Tommerup,	H.,	A.	Dousmanis,	and	T.	de	Lange.	1994.	Unusual	chromatin	in	human	telomeres.	Mol.	Cell.	Biol.	14:5777‐
5785.		
References		 	
 
 
99 
Topark‐Ngarm,	A.,	O.	Golonzhka,	V.	J.	Peterson,	B.	Barrett,	Jr.,	B.	Martinez,	K.	Crofoot,	T.	M.	Filtz,	and	M.	Leid.	2006.	
CTIP2	associates	with	the	NuRD	complex	on	the	promoter	of	p57KIP2,	a	newly	identified	CTIP2	target	gene.	J.	Biol.	
Chem.	281:32272‐32283.		
Tsutsui,	 T.,	 S.	 Kumakura,	 Y.	 Tamura,	 T.	 W.	 Tsutsui,	 M.	 Sekiguchi,	 T.	 Higuchi,	 and	 J.	 C.	 Barrett.	 2003.	 Immortal,	
telomerase‐negative	cell	lines	derived	from	a	Li‐Fraumeni	syndrome	patient	exhibit	telomere	length	variability	and	
chromosomal	and	minisatellite	instabilities.	Carcinogenesis	24:953‐965.		
van	Steensel,	B.,	A.	Smogorzewska,	and	T.	de	Lange.	1998.	TRF2	protects	human	telomeres	from	end‐to‐end	fusions.	
Cell	92:401‐413.		
Varley,	H.,	H.	A.	Pickett,	J.	L.	Foxon,	R.	R.	Reddel,	and	N.	J.	Royle.	2002.	Molecular	characterization	of	inter‐telomere	
and	intra‐telomere	mutations	in	human	ALT	cells.	Nat.	Genet.	30:301‐305.		
Venturini,	L.,	R.	Erdas,	A.	Costa,	A.	Gronchi,	S.	Pilotti,	N.	Zaffaroni,	and	M.	Daidone.	2008.	ALT‐associated	promyelocytic	
leukaemia	 body	 (APB)	 detection	 as	 a	 reproducible	 tool	 to	 assess	 alternative	 lengthening	 of	 telomere	 stability	 in	
liposarcomas.	J.	Pathol.	214:410‐414.		
Vera,	E.,	A.	Canela,	M.	F.	Fraga,	M.	Esteller,	and	M.	A.	Blasco.	2008.	Epigenetic	regulation	of	telomeres	in	human	cancer.	
Oncogene	27:6817‐6833.		
Verdun,	 R.	 E.,	 and	 J.	 Karlseder.	 2006.	 The	 DNA	 damage	machinery	 and	 homologous	 recombination	 pathway	 act	
consecutively	to	protect	human	telomeres.	Cell	127:709‐720.		
Vergnaud,	G.,	and	F.	Denoeud.	2000.	Minisatellites:	mutability	and	genome	architecture.	Genome	Res.	10:899‐907.		
Villa,	R.,	M.	G.	Daidone,	R.	Motta,	L.	Venturini,	C.	De	Marco,	A.	Vannelli,	S.	Kusamura,	D.	Baratti,	M.	Deraco,	A.	Costa,	R.	
R.	Reddel,	and	N.	Zaffaroni.	2008.	Multiple	mechanisms	of	telomere	maintenance	exist	and	differentially	affect	clinical	
outcome	in	diffuse	malignant	peritoneal	mesothelioma.	Clin.	Cancer	Res.	14:4134‐4140.		
von	Zglinicki,	T.	2000.	Role	of	oxidative	stress	 in	telomere	length	regulation	and	replicative	senescence.	Ann.	N.	Y.	
Acad.	Sci.	908:99‐110.		
von	Zglinicki,	T.	2002.	Oxidative	stress	shortens	telomeres.	Trends	Biochem.	Sci.	27:339‐344.		
von	 Zglinicki,	 T.,	 G.	 Saretzki,	 W.	 Docke,	 and	 C.	 Lotze.	 1995.	 Mild	 hyperoxia	 shortens	 telomeres	 and	 inhibits	
proliferation	of	fibroblasts:	a	model	for	senescence?	Exp.	Cell	Res.	220:186‐193.		
Vrbsky,	 J.,	 S.	Akimcheva,	 J.	M.	Watson,	 T.	 L.	Turner,	 L.	Daxinger,	 B.	Vyskot,	W.	Aufsatz,	 and	K.	Riha.	 2010.	 siRNA‐
mediated	methylation	of	Arabidopsis	telomeres.	PLoS	Genet.	6:e1000986.		
Wang,	R.	C.,	A.	Smogorzewska,	and	T.	de	Lange.	2004.	Homologous	recombination	generates	T‐loop‐sized	deletions	at	
human	telomeres.	Cell	119:355‐368.		
Wang,	Y.,	H.	Zhang,	Y.	Chen,	Y.	Sun,	F.	Yang,	W.	Yu,	J.	Liang,	L.	Sun,	X.	Yang,	L.	Shi,	R.	Li,	Y.	Li,	Y.	Zhang,	Q.	Li,	X.	Yi,	and	Y.	
Shang.	 2009.	 LSD1	 is	 a	 subunit	 of	 the	NuRD	 complex	 and	 targets	 the	metastasis	 programs	 in	 breast	 cancer.	Cell	
138:660‐672.		
Watson,	J.	D.	1972.	Origin	of	concatemeric	T7	DNA.	Nat.	New	Biol.	239:197‐201.		
Weinrich,	S.	L.,	R.	Pruzan,	L.	Ma,	M.	Ouellette,	V.	M.	Tesmer,	S.	E.	Holt,	A.	G.	Bodnar,	S.	Lichtsteiner,	N.	W.	Kim,	J.	B.	
Trager,	 R.	 D.	 Taylor,	 R.	 Carlos,	 W.	 H.	 Andrews,	 W.	 E.	 Wright,	 J.	 W.	 Shay,	 C.	 B.	 Harley,	 and	 G.	 B.	 Morin.	 1997.	
References		 	
 
 
100 
Reconstitution	of	human	telomerase	with	the	template	RNA	component	hTR	and	the	catalytic	protein	subunit	hTRT.	
Nat.	Genet.	17:498‐502.		
Wellinger,	R.	J.,	K.	Ethier,	P.	Labrecque,	and	V.	A.	Zakian.	1996.	Evidence	for	a	new	step	in	telomere	maintenance.	Cell	
85:423‐433.		
Wong,	 J.	 M.,	 and	 K.	 Collins.	 2006.	 Telomerase	 RNA	 level	 limits	 telomere	 maintenance	 in	 X‐linked	 dyskeratosis	
congenita.	Genes	Dev.	20:2848‐2858.		
Wong,	L.	H.,	J.	D.	McGhie,	M.	Sim,	M.	A.	Anderson,	S.	Ahn,	R.	D.	Hannan,	A.	J.	George,	K.	A.	Morgan,	J.	R.	Mann,	and	K.	H.	
Choo.	2010.	ATRX	 interacts	with	H3.3	 in	maintaining	telomere	structural	 integrity	 in	pluripotent	embryonic	stem	
cells.	Genome	Res.	20:351‐360.		
Wright,	 W.	 E.,	 O.	 M.	 Pereira‐Smith,	 and	 J.	 W.	 Shay.	 1989.	 Reversible	 cellular	 senescence:	 Implications	 for	
immortalization	of	normal	human	diploid	fibroblasts.	Mol.	Cell.	Biol.	9:3088‐3092.		
Wu,	G.,	X.	Jiang,	W.	H.	Lee,	and	P.	L.	Chen.	2003.	Assembly	of	functional	ALT‐associated	promyelocytic	leukemia	bodies	
requires	Nijmegen	breakage	syndrome	1.	Cancer	Res.	63:2589‐2595.		
Wu,	G.,	W.	H.	Lee,	and	P.	L.	Chen.	2000.	NBS1	and	TRF1	colocalize	at	promyelocytic	leukemia	bodies	during	late	S/G2	
phrases	in	immortalized	telomerase‐negative	cells.	Implication	of	NBS1	in	alternative	lengthening	of	telomeres.	J.	Biol.	
Chem.	275:30618‐30622.		
Wu,	L.,	A.	S.	Multani,	H.	He,	W.	Cosme‐Blanco,	Y.	Deng,	J.	M.	Deng,	O.	Bachilo,	S.	Pathak,	H.	Tahara,	S.	M.	Bailey,	Y.	Deng,	
R.	 R.	 Behringer,	 and	 S.	 Chang.	 2006.	 Pot1	 deficiency	 initiates	 DNA	 damage	 checkpoint	 activation	 and	 aberrant	
homologous	recombination	at	telomeres.	Cell	126:49‐62.		
Xue,	Y.,	R.	Gibbons,	Z.	Yan,	D.	Yang,	T.	L.	McDowell,	S.	Sechi,	J.	Qin,	S.	Zhou,	D.	Higgs,	and	W.	Wang.	2003.	The	ATRX	
syndrome	protein	forms	a	chromatin‐remodeling	complex	with	Daxx	and	localizes	in	promyelocytic	leukemia	nuclear	
bodies.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	100:10635‐10640.		
Yamamoto,	A.,	S.	Kumakura,	M.	Uchida,	J.	C.	Barrett,	and	T.	Tsutsui.	2003.	Immortalization	of	normal	human	embryonic	
fibroblasts	by	introduction	of	either	the	human	papillomavirus	type	16	E6	or	E7	gene	alone.	Int.	J.	Cancer	106:301‐
309.		
Ye,	J.	Z.,	J.	R.	Donigian,	M.	van	Overbeek,	D.	Loayza,	Y.	Luo,	A.	N.	Krutchinsky,	B.	T.	Chait,	and	T.	de	Lange.	2004a.	TIN2	
binds	TRF1	and	TRF2	simultaneously	and	stabilizes	the	TRF2	complex	on	telomeres.	J.	Biol.	Chem.	279:47264‐47271.		
Ye,	J.	Z.,	D.	Hockemeyer,	A.	N.	Krutchinsky,	D.	Loayza,	S.	M.	Hooper,	B.	T.	Chait,	and	T.	de	Lange.	2004b.	POT1‐interacting	
protein	PIP1:	a	telomere	length	regulator	that	recruits	POT1	to	the	TIN2/TRF1	complex.	Genes	Dev.	18:1649‐1654.		
Yeager,	T.	R.,	A.	A.	Neumann,	A.	Englezou,	L.	I.	Huschtscha,	J.	R.	Noble,	and	R.	R.	Reddel.	1999.	Telomerase‐negative	
immortalized	human	cells	contain	a	novel	type	of	promyelocytic	leukemia	(PML)	body.	Cancer	Res.	59:4175‐4179.		
Yui,	J.,	C.	P.	Chiu,	and	P.	M.	Lansdorp.	1998.	Telomerase	activity	in	candidate	stem	cells	from	fetal	liver	and	adult	bone	
marrow.	Blood	91:3255‐3262.		
Zellinger,	B.,	S.	Akimcheva,	J.	Puizina,	M.	Schirato,	and	K.	Riha.	2007.	Ku	suppresses	formation	of	telomeric	circles	and	
alternative	telomere	lengthening	in	Arabidopsis.	Mol.	Cell	27:163‐169.		
Zeng,	S.,	T.	Xiang,	T.	K.	Pandita,	I.	Gonzalez‐Suarez,	S.	Gonzalo,	C.	C.	Harris,	and	Q.	Yang.	2009.	Telomere	recombination	
requires	the	MUS81	endonuclease.	Nat.	Cell	Biol.	11:616‐623.		
References		 	
 
 
101 
Zheng,	P.,	Y.	Guo,	Q.	Niu,	D.	E.	Levy,	J.	A.	Dyck,	S.	Lu,	L.	A.	Sheiman,	and	Y.	Liu.	1998.	Proto‐oncogene	PML	controls	genes	
devoted	to	MHC	class	I	antigen	presentation.	Nature	396:373‐376.		
Zhong,	S.,	P.	Salomoni,	and	P.	P.	Pandolfi.	2000.	The	transcriptional	role	of	PML	and	the	nuclear	body.	Nat.	Cell	Biol.	
2:E85‐E90.		
Zhong,	Z.	H.,	W.	Q.	 Jiang,	A.	 J.	 Cesare,	A.	A.	Neumann,	R.	Wadhwa,	and	R.	R.	Reddel.	2007.	Disruption	of	 telomere	
maintenance	by	depletion	of	the	MRE11/RAD50/NBS1	complex	in	cells	that	use	alternative	lengthening	of	telomeres.	
J.	Biol.	Chem.	282:29314‐29322.		
	
